var title_f15_23_15728="Benefit carotid endarterectomy";
var content_f15_23_15728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F67785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F67785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benefit from carotid endarterectomy is related to sex, age, and degree of stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 488px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the European Carotid Surgery trial of 3024 patients, the benefit from carotid endarterectomy varied with sex, age, and degree of carotid stenosis. Men derived more benefit from surgery than women and there was more benefit with increasing severity of stenosis. Younger patients showed definite benefit from surgery over a narrowed range of severe stenosis than did older patients. Curved lines connect points of equal months of major-stroke-free-life expectancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from European Carotid Sugery Trialists Collaborative Group. Lancet 1998; 351:1379.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15728=[""].join("\n");
var outline_f15_23_15728=null;
var title_f15_23_15729="Isoconazole: International drug information";
var content_f15_23_15729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isoconazole: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1979127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fazol (FR);",
"     </li>",
"     <li>",
"      Gino Monipax (BR);",
"     </li>",
"     <li>",
"      Gino-Travogen (PT);",
"     </li>",
"     <li>",
"      Gyno Icaden (BR);",
"     </li>",
"     <li>",
"      Gyno Mycel (BR);",
"     </li>",
"     <li>",
"      Gyno-Travogen (AT, BE, CH, CL, DE, IE, LU, NL);",
"     </li>",
"     <li>",
"      Icaden (BR, DE, MX);",
"     </li>",
"     <li>",
"      Isogyn (IT);",
"     </li>",
"     <li>",
"      Mupaten (AR);",
"     </li>",
"     <li>",
"      Mycel (BR);",
"     </li>",
"     <li>",
"      Travogen (AT, BE, CH, CL, CZ, DE, HR, IE, IT, LU, NL);",
"     </li>",
"     <li>",
"      Travogyn (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Isoconazole Nitrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of topical and vaginal fungal infections",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Topical: Apply once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Vaginal tablet: 600 mg, insert once at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Cream: 10 mg/g (20 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Solution, topical: 10 mg/g (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet, vaginal: 300 mg, 600 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10399 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15729=[""].join("\n");
var outline_f15_23_15729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979127\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979120\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979122\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979125\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979121\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821085\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979124\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10399\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10399|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_23_15730="Atopic dermatitis (eczema)";
var content_f15_23_15730=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/23/15730/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15730/contributors\" id=\"au5636\">",
"       William L Weston, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15730/contributors\" id=\"au1640\">",
"       William Howe, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/23/15730/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15730/contributors\" id=\"se7157\">",
"       Robert P Dellavalle, MD, PhD, MSPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/23/15730/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15730/contributors\" id=\"de7805\">",
"       Rosamaria Corona, MD, DSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?15/23/15730?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ECZEMA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Atopic dermatitis, also known as eczema, is a skin problem that causes dry, itchy, scaly, red skin. It can occur in infants, children, and adults, and seems more common in certain families. Eczema can be treated with moisturizers and prescription ointments.",
"    </p>",
"    <p>",
"     More detailed information about atopic dermatitis is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link\">",
"      \"Treatment of atopic dermatitis (eczema)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44457?source=see_link\">",
"      \"Management of severe refractory atopic dermatitis (eczema)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ECZEMA CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The cause of eczema is not completely understood, although hereditary factors appear to play a strong role. Atopic dermatitis is caused by dysfunction in the outermost layer of the skin (the epidermis). The epidermis is the first line of defense between the body and the environment. When the epidermis is intact, it keeps environmental irritants, allergens, and microbes from entering the body.",
"    </p>",
"    <p>",
"     In children, eczema is rarely linked to food allergies. If a food allergy is suspected, the child should be evaluated by an allergy specialist. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"      \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"      \"Role of allergy in atopic dermatitis (eczema)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ECZEMA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Most people with eczema develop their first symptoms before age five. Intense itching of the skin, patches of redness, small bumps, and skin flaking are common. Scratching can cause additional skin inflammation, which can further worsen the itching. The itchiness may be more noticeable at nighttime.",
"    </p>",
"    <p>",
"     Features of eczema vary from one individual to another, and can change over time. Although eczema is usually confined to specific areas of the body, it may affect multiple areas in severe cases:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In infants, there may be red, scaly, and crusted areas on the front of the arms and legs, cheeks, or scalp. The diaper area is not usually affected.",
"      </li>",
"      <li>",
"       In children and adults, eczema commonly affects the back of the neck, the elbow creases, and the backs of the knees (",
"       <a class=\"graphic graphic_picture graphicRef57650 \" href=\"UTD.htm?28/4/28751\">",
"        picture 1",
"       </a>",
"       ). Other affected areas may include the face, wrists, and forearms (",
"       <a class=\"graphic graphic_picture graphicRef81398 \" href=\"UTD.htm?5/12/5314\">",
"        picture 2",
"       </a>",
"       ). The skin may become thickened and darkened, or even scarred, from repeated scratching.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The skin can also become infected as a result of scratching. Signs of infection include painful red bumps that sometimes contain pus; a healthcare provider should be consulted if this occurs.",
"    </p>",
"    <p>",
"     Other findings in people with eczema can include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Dry, scaly skin",
"      </li>",
"      <li>",
"       Plugged hair follicles causing small bumps to develop, usually on the face, upper arms, and thighs",
"      </li>",
"      <li>",
"       Increased skin creasing on the palms",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       an extra fold of skin under the eye",
"      </li>",
"      <li>",
"       Darkening of the skin around the eyes",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      ECZEMA DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     There is no specific test used to diagnose eczema. The diagnosis is usually based upon a person's medical history and physical examination.",
"    </p>",
"    <p>",
"     Factors that strongly suggest eczema include long-standing and recurrent itching, a personal or family history of allergic conditions, and an early age when symptoms began. Other factors include worsened symptoms after exposure to certain triggers or any of the skin findings noted above.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      ECZEMA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Eczema is a chronic condition; it typically improves and then flares (worsens) periodically. Some people have no symptoms for several years. Eczema is not curable, although symptoms can be controlled with a variety of self-care measures and drug therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Who treats eczema?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many patients with atopic dermatitis can initially be treated by their primary care provider. However, a skin specialist (dermatologist) may be recommended in certain situations, such as if the condition does not improve with treatment, if certain areas of the body are affected (face or skin folds), and if another condition could be causing symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Eliminate aggravating factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Eliminating factors that worsen eczema can help to control the symptoms. Aggravating factors may include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Heat, perspiration, dry environments",
"      </li>",
"      <li>",
"       Emotional stress or anxiety",
"      </li>",
"      <li>",
"       Rapid temperature changes",
"      </li>",
"      <li>",
"       Exposure to certain chemicals or cleaning solutions, including soaps and detergents, perfumes and cosmetics, wool or synthetic fibers, dust, sand, and cigarette smoke.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Keep the skin hydrated",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Emollients",
"     </span>",
"     &nbsp;&mdash;&nbsp;Emollients are creams and ointments that moisturize the skin and prevent it from drying out. The best emollients for people with atopic dermatitis are thick creams (such as Eucerin&reg;, Cetaphil&reg;, and Nutraderm&reg;) or ointments (such as petroleum jelly, Aquaphor&reg;, and Vaseline&reg;), which contain little to no water. Emollients are most effective when applied immediately after bathing. Lotions contain more water than creams and ointments and are less effective for moisturizing the skin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Bathing",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is not clear if showers or baths are better for keeping the skin hydrated. Lukewarm baths or showers can hydrate and cool the skin, temporarily relieving the itching of eczema. An unscented, mild soap or nonsoap cleanser (such as Cetaphil&reg;) should be used sparingly. An emollient should be applied IMMEDIATELY after bathing or showering to prevent the skin from drying out as a result of water evaporation.",
"    </p>",
"    <p>",
"     However, hot or long baths (greater than 10 to 15 minutes) and showers should be avoided since they can dry out the skin.",
"    </p>",
"    <p>",
"     In some cases, healthcare providers may recommend dilute bleach baths for people with eczema. These baths help to decrease the number of bacteria on the skin which can cause infections or worsen symptoms. To prepare a bleach bath, &frac14; to &frac12; cup of bleach is placed in a full bathtub (about 40 gallons) of water. Bleach baths are usually taken for five to ten minutes twice per week.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Treat skin irritation",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Topical steroids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Prescription steroid (corticosteroid) creams and ointments may be recommended to control mild to moderate atopic dermatitis. Steroid creams and ointments are available in a variety of strengths (potencies); the least potent are available without a prescription (eg, hydrocortisone 1% cream). More potent formulations require a prescription.",
"    </p>",
"    <p>",
"     Steroid creams or ointments are usually applied to the skin once or twice per day. These help to reduce symptoms and moisturize the skin. As the skin improves, a non-medicated emollient can be resumed. Strong topical steroids may be needed to control severe flares of eczema; however, these should be used for only short periods of time to prevent thinning of the skin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Other skin treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Newer skin treatments for eczema include tacrolimus (Protopic&reg;) and pimecrolimus (Elidel&reg;). These are effective in controlling eczema, although they do not work as quickly as topical steroids. They are useful in sensitive areas such as the face and groin, and can be used in children over age two. Due to safety concerns, these treatments should only be used as instructed by a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Oral steroids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Oral steroids (eg, prednisone) occasionally are used to treat a severe flare of eczema, although this treatment is not usually recommended on a regular basis because of potential side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Ultraviolet light therapy (phototherapy)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ultraviolet light therapy (phototherapy) can effectively control atopic dermatitis. However, this therapy is expensive, may increase a person's risk for skin cancer, and is therefore recommended only for people with severe eczema who do not respond to other treatments.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Immunosuppressive drugs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Drugs that weaken the immune system may be recommended for people with severe eczema who do not improve with other treatments. Treatment with these drugs can cause serious side effects, including an increased risk for infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Control itching",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Oral antihistamines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Oral antihistamines sometimes help relieve the itching of eczema. The over-the-counter antihistamine diphenhydramine (Benadryl&reg;), and prescription antihistamines, such as hydroxyzine (Atarax&reg;) and cyproheptadine, are most effective for itching caused by eczema, although these drugs can cause drowsiness.",
"    </p>",
"    <p>",
"     The nonsedating antihistamines such as cetirizine (Zyrtec&reg;) and loratadine (Claritin&reg;) may relieve symptoms, and both are available without a prescription in the United States.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Wet dressings",
"     </span>",
"     &nbsp;&mdash;&nbsp;Wet dressings help soothe and hydrate the skin, reduce itching and redness, loosen crusted areas, and prevent skin injury from scratching. Dampened cotton garments may be worn over the affected area and covered with a dry garment. The person may wear these dressings overnight or change them every eight hours during the day.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287322531\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5394150\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/30/6626?source=see_link\">",
"      Patient information: Eczema (atopic dermatitis) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/5/22610?source=see_link\">",
"      Patient information: Seborrheic dermatitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/41/37521?source=see_link\">",
"      Patient information: Melasma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/35/17971?source=see_link\">",
"      Patient information: Peanut allergy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5394158\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37318?source=see_link\">",
"      Approach to the patient with a scalp eruption",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/37/25175?source=see_link\">",
"      Introducing formula and solid foods to infants at risk for allergic disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20119?source=see_link\">",
"      Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17304?source=see_link\">",
"      The impact of breastfeeding on the development of allergic disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44457?source=see_link\">",
"      Management of severe refractory atopic dermatitis (eczema)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"      Role of allergy in atopic dermatitis (eczema)",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute on Arthritis and Musculoskeletal and Skin Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niams.nih.gov/hi/index.htm\">",
"      www.niams.nih.gov/hi/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Dermatology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aad.org/\">",
"      www.aad.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Allergy, Asthma and Immunology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aaaai.org\">",
"      www.aaaai.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       EczemaNet",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.skincarephysicians.com/eczemanet/\">",
"      www.skincarephysicians.com/eczemanet/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Eczema Association for Science and Education",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.eczema-assn.org/\">",
"      www.eczema-assn.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?15/23/15730/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 16, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?15/23/15730?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15730/abstract/1\">",
"      Brenninkmeijer EE, Schram ME, Leeflang MM, et al. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol 2008; 158:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15730/abstract/2\">",
"      Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15730/abstract/3\">",
"      Fonacier L, Spergel J, Charlesworth EN, et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2005; 115:1249.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f15_23_15730=[""].join("\n");
var outline_f15_23_15730=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ECZEMA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ECZEMA CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ECZEMA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           ECZEMA DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           ECZEMA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/4/28751\" title=\"picture 1\">",
"           Flex atopic dermatitis PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/12/5314\" title=\"picture 2\">",
"           Atopic dermatitis papular PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f15_23_15731="Cholangiogram following stone clearance";
var content_f15_23_15731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Cholangiogram following stone clearance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 466px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHSAdQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDlEYIPlyRwck5rWtxxyccZrCiGBgknH8qvyzbYo0Gdz9vQUAXWl89y3Re30qxA36VnwE7SccdKu2x6HGPfFAGmp4GelWYojJhjyvTHrVe2iJYEng9MnrWjH028Y9qAJEH3eePWrkIKkHAx1AzVcKoB25OMHA4BrQEq4VWQY7+v4UAPCiT5lcc9an2gLuLAg4J9qhQxRAtIwABzTnmyV6bR0FADmcMhLgqo6D1qtPJlTj/9VSTSRupCkgdwTzVd3UjYpyvrQBHHjb04qeMH6Z/WoFAHA5+lTIVH1x09qAJ4wAeTipGwvQc9KiiPzAD61O0e7DN35wOv/wCqgAtXdJAVyo6k9vwrYKmSIjYRnrWUo24BB47en0rQsnG3HbocGgCqUAPzckGmbz5mSMjvU93xI2O57VVdscD8KAFjkySrBsZJqz5iqo2AiqSLkgk89cZzVhCF/wBon8fzoAlYtIcLgDGTmmbwpAByO57VJv8Al+bb6gdqhOPL+6QTwPSgBm4LkAH60AncMdTSElSBx04460mN3GaAJRyvPB5FOQnZgYbPPSod3BqTcQCQefT0oACRjn8QRTWAYdxTuHHAO7r0qI5VuODmgBQMHqCKdHIFPUZNRu7DG3qO5pCGOTnHT8aALs67V5bPoAe1VlhZ2O0t9TVqNFeI4J3D71QnAkGM+n0oARUiEEzMCWXHfFVGyQCcKeoXpWlbbT5obBXGDj1qtcxKQX5+p6UAVYwc5GFIH1qGYAM/ByTjNS9uMg+tQvk5OcAevNAFVlPVThScHPpTkTa27sB39/SkLEcnO7Gfwp4kwpycsOeRwKAKcsSsW3IAOvvVKYjbhVx6EjtV6R2kb5BlicBaha0uWlA8sg9Pm6CgDDuYS6jJx/dNULuIQRSszHa2Mdjmuo1rS4rezt5YLgPKxIkiPGysK9jMkBXbkDp70Ac9K2I+CSR1Y1Xf50J42kc1oXdtshYjndyTWfE0ZTackkdPWgCG5gJjCqmWKkgVzH2aQTMJgFCtu2nqRXbhBJF0O9MEc1zGp3BE7NIoKo3LetAGJe3CiJU2jgkn3FUba/SGQrxtbtVbWZtspGfesa3lJuQTyM0AdZbalIJ1AJwW716ToEjgCWYnzSvAHZfevOtCiWKRZ5ly5/1eeg967nS7higKuPVjjqewoA72CfdbqwI6cknpWn4KzeeLLCEjcxnzgj05zXL2Nx+5CcccHPaus+E6CTxvA5VmaCJnAH97GOT+NAHuMKwm/kIx5uPmf+9TbyYeZtcAhm7d6oaTA6X08k0gfPOR79hVtLdGuvlxtDA49MUAXVeP+0AFOWCc+1YnjeYjwnqrNwMeWvHXJAreiVTclyvzbefpmuT+Jl15PhwRrt2PMu5j0HegDymIfu1HlKMDHJNFW4pYVQbCrZ5JPrRQB5VbASWvmKclSAfx6U1JDLMWOcDgfSnaSN+h6sFX94scRTHchufxwTTLGCRhuZwiYx81AGnbgMMA1qWKbmy2fL6Z9aqWlvlNo+Ud2PetSJsqBhQo4C0AXk52nAGOnsKtICQfTrVa3XOWBAA61OrKCw9s5NAFqMFuABVx7dxGrmT5B7c1UtHXJkZgAOMdzViK4LpvJBAH4UARjdKwz/D2B6VaU4jO0bWPSooWDKWQYolkwcv17CgCFyWOG4IqQKAeB+NQg72OT82OOOpqdBliQeD0oAkQjuf1p2M8EcdqRAWIABJqeJdvXk/SgB0CkYLdelWTgDjrUcaYOTjFTShdvJ5wMigBAVHAHHrU0Eozg8DvVZm9Bt+lEMhEiFjlc80AWbpNwyCfTp1qnNnC5IX1OelXpGVQ4ZiR7/0rMlZmGBwv0oAcjqvQ5HrUkLkSblGTg4qrGA0nB5Jq2MIPrxQA9Q0h654/KnEck5yO1NVdvOckcdOaeRg4IIPegBSvGByBwRjtUTphsdenNT4OBnp/SmSjHtx9fxoAYQce+cexpVIVvnyVzyKC2SAPpSctn0oAnLMshwPkzxjmmvHk5Axmpo1ULnkf1p6nEbcq3HA70AVcKoBxnPr3pOTk449x0qQgMM8gikA2tgnPYcUACPtOcgccDFNkZG+7uLDtSKGf5V+Y54Xv+NTXUXlxKpJB6k4oAgeQRKFT73U+lMWQyq28FsfpUZA4Yk4PHWpoSREdmD689KAGOFCcox75NVXiUwtI2Bn0q1KMhQ3TvTZYk+yY5Azk0AY7nIwBhR1NWIbNmUGVtqnnHr9a0NI04XG6aQYj/hHZjUGszsJTCi7MDLEdaAGJLa2bghdz5xuHNVrvU3knUIFSM9zyQPpVZRlDtUEfWoJMlwG+7igCpc5lZzI+7PGaqyIfNUj7oGOB2q75Z2Fj0JpgQueB7CgDFvrdjHIAQBg4x3FczbrsmIP8PH0rtbiNlymBuz29K5zU7GSGXfGBgnvQBHDKscmcfL6+tcl4z2weYgHEv7xR6n0rorm8jggIwGkHp2+lc94pBudMWQn5o+hHvQB5vdTvNIPM4KjFOsYf3qyNygOcetNaPdMWP3M5J/pWpaESuiogBHQUAdJZOCi7R8jD8q3NKYxuEJOcDjtXORKNg5wR2HetfTpXjVVwrOOm44IoA7vSeS0Z7DkV6d8IYhax67fFM7YVhQKfmJJzxXj+k3QE8TyE7Rx1zmvePhssdn4NOpEBDeXLjL90HAwKAOo8PPdSQzSSfIGIAB6irlgZGeWRhyGwcdKjsriI2ZcNksTkirls22KJXHzO26gC5Er7mOcLtwB61578Wp0EGl2CS7Su6Rl7+xrv1mcxlkGSSAA3r3rzL4gxm48Z+TnKQxKCT1y3J/pQBztpBi3QINqj+91orW2QQ/IXYkdcUUAeQaJdQxpOqQkSOqbnHOcHPSp/sEiyjbzHJllc9AP/AK1ZdnqMigonG5cEDvWmlxJJbNCzMf5A0AX2dY1EUeTgDLVLAcsAeW68VTsoTIQFH0zXQ21quFVQMetAE8B2IgZR0zT1AcMwUH0zxmq94fL5LcAdB2qOKbzA4LADqoznAoAvQQkuNxLEnkDke1WcfuyCMY6f/XqhBKQ2wEkdyegqy04A5YZ/nQBIJCijafwpu5mOW61EH3HJP4elPU5IoAnVeMNwKmiXeecBfXOMU2JS+Cc7R0zV23QM2D0XjHegBwiCJlentTlX3NTBdi7dox1+tRkbVHIHNAAAyng/n3qRFygZicdKhJO7tt69akjJcbVBFADDIF5wSw4FSbkCAEbmz26VDKNpO0Zbuc9abGpjHt9O9AFqN98eJOoPpxUEgI6cg9PShG2ksccjBz2p0zfIOmQaAKy/60kEAHvV3GVBOCfT0qocZyDweRVuLDICcH8aAJITgg9lP51O7BucZx6GqxOU47cU5WztBIAH3sDrQA93zkep4zSDD9u/+RQBk84Xnt0qZQNuPu+nNAEKIC4HXv8AT2qQqP6H60oPznHIHfoKCQQCB70AOR9q7Rzn7uaBJzjAx/s1G+B05HfFKr4H8PA6YxQArf3uo6Co27jB6/manKlsEdCOD6Gp7K2jWUB33SAfL2FACWcXks80pAbsB1FVtUuAdqqM7q0LtQq7SeMg4HasW5yZCfw6cYoAruxKjzCCenHao1do2G316UpUjcVBz0z600qQDjgZ60AW2vARh0AHb60z95cOsVurMfpwPXNP0yxN7deU3yon3mHeuhv1i0+0ARdilvxNAFePFnFHGh2lByew965rWbv7bftLgDPGR3q/e3EkkBUsQjnPPU1lGHBG4ZHXpzQBFIpRQF7nge1QuuTtY471baMH1yfeoig4LHJ60AUpCCCvQeh70yFGUEEEHOaty4L5VSPU4qNs84AHcGgCjLEPOL9DnHWqWsQZsnUrhmGM+nvWpOPvHPv7VnXM+/chXfxxxmgDzC7JgmlWRuVHB9ahWE3tjKJSVh/X8K6fXtMDqblsKB1BGa50sXWQZ64yPpQByOpWAYsIsDYOVHpWbZsVuFxkZ4rqr1VZ2k6fwnsT9K5u4Ux3O0cKTxigDZtXycDB9Sela0DRoo8w4Yn5cHJx3rmI5yBkHla17GY3CqjDpypz+dAHWWckLfKXYehzX0/pGixR+HtH068IeW2hBQA4Ubhn8+ea+X/BNl/anirS7Uo0kTToZFHdAcmvqedbu51uad2CWYP7tFGOAMDNAGx5QSDbgYLbc+orQMaxMiDBCJxjtWbpNvKPKDEPsyxb6mtB4vMuBy3rweetAFvKInAyV5x714rrV/Jd+IL6Us0mZyBt744r2LUp0sbW4unILxISoNeOtb7HJMYwxLDPuaALkcKSoHIIJ649aKBIyALECUHvRQB4JYp5R3sQWxnjsP8AGtm2YkgZ+8M//WrAt5GbYwIJA5HrW3ZZbDE8nn6UAbVq+2IA/wAJ7d60LKRgpyecH8KyLeQCXPY8cVatnb5/LYkjueaALJuVmJB428fWmKT2Py1BLjeVwNx6n1p8XGAKALqMcAAkD2PWp0YkBic+lVohkVMvBGKALMZyePx4xVuEcjNVokI+9+VXohk59RQBahU+YAOlaQAUbVx9P/r1Ws+EJK81JMRGmTklhjPpQAsztvwMkjoB0phdmJGCQOlQliBzj8KXIHzEnigBUOVyDxTjKVOFHHHPSoNzEEHpSopLZPHfmgC8F3oCAA+eagYksQRjbxUkDbVxkfj3pJVJbPvnigBI1yuD19uKinRlZOcgn/JqaBDIwA/SluYH4DYGDkEUARN/rCqjBxwT0q1HymOPXHp7VAyoSh3HPP6VMCGUEUANbl8DpU8OfM4we+OuaQKMDNPQlRwfyoAkK5UoCM9/ag5XnqKCwK4z+Hc0zJJXbgt70AKW4xn5s5IpAfl+p9OaABnkDPWh0BG7p64OeaAEL85XjtzT417sxBPT3qNm4x/KnwsAPnGR25oAkfJGFzgelW7eEpKjcmTHHfmq9oMyHoc9q0UKxgueQvQUAULmZxNMCeNmB9azWO7gg+pPqavBmld9x6k5z2qva2z3DlU3YA5b0oAqbWyBhs4zx1/CrSabcMcnC8Z5NbVtawwEEIM9M9zU8rBV64+nFAGTpJbT7mQyEFWXGcdDUGraiLyUr83krwPUmm6pdqQViwXH8XYfSsznauec0APkkMnzOflzwAMYFV3OM7QenrUrZwATx6elMO3sceooAjLfNx+PNNYBiflGc5p7kbeOv5UhAJDEcYz1oArsCRjkimlMs2M4x3qaOJ3Jx169Knt4VjLMw3Hoc/0oAzJ4GKEE4yaouiRE7Oveta/BDkDAPcegrPZAEYkfMRxQBlXMYl3CUAjsK8/1qzazuXLDarH5cda9GuRgkc1ga1ZrdW8it9/qrehoA84LDzjzkHt6VianbEue5zkGtq4iaKV8qQ4ODmoJk3gDgnrQBg2LeXKQ3Psa07R8NhDtYelUp42im3AcjtVmzyrhyMevtQB7v+z3ZxNf6xrlyvyadbFIj6yPxj34r2Ww1XfZPLsZ4H6Z7Y69K4/4U6IND+HmnmdQ0+pE3jD0BOF/lXckIqJFAIwWwuxcAgnrQB0OkENbpKAfn+YZ9KuW7FpZGKkY4Ge+PSkiAhgACjCqMe9TRqsUG44BC5Y0Ac341kYaWsTEhp5AgXp8o5Y1wt1y4Zs/3RXS+Mr9pb2KAAhI49xz94lutcnuM90PTHHYUATpIVUZbHsaKWZ9sjDC/lRQB89aYqvvXrKBlQP5V0FvGmwFXBXHzY6rXHWUhVVc5BHIPSt4atL5BIK7m+VTjrQBq+eArBR856+1TwXTY2p8vv6isa0kLYznJ6/WtK2PzAUAaMP3snGTzVlODVZAOCTxVhG4BP40AWlY4AFWoF9arQLk5P4VehXkf5zQBajGMdzVqM/pVVM7Ru6ngc1PEcHaT9aALkUjAjBwKdK2G4bOB3qoN4OSPlFS8KfnP0oAkDY+Yn8aZv3lvQdKhf5mbJzxwKfGfl+lAEy4HU1J+BHvTY1JwQauxjIxkHH4UARxxMeSeBVmONXxj8qgZ2HC5APrQjGMgAYH1oAsIq2z7hnYB6c/hUVzcb5AEU4A4461KX39Rx7CoWU788Zx170ATyWyOqEkY6kjtVWEFJSrHjoBWrAN0AyR0qpdw4Xeo5Xg0AKeB1OOuKbk59TUUcrHj+LHBqUcAAd+SP8A69ADt2ABj0+tPA4ztAA9aFGWHPA5+nsKlJ3OEjJ98UAMRkQMSBn+lJtJH3gVxnA61ow2CbDJIcsfbp71KE2sPLiUKD2GSTQBh53dQfpVyysLi7P7iCRlHVsYH510UGlx5Mt4oeTgrEP6n+lNuS7qA7/ul4EY+VQPQCgCnHpzQY824tYcddz5P6UotIZI5CNQhbbzkKcZqGWLzWYFQFHPA6in2qOtu67eD3oAhj0tyrG3nhuB1Ow/N+VSwCOKIIvUDBP/ANar+kWyrMshXZs+Zj/dHrWXquDMzKMDOcD0NAEc+oKjsAGIHH0rNuLqSfOWx34q0REbN5JD1+VQOpNUNvX2/PNAEYXntUJHIDAliOcVOy4wWyAO4puPmPQYHB9KAK7jJ5pCMHnFWGjDdPXPNKIBn5yfXA70AVGXIyBk56etOEBCrvGMnGB1q5tCAKo2juMUIC3JAyOORQBEi4ARVAHc0oXarNjDAcknOamfGfmBHqKhuDiHnOT1oAybhTvYk5Pqe9U5cBW2nnFXZ3AySFI/nWfcNnj9KAKNy2Y+nTpWTc8sSfqK1Zjng+tZdypbgdRQByniXTfNj86LHmDrgdRXIkEZIr0mYYDIwz6e9c1q2ljLSRjB6lR2oA5mW2NyflGDitXwz4dn1zXtM0u0XL3EoVgeMKOWP5Cm2ypuUOvGa9o+BmlpbvqXiCSEtJbxNb2jEcb26/U4oA9Hm06O51CBxO6Q2sSwrGnACoOMCr+h2Im1dZkO0RZJHqx/+tVbT2uZLNpJY445JDkADk49f5V0mg27Q2u+ZQJGBJ+p/wA4oA1mQMgxwM5J/lU0oTaok+4vzNzjgetES5ChhjIyfb0rF8VXb2mmXMxbk4hiU8DJ6n3oA4LXLr7XfXM65ZpJCc5xx0FVACg+UdRgioljZsNIxA3Z69KXhicbse3GPwoAvR2/nIHyvPv0op0DbYwI0IX0ooA+Xg5YRgnA45qRJfMmLL90cKPaqd4+x1iU8nt6CrFoOQB0oA27JzkVrWpLMMfpWRZgnGOtatqSBkHFAGxChY4wc+9X0iRFUtkn0qjazscYJPH51oQbndGIIGeuKALESnbyMDPerUOT8o6noahDkoT+VWYSIojIRlj8oFAFiELuG/jHUirR2DhDuUjn1zVBXHJJAHYVYicLGXf5TjOKAJXICgHlupqIyZ54zULyFmJ6nvTgfYAUATxk5wOg71Ipwyj+H+dQL0x/k1ZVPkBU8+hoAmSTH4GrUJ3c56j0qkpXvjPTFTwkgMePagCU+rj6Ed6Td3bnsKEky2CQeM5qVArjP5/40ASQfMAR1Pr2qWWIKdyjOeR/jTIkKtwMipp3w/GcdMYoAW0ffLtAwOvp+taiwK642kGsdH2nOeev4VvWZ3wZXtxxQBz91btBKMA7TmkBwvqT2Hetu7h8wBcZ7cc1lXEIt/lVdrZ/yaADJCkHAz1PerunxAJuPc8k/wAqyvMaRznOfUCtm1+dAo6+mM0AXEbIAx1+6a1bOJUZmXAcDAP933+tUrXy1d2uGIHqoySasC6thnbFO47nIFAGiqqExxk8nPeqN26sNuOG74/So59Utol27LknOOCOKoS6pbRgHyLhh0+ZwAKAJbgxxQEkhc+pqC0Esw3keXAD/rJPlH/16kF/Gw/cQ28TDuw3n9elUJr1ri4HmyPMRwCRgKfYUAWrnUEcC2tNwiHLsRy//wBaqIBmZlfdt6VIzqrs4IJ9utDtvYBW59RxQBTu4vLbC/dHAGarkclRnB6irjhslXzweP8AHNRyx5bJGCecetAFPaN2AuTjoTShAQNxA3VbCDoqjPtTGjz9049TQBFHhEOzpjmkQcc/rVg4I+UEEHPTqKZznOMnH5fWgCEg+Yxznb6/0pVGFIAIX1pcfeC54Pp0pfM2YABx+VADduRnoPQ8VQvpgGwADt7VcnlKDcTxWLcvuY4Ix7HrQBVuJM84zn1NUJXyccZ9RVqVlGTnnvnpVJsHtx1z60AV5mHqPrVKbJYlelXLg5Py/dyM1XmGxiucEGgCjIBj7tVp4wQCODmrzrk4qNlXOGAxQBzup6WftKi0QPJI2FAHc19I6FplroegaZoStungiDSOP4pG5Yj8+tcD8LvD41PXX1C7iV7CwTJDdGkP3R7+telR23+mSXM58yVO4X8qANazjEk6IoASP0PcetbELLNcCMcqDk/T0qiqCysSwGZSCQDV/SYmhs1MgHmScnPb2oAsNKI43kb6cVwPj27lub2K0VsLEu5/Ymu2vbmG2hkuJBlIQSR6mvJ7y6kvL2WaUnzJXLN7en4UARxRLHgnnqcZ4qzC6j5go34GSe1Vm3ZPy54xxTozjGeMfzoA0RK2Pl6fXFFVQ/HJwRRQB8pzuZdXu3PRZWRR/sg4H8q1LQZPFZkq41Cb/bbeD9etaln94e1AGxacAY61o2/3io7Vm2xwvvWzaR4I4yTQBqWcYIVQdoHX3rQDjJCcDpx3qlbD5QB1q1HlMc5A6UAW1yBGg71blX94qAkBBiqdu+xt4AIHY1dJzIST15oAYhAfJHParkZCxEyco/HIquUBUuRhR1yOajE7M5KZC4wAelAFpwNoxwTTVyDziow5IJJp8Y659c/SgCwnI4+tXY8FB0NVrdOu4Hp0q0v3lAxn9aAGFcMTxk9xnmpFBAYd8UjHL4H1FSoBnPWgB6Kcds1KoIx7UwAjvRtB68+9AFhJWUjB/KnlllPofWqgOQe3FOLcZB4H60ATkEcsPzrodGila1RnU4HPPWsWwCyToZcBV6A11+nruDOoG3oOaAIlh+QE9cdh0rN1O3EjjbzjkmtyYKyANwfTGao3KBiccdse9AGB5CruwMOOueKs6dueUqSuR3PpTJ4yJG4xT4WMNuzYHPPpxQA6ebfM2ScLwP8AGn/2hDGvzOM988YrN+0eY3yjBbtThamXO4YGcfjQAlzfRMxEeW/QVAH82MsxyD29KsHScxb1wuBgCmNA0K7X6Z7UAPsBiYluSR+lOmUJdOcZJ6GktlAkPP3ePzqR325ZgMj9aAIGcq2w8heDU1sPMbcflUfxEVB5Yzlx/tZ9KniJAw3HFAFiVQUDEcn8MUySMomO465qSN2Uncc0yVsk7ucjNAECjAPoex701/l6dDUrIQAT94/nUL/ewfWgBGwxwCeKYwI4zxT25yD82OvGDmmM3B3Ek45zQAzcAeR164qvLJufHJHTFTXLAycA47elUnABJ3E0AR37kfJ1Ddfas6faiYH0q3cMWbeep5qhOCc54yOBQBQlJJ3flUTrxndn1q3IAAOOOlQsOCRjPQHFAFOROM4qrIvJLde9aMi/Ljv3qpInBoApO2McYI700I0rqqIS7kKoAzuJpzY3kdK7n4XaQJtWGq3a7rW0PyFhw0mOPyoA7LS9Gm0Lw3DpsPNyxE0p7ByOn4etb+kW0pEazspCDe+BxntzVWyvF1C4y6MXUkNxjBzWrfu9pa+TbFWnl5Ax3NAFM/8AE31NYVZhFAfmA6N+FdDcu0cDeWfmxheM4P8A9aqWi25hiLuo3n7x9T3/AMKZJfq1w7BgIos89Bx1NAHLeP8AUzY2cOn5DT3OJH4xtUdB+JrlVZSAwBJxnkf54qhrGo/2vrVxdliY3YhN3Ze1X7ZF8pSSqjHvQA8OWwcKB6NT1zg5YdegHWnIkQY/vCw9AKuRhFBCRgsBnDUAVNrE9M/QUVol5lJEa4X0BFFAHyQ6/dycsvBP8q0bPpzWeo3R/jnNaNkN7Bf4e/0oA2dPX595HHatm2bbyByazLPHy46dq1YQMigDShwwwvGKtQxuTjjHqagt0ZeXwARjrV60lCfK3UnAHrQA4wbRkk57D1qeOMhFywPGc1HFMskpjXO4dM81ONqPlTu9fSgBJw7APyyjjn1pIwKkdlCnk/QVCv1oAnUflViNSen61DD0x3/zzViHk9fzoAtW8ZQFjwSOmasOwGABgDmoyVUBucjgD1oznAPXvQA6IdSefX3qUH2w3p7VEhx+Pc1I2evNAEitwef0zTi+M4HNRKCxGzknj8atx2jMuZHwPbrQBX3Y57/yoTLuOpB9O9aS20DJ1H4H9afaC1iLRocnP3iM0AV0R1VXYBR0rptGvo3tspuAyQMjrWFqC7oiI5M45wB1/Gr2hL5drGG469aAOitgSpZ+SeR71BfrsUFc9ecGr0QKxLwBkdKguh5hVOCD6UAZN5Bti98Hn2rn7m8SXdGjZCHBHqa6+4tzcQkEkYHFcjq+neR5ckWNw+/j9KAC0j/eCR84NbVuBuxwfXvWDFO6qDwT7jgVat750OGwR7UAdCEwcAEjt2qrfRqU5wMDjtzRBP5ihhnkZ61OY/OA38gUAZ0Cx28XmSsCSCcY61ULM7F5CBnjA/pW1fQI8YUKMjpgVjsuDgjnOCcdDQAwjKk4470qEhjntwKAMZxjPfPagN7Y5xzQA48KDgFjxyOlOib5hu5Hv601mBPJGBx0ppY4wuM+poAtZ+bJOR61GyDzCTkd+BTYXyoPyk+npUjMAnP8XOaAKLNyee5qGR9zYHSrBjMpI4Vc04wx9E5xQBRf97Koz0H4VXlfjbt9TxV90IZhtAPcVRvGH8IAI70AVZym/AbtVScgsT0HT61JISFw2CR6VXb34oAhkGRUYUKwJqcg0wg7snsMcmgCtIuQfbrVRzt5IyPStJxlcY9qpOoGQelAFe1sJb6+itrZQ80zBEH9TXuVrZW2l6bBpUDIpt1DH/afuxrmfh/4fWCxOrXKHz5QRbqeyj+L8a6Gx017rUFnaQjH+uJ5JH+NAGtZQR2cUl1cYBHzA4wT/wDrqvZobu4N7ISGfhAf4RUl9Kbq4W3jH+jRf6w4/IVpWiIqB2AXBwBjpQBLK4ggA+6xGPpXCfEfWU0/S/7OteLi6Gx2HZOuPxrrtQAAlmuJdltAm9n9BXiXiPUJNW1ea9b7o4jUj7qDgCgCjbb1bJBIDYHvXS6aN0RVjkA7h61h2wYSqMkqfT0rotNR2mU9VPHTFAF2JVGPlBJ7gcVcQDaGI4HGKIUUxtwBjnIqdofkAJAXtj1oAUrjHQZGelFSpGrKNwxjjgZooA+O7blQB3GK2rOLykVV/wBYT8x9fasvT0wPMI9lNbdmN77ScZoA0LJQNnc+lasOAeCfxqtb2gCgqxz6VKhw5HYdaANOOQnLOcqBViJ2dkYjrVGORdmCcr6etWomVmUrxgcD0oAntpfLkJYZbtir8L7irKQE71TXaYxsQBz1FLIPLbaO/J+tAFieTe/Bp6AsQF+96VVXPI79T7VZicq4YdR60AWoVYsARzVpVKt0/CoEX5C6thyMEVNbs+wsevegCdS6ng/P29qkiBAx1PWoA5Llh1P6VLuXHIoAsxhTwxwKlDwr2LVUX/a6Z/WnDp1oAtNcnHyKFPqaryTSNnexPcD0qMk98+3NOBzyRzQA+Fyjbge1SbykiyE8HnFQMSRg9KhmlG3bmgDXjv0dCChUjp710OjOrxxMpI3DPSuHgc4PJAPeu08KAm2tyc5ANAHUrwuOcVE4AcEZqUAjnNR3DFUz05xQAkrr5Lg8Ajk1zupyIY3YHqNvy9qs61P5dnIVPzEYArChdg3B4I5oAr98AfhjpT40Ykc/hV1SrnJ7dzUyouO35c0ALab4mBPRuvtWqsuYxjJLfnWeSdvBz9Kbbz4bDHvxQBqY3Dd2FZl0h8yRh0PzHjvWjC2U5GOc4pqMrO+SoYGgDH2sUViTz0GKRVJJz261qXKBMsDyTyBVFpBuY89eKAItrcc8+mKRYi7FcgfhTZJW3cdKaZ3HJYfjQBMYBDnnr3FRNcbQR1FRPLvyOSfrUKDex3nGOeaAJxJ94jiPFQxzsX2g8HpimvIwkA7Hj8PSo1fZNkHr+tAFm5lVySevvWc8gZyDyDxxUt3L5jcdutVWIjiLdyegoApyDbIVboPSoSPmIzzUshJb5uvWmAAUAMIPbH06Uw9dvX/PWpQMnmmbM8Lz3x60AMYYz6dTWj4X0R9X1AqQRDEN8r47dh9TUVrbSzzpFEu6ZzhQPWvQ9NFvoukLaQkm4LbpnHVmoAnuZbuQQQ28GAmEVR0Kitp8W8SwQACZhlj/AFNR2ESQx+c4LPIOncUxo2Em7aDLIRu5/T6CgCa3tgxCRswQfMzDqf8A69WZJiiA7e2AMd6ijKx/ukb5x8zbR29ap61rFvpllLdPhhEcBf7zdqAOR+IesyJDDpoOyR03yx54UZ4B9/avPQpJAOcHjParV7dS315NcXLlppjuY/4UyJTyxz04GKAL1vEECkZzjGe1bFlKY/lBJY4qkkQFuhIA7Z68+1TWpZyRkgjqAMUAdHbKQV5G0jJA/rVqaMCMLxv64FULefDKeccDGOo9a2L6HMkTQ4ZQvIY4P0oAqw4KchmxxnpRV2O3KoN8hUnnAAOKKAPjxotoiYE7SMnHQVp6cNsyE+vesxZV8uNRzuxgVpWu4EH0oA37R8yMRTHf942OmeapRzFT8vfip4m3MSe9AF2PGAV655q1Gec56c8VWiOD0yKvogMe4DHagCxDdSBfup9SKcGLNk8nrk1AilTk9KnQjsKAJkyTnp35qdOvJBNV04PPQVYUg4wKALER+bC8D1q2HLDGMAcECqkSnjjgVMG5wOpPNAFoA57ZPNTJ93JAHGaqI2GH5VIWxmgCVGyAGPenMW4xUCMc4JOKfk9qAJs569aCcdahyetKGzwaAH7yzYHSoJI3MvH3asgAfWnYz2/CgBYEAVfWu08MEG2g29ADxXGr0wD+NdX4PJKED+EnFAHV5YZ9KrXZPkk+nNT5OPrUVwP3TDvigDldYl/dBG6luP8ACs6F2Un0q5q4zcJ3HOBVbaNgz+negB+/pjaPapYp3HU5+nFV0B7cn6cVIFGc4+lAGhG2/uabLGfvBeTxgVXjZl5Q/mKtJOOjfeNABGJf4SV+tSx+Zg8n5ailn5Gw5FPjuQq7PT1oAekhdir4GelQXcZAO3uOtDBnOVp8ro0YLMAe3NAFDHHPWoZMg1NMSjEkdehFVmbPB6igBu7A4579aZ5hU4B/Ckc5OeeTzx0qAt60AWmlVsDG33NMlkjAPI3Y7VAxz1qFzz2oAfglRgk+metMuB8gHoaBIQc1FI7OecUAV8E/nSEZPH5e1PIz0yPrRtLcYx29c0ANCk8AfrUoTbyMYHU0qoRgLz710XhbR/t07XFyD9hg5I7SN2FAGp4R0sWdnJqM4Q3EgKxIx+6vc/U1vQ2yPKLl1GAeFA71VNr51yJQw8rbgL2I9PbFaKfuuGUAAbVB7fX3oAfIWiyzEs3oO3tTkcRwmWTczMcBc9T6Use1ssxAUd/WoYYzNcC4dz5SfLGpGBj196ALSR+XGxIVZHOXft/+qvL/ABlqyalftb2mRZW7EA95G7tXSeOdVls7d7WN9lzMvCg48tPU+59K89jT5ARnHOTQBEseXHGTjmr9tFlMDkgcDuaaseF5AyOtTWWRdR7uVzzQBbKAbcjJ7ZOMU+3RROPmJBwSAaahJJLHgdqsowCEg4OMYAoA0bRd90m4HJPOD2rTmlJm5J6jI4zVDSVZnkkOSVXr71aixu+fPPtQBDcXSLJgtg+5oqrcMrzMQike60UAfJloMPkHBHIrbhmyAexGa563JJB3YrVgkAjXH0oA1IX3Gr8XJyO3asy2rTtVywLc0AaEClwOKvDgBT0Haq8bbRgdKkj/AFoAtFvlAxxVqADAP/6qpJnIq2jYUUATZyd2Bt61YiXoarRLk5xVxODQBOvJIPUU1uDmgdc9M0kpwAcg0AS7xwaRpCx47c1WZ8Ckt3IYkjNAGgD8oqRDnvVeNs49qmTA6nFAEw7UoTJBGMU0U5V3HNADmbFIJgPQ/T1okBxVVgQ2aANBJA5GDjqa7DwWubaRwDgNt+lcHC5z/jXf+En2aPER8xLFm7c5oA6U4xj0qOfGw9Mgd6A+4dh9KGOOv40Achqw/wBJQADoRnPFVmYbcc9ulW9aX98Gxyc1n5wD6+lAEq5BP+cU48nH51HjDYz7Zp5YcjHWgCXjaM88ZpAfQZFRb+fxpd/B5A+poAlzg+mKGk8wDA4/lVC4vFXgAfX0qhcXzE8t19DQB0Mcw2jMig+xpxMMkRwwDHqSa5RL3YSTyB29asLeYTKEsp4OeRQBt5Vco2Sp6E+tVpQQ53DB/nVOC8wMN93pg/zq55omjIVt2BkE0AVpCTwKj6danAGcU2RMDOcfhQBXd6hLcUSZye1RYC/xZP6UAO3fKTzUZ557UF+ORipIkyNxoARYy3OTQTluOO3NTAc4I69BU1razXd0kEAzK/GcdB6n6UAWdE0+TU7kwISsS/NK+M7V/wAa7KMSQrFawIFs14B6ZNRaSkVhB/Z8RYuTmSQDv9a1oQIolBGGHbOfw+tAD4SFRVfCk+nQVIULjamF9fYe5qDymHK5DE8H0qNrk7mgRWGCAxx19hQArGSWcQw7VgU46ZJx/SjVdVj060lfbuWLjnozdlFWy8VpCWZlVf4jXnXiLU21a9YqCtqhKxIP5/WgDLv55765e4nYmRzkiq8S7ck9ulWUQqeR7YxTSuCT3Hb+dADSCOcj2ojJDK4OCKcgJ6HGOlPhQ5w+Pz6UAXLVQ6lmZVJPy54zV+KFQpXaS56E1UiG0Dcu5j0ya0bEMr4ViQOCM5FAF+JfLtgu7LOeTn9ajYssWWAGCcHNErgylDkdPu9KrahIAFQcYGSD2NAEJ4JH9KKrSyHedhfHsetFAHyo0AjUGN8+x/lVuwJZjjnFUUkDqS/GBgGtTSYRxtJPpQBrWiNtycDvzWrbfd96phSFXdwxOTV23xxigC2gbHIOPWrEZ5xUMfU+mKmjNAFqPpU8Y3MBUEfQbeTVqL5TnOSf0oAtIcDp061KrZPSqyPyNwzUytigCwee+KYYz68/0ppfA5/KmmTucZoAcQMYpyL7VGGzz2qaMkHnr70AWIwB3qbPtmoI5M8Lwe9SCTb6D60AWF75AGRipoHCsM7dvvVMTL9cUNcqT1NAGtcFXXglRnjA/WsuUhWPTHTpTVuF6B8U1iuSQwGeR3oAlQByNoJauw8JTE2wjOcqW4PpXFxyIpG18Hsfxro/DFx/pbpkHjdkc0AdzG4zjHPtSvnGPXp71Wjb5eOVx6093J3cgke9AGLrQyM4OVOcYrHz78DtWt4jmEenyvycDOM9a4SXWpdvyfKD0oA6TzOcmkMyjgsBiuOm1fGTI5P41VbXGx+6OMDigDuHuVQc8DvmqE+oBiR27Vyv9pu7EO5J9zTxdq3VqANae665NUHuNy4Ld6rzTZTPes6acA9aANbz8nGePapVuGRh8wH0rEjuh2yp9alW5B+WgDbkvWkG0kYHNW9NvWSTGcg9fpXOxy/Nx0q9bP8AOKAOuBBUMpyvrQHDA4PSs2ymwNjYC9smrDIzck4HagBJ1GSRz9KgI3HAAqdVGcFsD+dPeFe2VoArKgB5wx7mplIzx0ppXHGc05FbcFCls9AOpoAmiikmZUjUsxOFArtNDsorG38v5WvZx87eg9Kh0HTvsNus7ENdyjAA5CD0rXht0gUyLjeTkmgCSOJI0RicsD2FMCSK5c8EdB2X/GiOQs+GA47j0qdySmxcH3PagBvnKxaNZOnXjrU8UQwrFQ3Hy44x9arQ24ZiwB45Oe/vWb4g1E2sf2eNh9oYc8/dHqaAM/xReiaZrS1bcmczSZ+8f7o9AK5zywDggDI5zxVnOV29F61ERxjk/WgCIJkYz09DUciYH4VYHU5HWmSDrnJJ60AVQrZ/kBU6qMYbPPpyDTRxwOo79aC5BwMDtnNAGgo3hSOXPymtS0UKCTzisjT2CuGYAqTjFaj5T7vPuPSgCcxpkFn/ABrPnTfIWDjB9P61dk+WE9Mjj86zjkvtPC9eO9ACxRxFMuwLGim8/wAJAHvRQB8pJyFZlGegXt9a29MBGxi+cHoO1YMchmmZUAHoBWvpzAZBGAQDx1oA6JHDYLKdx4qWH5G4/CmRRnyI2kYDP3RUoGHPp2oAsq+MDtip4zlh6VTU5NTI5BAUZNAGjAcE56DrVoMTxnNUkIGBnOB+dWo8YznAoAnTnrUquACzdBVQ3EYbAPIqGW9BOFACj3oAvGQk5J/WnqQ3cnFZsdzuPQYq6JMRErwT2oAtpwBnAFOEwXgAH3NZbXB6E80huDjBNAGkZzng4pDce9Zpnppn/D6UAafnZ74pGnwODzWWbkeoFIJs8tQBoic7gSead9oI6Histpx9KcJjigC+8m45zWt4YuzHqsR34O0jA6GueVt4UD1xVvSW261AR05FAHr1vc+YoyAB2FTNIQCR1HQVmWR4B9elWZ5So4PWgDP8Qtus506ZQ/yrxu+1YopC8tn16V6xq0reUyH9fevn/UZWS6mjOdwdgfzoA0n1B9xPGDz1oF6WHJrn/POalWb3oA3hfFQcHFOi1NyQQxVa503BLEE8VKk/OSaAO1t71Zoxk5YVTuWw59DyKx7K62ODn61fuJC6ZHXqKAASkng0+O6ywANZs0uz7vWmpJg5XrQB0ttOSQB1ratmG0EdRzXI21yVK5YdPxq/Z3snngAkj+dAHXRNldwOcCtG1mMoKvwcZHuKw7K7SH5flJbsa07SUoVY9uo7UAaIYrn1xinZbYeu4UNtAAXqeRSAnjgnPagBflIAUEnvXU6PpBtYxLcoXunHyI3SMf41Fo+jG1QXF0pNy4yqEcIPf3roYxjcDln6kY/zxQAW8ZhLEnzXbGSeP8ilMu5jGh3E9/XHakdxITHGDnOCf6UgiWJcKDz1buaAJigVcr1PH41HGGDkg/KOtJA7OxDAAD+PP8qS+vYbOBmlIYH5Qo/iNADNW1VbCBGTmR/ug/zIrkJWeQs8rZdjks3VjU1xO91M0tz8znvjhR2A9qimiYngr06d6AIR833c89Md6MdO1BGM80zvjGCO1ACjrgVHJ9TSbiGpGySeOnJoAaD2/SmoCzBRyenP9aXOO+KkhTAyVDM3agCzAoCnqOOtXrWXcq7wMgkZBrNdzjA6dz/ntVm1cMcH9KALcjkqADklsn6VBg7z19qXcGmfZ0FCv83J5AyeKABVVVA6kUUqAOoLAk9OtFAHyRoynzwW7KcmteKQCbEYHXFUrYDymkUfPIAAK0oISJdynA7igDdJY4YEMVUcelIshLDk+9RNMIYox1kIxREwz0oA0UPFWrZRu3H8KoRtuO0daumUQw89aAJ3mWH73J7Y7VXkvGJ+9ke1Zk9yzE4PWq73AjUknJ7UAaj3Yzjo3r7VGs+TgVkfaQRyfmJ5qaKYDqaAN22f5hzxV0y4PDZrn0usDA61Kt8QMMP1oA22YMPeq7ybTg1UivFIHOPapHlSUYU/NQBIZ8dTUMlx71UknKEgjFVZZ8mgC+bjn5jz2qRbknqfyrMQsepNSIxoA00mOeTzUyS96z436g9jj61PG3PtQBqWkwjlBf7v8q3/AA9bM+sRMqkryR3B/wAK5XOYmJ4GOa63wNqKeYYptom6An09aAPSoo1SNSMk4qG5bqDxipYXBXk/Lnmo70qI8cYFAHPaqxKEjsOvrXhPi/8AdeILrAC7jkY4r3HUwcHCnH1614x41spJNd8yThJF4+o60Aczv7nOaUynHHWrot4ol45IqrIgc9AB7UANWTH3qeJh2NQfZ+flNIYnXoM0AaUMvIrTS63RgZ6VzazY46GrdrNtOG5zQBoSvk8E/jSRSBep/wDrVDLIoXNVWm3nHb2oA01nDA4yQDgmrtjeGJtoPB6Z6j61hJKF6cn0qSOfkjnB60AdzDKTsdSckc10+n3CFQjc4HFcJol5ttyjtkjpXTadK0gQINzN8oA7n2oA69GzEh53Yxx6+ldToekfZilzdY84YIQ87f8A69M8NaO1nElxeopnHKrnOw/410SgFvMc8E5oAeq5O8jJPfd+VRzNuXZDnBOSe4pJGY7cAbBQG8oZyQT0HegBV2wxE4I9SRToyJlDSAqmOBSBM7mY9Dnr/P3qO5l8iIyzN5cCjn/a9gKAJL+aKC0Ms/yxL0A6v7D0rjry7e9ujNINvHyqvRB6fX3p+pXkl3KJJPuD7qE9B61UBYjBP14/KgCXecY7HoKA20dTwelRFvz6Y9qcDxnv2PbFADnbdnOB9KjJwf8A6+aXb6dKQ/r70ARN19qaCcYbkg5NK/Jxj86WNc/Menp60AJGpPJbAB496euSwOfm9SKJCPy/QelR+ZjgnJoAf5i5xjp2q1AfklYYz2571QLgHCkt61cQjaijn1J70ATRcMmOw/WrMaAOd2cEcYqvbjc69R/UVcXBCc5PSgCDbyc8f7vSip2XLHkD6nFFAHyXZCVVJxkk5UVpi4ERDO0YwMnnBzVW2YfZ2IPzIu7P9K5yS5Msrsxzk9+1AHT/ANoI0uck+571egvkJC5+WuOiuDnHWrsMxDcGgDu7Nlc7kbNQ3lwWJ6gDjFYlvetFCSpwcdaYuqCU7Zjj3oAvPJ681SuLgs+M8DinTSbU3g5HbHSs4sc8mgCyshz1qykvuazlfarMT04pqTSSv97atAGusuT1qTfjq1ZqEkgLx7mpvLcDJOTQBfSbB4P41cguH7Hb79zWVC2ABjFW4iSQOp7UAaxjE6ZB+cVUdc4wKsWrbGAzkHr6VNPDvwycfSgCoE4GRx7VKkeeaWIdasItADFWpQMD+VIR6U4E96ALEY3gj1FSW7vbTLJGcFTk/Sm2zbWU4yAeat3UITeev0oA9M0i9MtojhtwIzn1qy0xfOTXGeDrqQWskLOSFPygnoK6lHO0EHr7UAJcoGXJ6ZrzH4gQ7Y43XqsnX616VPMCDgH3zXB+PIt+myuOSq5x9DQB5tM2FxnrVYkjsTUsi7wpP1xSoMDg/nQA2JS3XilaItwh5qZDzzTtqjn5hQBnyW5X7459qhZ/JBJwcdMVpTOu3B5J9KyriJozz0NAEguN4qJ5eeOKhGQSRSlt3OKALcL7sZ61YRwD1NUImwQOxq9YQTX91HbWcTzTydEUdvU+goA3PDxeW5FtCjSyTHCqByx9q908CeHF0aL7VqUYa+Yfu16+WO+B/Ws34feELXw7Ypcz5n1ydeCRxEvoB2/nXc2am1OblmkmIyB1z/8AWoAvwJ5YMkvLMPlXOSalGWw0oG8dFB4FQfLAPOkO+Vui+n0pYt8reY/yg9BQA8Mx4Vfn9c8CnKqxqxYknOQT1pkjqi84BFRtKsUJnnZfLHTHc0APlmEcTyzHbEnI/wBo1zWqX8l66s3yoPur2FGoX0l9Lz8sQ+5Hnge596pS8KMk5xnFACPkksxyf5Cg4A6//XqOM5wSeP5U5s4yOecUAIvJP9aeMHkelNZMH5Tn6UBfegB5PoaZnn+VITt6nNH3+lADWG446d+tOyFXHTHfPFOA28A/pTZDigBHZduVyw69P1qFQcZPUjPSpFXdz/Dnk9jQRnqTkdTjtQA0R4wG71bjBIzjLZ7cU2LGwc4HtUquozyd2McUATRKySxliMHt6fWrbLvYjoPXt+FUomORnO4dDUwfzMj7xUenSgC0sW/kMMDjrmipEhkVcZaigD49lf7Pp8ztn5vl+tc0XwT6Z4rZvpGltyXPbgVz0jZOaALsMgz1rQgf5gc1iRt+dXopMHHpQBttNiFgD15rPecg5zzSLLlG57VnvL8xJ6UAa1vqJEixk5FaDfMu5elciJv3ma3dOvN8Wwn60AX5VzajHZs0tsueKltwHjKt36UkClXI9OKALsA28Yq0oGPeq8ZqZT81ACsMHOKmiICn+939qYRkZqZT8ooAtRthuDxV+2mA4POazE6gHrV23wCOaALske3BOBmo3fCkAVYMZMW5apy5zgfjQAxZCO+DU8UxIwwDe9QDHbrSMTu64oA1IHjJG3r6VslPMj55BHX1rlklwwUHmur0VhNZKrdUBoATQbj7NrEcB6SKQR6mu2DAR5PPGcV5pPKbfWIpjxsbnHpXokMiyxIwPBGQaAHSHeoY9a5zxDCJbdw2CO/0roGyOB1FUL+JZImQ8Eg9+DQB4hcAxzSR942KmmDJHNa3ie2a11beR8sqhvYkcGs1Rkg+v6UAOjBqzlAvzAk0yNMYxyTSOCetADlAHYUk8SMnzLnNEeB0GfrxSM5LBR0oAoS2QVsxg89qptGYiwbtW8OQec++Ks6B4XuvEuqRw2zJBbgEzXMh+VFHUj1NAHO6Ppt5rF8lnYR75XwMn7qD1avoLwv4StvDVgsOlyGa/kAa4uiMMWHTB7IPQdan8NeHItDC22kQ+VYLyzlR5l0x6yux5AHYV2UaLsPkENu5Z2HH1oAZp6hQPN3PcN8xLdSfX2HtU11cfZCHEZmnfovYfWqc0gtpD5YfLH6sTVy2IXaZWVpMZ45x/wDXoAl02GQAy3k3mXD/ADcjAUegHYVYmlJysXXvVSaXZhc/u88+9LcXdtZWglupMMfuxDhm+lAErzwW0LT3RwPQDkn0rnb7UWvpd8g8uNRhIx0Wor6+kvn82U8D7qDolVQfU880ASlwPQtjPAqNmbcT0J7elB4HWgtg/jj60AAGMr+h7VIp8vafvEUz+LnrTiRnnIoAeXJH51H298Uufcc0lADRkjGcU9eOKdgADpnvTTxQA5j8vb8TUJ5YDoO9K5zxTX4AIPvQBIpyp7Y6D0pC21ffFNVgAchvbikHzEluD0FAEsJI6DPr71Mil3G1gG75HWo4QV+XjPSpApHGBnHBBoAtxrtIDoCffnFSKW398d/eqiSg/LjI/WrsZ/hBGcd+PxoAuTEjYF3AbR92ioWMWfmYE+uetFAHxlMMxVz7Dlq6B+YSewrm5ZQWOKAHKcNVhH5PvVJWzUsb80AX1c4P0qjcMcH34qdWqtd8MB+NAEKtV/TJ9kwU9G/nWbmnRuUdSOxzQB3to25c9x1qdRz9ay9LuA6Rtn5WHNa+MNjuKAJozgc1KATjb+NVS2GxVyA5XA645oAl7U6M4PtUZbilB+UYoAnV/nGO1XIGGQTVCIEHJGatxgnGARn1oA6C0dZbUhOSDVO5QLwOlSafiK3Knqx6etNuj3J6UAURkNQ5P41KwGOOtQnIPNABHnOe9dNo0my3469652JcjPetewk2xkjpQBavoxM4lX8fY10vhy7EtmEdsshx71ytnKVnyR8vcN3FbGnsIL/ER4kGV9KAOpk+ZemCOnHWqVwgz3/GrK7iQTkH605ow2QwoA8/8bacstg0mNxicOD6ZrhkVgSOp9DXr+u2pa0lQLw6Ffxryz7O+/BHzZxQAyJCvQjJ9aSQZ7596nNu+cE4+tT+QpQY5NAGeykjgdKFQbSxwMVdeJQhUcHp9T6V3ng/wIzpHqOuQB4yM29n/ex/E/t7UAYvgnwc+uM1zeN9n02HBb/npMT0UDtmvXND05ILdYprWO1sw222to0ALKO7+vNbOm2w8hHeGNNoyI1UKqn1qW4CRq84YAKuXdjgY9fpQAk1ms8e11ZUJzgHBP19vaoI1ZCUlby4ewHekh1WGeAyAkQr/E3G4ev/ANasLxBqTTRFoPkYHgHqR2oA3LiaMJIquF2j7+OQPQVmWt83nvCvy4AxxkkH0rI0Oe51Bx5j75S2E2r1A7Yq3rOr2+iI6Ltl1Rz8oXgRD3P9KANjVtSg0WFZZ3WW4Zf3UCHOfc+griri/mvbhp7h8uTnHYVjNcvPK0srl3Y8k/56VYikB60AbdpKC2M4HrWgcY+UcY4J71gW8gyMdK2LKTzAVPJHSgCbpxgjjnNJn+VKRg8cAenemtkcmgADYFLuqI5/CngHI9KAJVJ/+vTgPXpTFx6cdj61IPX26elAC5wDwDnuajY8cc04kDjNR9ev5YoAUccGomyTxjHqTTnPpUTEDnjPvzQA4HPBJP1NIJBnr0qME4bbTFY5IJH4CgC7FKZFC9MdD6VMkxRQWBPbms4yEdCD6YHWrdsyzICykc96AL8Qhba3lNu6k54q3HCiqxyctyQx5x6VXhQ4UcdSDVssBy6dOwHJoAesabRz/WikVyB1UfhRQB8W3kmyx2j7xNc0/wB5vrW9qTZjC+1YDfeNACg1Ijc1CKep5oAuRnpUN0cuTTg3y5qOTlaAIu1IOtFFAGzotxtHlMflzx7V19tKJoQR94cGvP7Viso5rrdFud3AOGHr3oA2UTIyetSr8gB/CpoUDqCvQ097Zm5GcelAEXXj0p6D8qUW+Bktg+lG0xhmyOnQUAXFdFVematRMCQw9MfWsuFGfaeBWgRtTC/e9aAL0chA5/GmTSrgAn61XL5Y5JH0pVUk89DQBJzs5PNKccA855qORVA3DrU9qhddx78CgBVGMYq9YjrnpUSpx0z2OKmjBXIBoASR9r/LV6K5IWNs4ZDlcVR27j/L3qePJQqpwwoA7yzkMkW7pkD8anbAIx3rH0C532SK3JT5a0TJ04wc9PagB84UqQy7j6V59qNisV5OFHAYn8DXeyzqvzNt25/OuO1uSRLtpPUbfxH/ANagDHZFGMrubsKSCBri4SGCMtPIcIi9Sas2Fne6xqKWtgokk6sTwqD1Jr1LwroFpoyYU/abrrJcsO/+yOwoAoeF/CFvpbJcalDFPfthgD9yEf1au8jSIR7mUKmMA5/lVeYRopYpuf7ypnqfUn0rNGqBLkQzSLJcum9UxgAeuOw9KALl/qMdph5iCh+6vY/Wqsl4L2BbqVgtpj5VxktRcRxzR+ZfYbHQHvXHXOq3Kak0bKVifOx+30+tAD9auZ47+OeNsRKPlg7KO59zWtpZe8QBf3rAZI28qaS2hjurfdL+7jH35GHyovck9q4/xH4tMglsNAnkisfuNcL8plA9O+KANfxJ4ig00fYNEffd5PnzpjajHsp7kVypmYk73Z3JyWY5LH1PrWfbhYkBYc+lOMuenSgC+su08Vbjl6c1jCXkYq7BJn6UAbdvJ7mtaxl2uDn61zsEnzcVrWkmTjOD+tAHRZGCeMdaGHGScD86r2cvmREen6VPg9D0oAYvJPcU7jd0GMUYxTWNAC5wfT3/APrUvmDFQk//AFvU00578UAWA3zDoMDFIThe2fc9ajUkZOM54pWOAeT/AFoAax5Odv49Kgc8/jT2bnHSopCDQA4sByePxqDfjjp+lOJ46Co24PTrQBLEGdgqGtGwX7zAfL90e9UITjhiS2MYA4+taVmpWPdkcnqPSgC/E2CAeew5p9zMyQgltu3kY/rVbcI1zxgDpVOa43cMdyntQBae/Ysdzn2x6UVntMkZ2nk/XFFAHyTqHLN7DFYjrya3rxPmPvzWRImMg+uaAKopwpSuKQCgCUH5aAflI9aTHy0LQA1hgU0DPSrPlqy8nApWWFF+XJNADII8kc4rc06RIXDO2cdvWsONi5+lXIm5FAHdWV6I1VkGUb1rRS4Mi7lbHtXJ6ZPmNkJzjpWjFcFScHFAHQhfMXDjDetROvOwrg/zqvbXw2YbmrqOkq8n6etACIAMcY+lTozb857d6jww7cUoZuuOc4oAmySB6k44qaKMnG8H6VDDy2Per8K9Mgk0AReWCenHpVuGPCihYvvZ45zmrKbepNAEeCNvXr2pQCPT8OlWgMgZpskeF4oArBtrH+dW7NMuD271U2HzGXHBOa0rNSuCeBQBpaXJslKjjdW04MpQhcA+1c1HKIp42/hLV0MDMpibdw3X2oAsmEMjcAZH1qnL4ek1dGXf5MKkFpgMn6D3rprCx81Q9xlIj0Xuf/rVuwwokYRUCxg42jt7UAZOhabZabaCKyg8tMY3nln9c1YnO3iMbQOABwPp9KjvJfLfOC2eynn6D+pqIBrpMTZEZ/h/vUAOhvvtDSLAxJ7u/H+R/OoruCG3jaZiMAbi5GWJ9qbfTJYwtNKyBBjOe57A+tZ0eorqbsjAAcBV7UARQav9skKTp5aLxtzkgds03VorG1tZNQ1CZIrWFd2G48xuyj3PtVbWJrPw7b/bb3ZLcynEMGeWHqR6V5f4o1298Q34mvnwif6uFeEjHsPX3oAv+IvFd7roW1jLWumIcrbLxvPq3r9KpQHIHt0qlbRM2S33R61bRgowKALLS4FM38+1RM272qPd8uPxoAt7/wA6s28u1c+nSs1H96sRuVYUAbltIMcn9a07aXGBXP28m0jAJb61r2h3YJ/DigDpdMk+celaW8DjP6ZzWJprAOOa0y1AErvjJPWmO1Qsx70hPBoAeH5JzyO/pSlh6cfzqAcEg9utOyRjPc0ASbhnnmgvxyah3Z9qTdg0AOOQfr0FMNOzuGCPxpp7A0AJSBN3J6/WngfKePenhc4PFACRdNpGfatOI+VAOmR/OqsCAOWb7oPT39KbPcElmz9PSgCWWUkHcfqBWfLISSDgkdqcJMls9/0qJuZASdueM0AHmOc5UE/7XWionfB4UN70UAfNckYkyO4PFUbu1PLAcDrWknDqRV82omgKxkAsOTQBxc0ZXtxUQHNbN7ZyRKQ6bgD1xWVKu3oMA9vSgBpPFNHWkc8j6UDrQBNnK4qBs5qUU1kbPAJ+lAD7fvVqPrUMMMh+7G35VoQWNw5GE2/U0ATWMuyQVqlsMeagtdJkJDMy/wDAatz24j+8R+NAEYuCp4NXra8PGayz5YPUUxrhV+62KAOrt71o+eoq9BcxTdMA1w8V627G8kVrWc+0gg8mgDrrSAKSRk59a1IF+SsCwvSdozxW/burqCvSgBw37gAKtxRs2MYBpEdQetTJMo6UACxncoAJ5qVISxHHPoaUNuGQTk09GwMZIoAiktuAQMHtSBJV3IDxj0q1I7MAQ2DnrVnT0e5ulhjQySsenp7n2oAzIIwLhBtJZjgAckn2Feg6FpXlqhvxunPzCIHhB2JPrSaFpNtaSltqz3X8chHyp7LXQ5SIkAAs3T1JoAlVQuPlC4GOOmKjZ2dsRgbR3HfFMQs5ycBB6HkipSdq4UZFAFWWNSxf779ee9ULu8jsxulbBPcnkn0Aq5dyiFS7cfSsm8sW1IxszBQASdx2hR65oAqzZ1dMKVbn5Rjv9KxdY1e18LMtvaRQ3GpkFmUtlImPr7+1UfEXilbEy2Wg7WJG1r3q3H93/GuDwxySSxY5ZicknuaAH6neT3l5Jc3c7T3MnLO3X6D29qpwxbm3OMDrz3qxtUMDjmkJ5JHX6/yoAeOOnSjPPU/nUbHvSqc0APzSE0vam0AOUjP3cfjU6nDACquavacglnEbAc96ANC0XIBA+vvWzaIcggYPrUWnWO4jjA6V0kVvFbRqAoLDq2eBQBHZQk4ZunrV48nNVTdRhsbxjuB0qZZFcfu3Un0oAActg5pT79O9NPB9T7GkDdeaAFJ5H1pWNMzzTuvNACDrTX6nHP8AX3p/XihlwOOtAEan0GD0JzTzz6fT1pFTdz0qdEUdaAGAjHXtxU0IA2k9O9QvjPHSlSUb1HTB60AWJ32xAKMA/rVQjLHbz2NWJACvPPp70mFXvyepNAFXYS+B3wPp71IU6Hpjjk4zTSSGO3gdR6moXlzywy3fNAD9qDjzPyFFUTOVJGM89TRQB88qv3fyrVsiFAHrxzWan3foau2zfpyKAG3oxxwR71z2o2gdWKDB68V0d2uCCelZ8wVulAHIt97ntxSirOoQGKUnsTVZRQBIKkDlQNtRoNxwKsFMKKAHC6mGMOR9Ksx3twP+WhxVTA9KcqksMUAatvezk8u2PrSzzk8bjVVP3aHPWomcnvQBIZDTGfPWoiTSZoAmjba2a2LK4HANYic1bgfaRQB2FlKOMdK3rW8EYAQ5HvXG2k7xxqcjmtaznaXqMe9AHY28okXOeasqRXPWtztTCtk9auRX4cAEkH1FAG/HLtXBpEJ3ZLZ9qykuWXjk++K2tC0+fVZGYloLFMeZPjOfQIO5/lQBa063n1C48mAYAG53boi+p9/avQdAsbe1g2WqsePmmYYLnvil0mxtobQRwQmC3HZ/vOB3NE939sZ4IdyWycPID972FAFxp1GI4VyBwWA4pyRnzNz5bjnB/wA4qtGgVVAwMLwemRVqB9wUADA6DHWgCYHGAo54GP8APapAwHXkk4HPWgYTgZOTye9Vrh0tVLzk/McqgOCTQAy+ijEUs1xJsiUZJJ4Fea+Jdflv4WtLQeTZdCFBDS/7x9K7TUrhr2Jt/wAqFSFQdBXll5lZZE5OCRQBmsgDNjBFRuAV5yKnc8VDIR3oArnpTelDZzxSEGgBG5pAcUGkGSemaAH7qCSelKiZ7GlK47CgBucA5/OtPSxg7z1bgCqMMJmOAPlFakJWBQW/CgDoba9EIwSCBjNQ3+rvcSFR8sfovAPua5y4umdcKfrUaS5PXigDoYrz5h14rSguT64+lcvBIcjnNasMnyigDqLe5VwAxyanA7/pWDbyAY53e2K2rSTzFHt0JoAlK4/Gl6cVIq9c9aNvrQBFTpGCpk07A6+1MljLKq/j+FACQuGYmpqjEYX7oAqXggEYx9aAIZCFjYnj9aoNJyece1W7v7mBwx5rOdicAdaAJ1uiODnHvVpZgwwSAfc5rLAznJyfSpIm28ZyfWgDSRVGOQue9QShG3BWVSR1I60xZGUcjHvmoHYO5JLYoAPKVySXH4dKKhOwEhJGx+VFAHhUKhgwx3qWMBCBio7c8H3GanJ5U+ooAlZBKrDuKyrmMxScitWM4YGk1KISw71GCKAOdvoBLETjmsRoWV8YrpOn3h+FV5rdZCSBigDJgj2tyKttDlQRU6WhB4x+NWEtwo5/SgDN8rJwuaesXlnnmrb4TIUYqFgACec+1AEUrc4qBjUhGeTUZBJoAbTTT8YphoAljqzERVNTip42oA1oZDtC1safJmOQDg8VgWr9DXXaVYmS23cgn2oAdBJ5LqrHk1OWYSbhjHr6VFd2MgzKpO1ejY616H4O8AXM8UV7r1qfIK74bNm2tKT0L/3V9upoAq+D/DsmrKLu/SePTgfl28PcH0X0HvXq9rBb2ltGqQpCkY+WMdBx60DFqqIIkRwoVVQcL7CoLh1ukeLccDhmA4U+maAI7mU6iXg3tHD0Yr1b2+nvThiFAiBSir+7jA4UepqIOLVRz8oX5d3p/eb29BUyMbpysWAwwWJ528dT7+1AD0ZpmwUG/bkk9APU/wCFacDKu2JSpkYEls9TWYVL77XT/lduWkHPPeq41aG3ufsNpMs0qLtklA43eg9aAN4kQop+9Nnp1H41n3CmSRmfls/5FMjlACtznuc8kUryMQWBJH8qAIHjDcdM8HFef61YtHfygJwea7yedwpJPP0rivFF5KL7MZUcc8UAYM1n3AIqobQnqKtvcTngMufQCoXlkQEyNhvTpmgCs9nz0yab9kAHK/1qVrhz92oXlmYdaAENsopGCqME8fSoXaTPJH0zTSz49fxoAnfATiogxU9eKgkmI4IxVaS4x0yaANQXDFgqEVHLdk8MABWcbggZUc1UkuDv96ANgOrfdalAI74PasiOYg1dhumAwdpWgDThkIA9a1bNmODkfhWAsu7JA6jFathJt25JwfSgDdt3AI5ya2bGTBGPy9awYCGxg1p2zFSCDzQB0fGwMOn9aQ5I+XOar2UhIKv9R9as84Pr9KABQWYk46dM0187c4IJ/SpeAACeePrTwMtkngDpQBAEKqc0D2Ax6AdKllXn6VXDZYigCtcndKeuF4P+NU9u5s4yTnirc4xKVzj3xmmxoCQTjngmgCEQrxnBPvUwAHGADjJAAp6Ku/5ByKeyrkDI+uKAKkqnkfzqArx3xWgYCwwChHu2OKha2YnDPFj/AHqAKG00Vc+yqOsoHtk0UAfP1uByM/wk1MhyVHYCqll93nrtIq1b89RQBYiAY8GrohDx81WTkjFXrflCPQZoA5rUYzHOQBxUUYzWjqa7hu9Tis5Bh8UAP20hBJp5BpVGaAIZYt44quYiOKv7cUhZQCduSKAM8WMshzwq+9Q3EIgOM5q1cXMpBCttH0rOlyxyzEmgCKRqiJ5pz1Gc5oAUPg1PCcuB+NV8ZxirMCbRnvQBoWmSwGO9em2rRaXp1v8AacmRl+WMDLMfoOtcR4R0ubU9WtliiMpZgI416yH0HsO57V9JeEvCNvpNzFfX2y41bb35WD02j1HrQBT8F+E5Ilg1TXLcJcgB7eyfpFno8g/vei9q66W7aBsSKXdj874OBn/PWpp5ys4WRWy7csOcHHU1XucqHjUks3O7HY9//rUAExV4GiV8Bhyy9MH096zGjGlbSM/Zx9yIdE9Sx7n2q7YQLYuYkY+RI+URudh/qT6VPPAJd/mkLhup70AUlRrss0TgA4LORnHv7n+VRzwedA9rZv8AZbdMmScNtwOpOT/OkvjA1oRNcfZdMhbLndguB296868Q+JJNVlMEZNvpoYlYRwZPTd/hQBra74oVi9npDutr91phw0v0PoaqaFL/AKVHzyOmO1cxGScFjzW94cOb5BQB6LGD5Sc7R1qTdnpjaKSD5oOOo/lTZfukdO9AFW8f5GxyPWuC16TzL4kDIAA9a7K9cLhcgZOcZrhNbYicsP4l/rQBm3d4IRhCGkxz7VBHuc733EnsaikCbwRz61oW67wNo4oAaqdaV4uOetXEiC4Pf+VO8hR/tntQBktCepxTUT5uma1Ht0J5Bz6U3ylHCj2oAzngEgwUqpJprE5VWAreClOoApSCMEjj+dAHK3NncRKS0Z2+orMkRkySprublQUBx1NZs1mjknAB9hQByyvn2qeJuav3VihOTw30qmYTEaALkUxUDitbT5Pl4BB96wEk4rT0+TLCgDp7N+D7VpwPyvBNYlnJjgVqQHgenegDbtJCCMnODWvj5xgcdawbYncBk/41vxE+Wr4GSMUAMmYhlAxuPNOhDkkt16UMiyPzwatBBHFgnj/PNAETYOcnnGKpnPme9W2PHt61XI3EsPy9aAILpeSQcA1VMmxs4q/cLmPcOOcY9Koso74oAlUg85xUzsqoMZY+pqtasGLJ1PbHNOkJ5HpxQApYyNk8Z7VFNF94Dp9KQPhxnoOTUhlUjIGCRzQBSkjcscZoq6WA7gn86KAPnS2BD/8AAauQdAexqpbtuIx9Ku2uCmD26UAWIhzWjCMRSGqcK/MKvRj9049qAMe6TfEw9ORWaoHWtRs8g/Q1WtrR5nIQcZoAjCZWgKBWjLavEoV0KnGcmqbgZxigCNhxUJXg1YIx1qNxg0AZ0ybc5rPn4NbsjQj/AFgJqBnsM4eIN9aAOfIdmwgZj6KM0PFKo+aOQH3FdLBcWKf6tVX2FJe3cEgUKykjrjvQBzsUTZztP5V0fg/w1qHifVY7LToGkbq7dFjXuzHsKj0vTrjV9Qis9PXfM/OB0Ve7H0Ar6H8G6V/Yekx2GkiJHMgNxK3LXDY4z6L6CgDoPBXhDTPCVgkVuEmvZFCy3TL8zf7K/wB1P5966UDDKECkjqxrIuVmWxJaUG6k/JWHTPtT7C+lmWGTYsiOSspU4CSDggUAXbpPJy8QJ8zjnkZ9aLZRBENxdvlz8wyR607e8e52JkDnOD2+lMjkjSUB5sMeV3HGKAIxHuHmlyBkMM9vwqv4l1HT9K0d7/Vm2wrwkQPzTN2RR3/pUfjDxBpnhvS1vtWBkd+Le2H35n9B6D1PavAvEniS+8QakbvVJVaQ8Rxr/q4E/uqP5nqaANPVvE1/ruoeZcYit1J8u2U/Kg/qfeqik9z0qhZuME9umauIRjIGaALkZ3citvw9KkeoIXOBWFCeParkDbXVh2PFAHq9jKGUL1GM1PN9K57RrwSRowPOK3LmQCLJODjmgDE1RwGYkjjqa5HWY9yRFfvbCf1rodTdjLwcjsaybyM7oSwzwf50AcoUJkB6DPQ1t26gINuOlOmto5ZvujIHOOOangtkx0IoAYuccVICCh7Y6+9SfZzkbOBTZLWbqpXGeaAItw2461XlQB+CQfarptpj0C4pv2aVTuKg/Q0AUIzu+9z9akVQQcY/OpvssxGUQDHUmhYj5mCpHbnvQBAycEH8KrsgxmtIxbuCAMce1RSwDdnpQBlSxluoP5Vn3EO05romiJHUYqvPaBoyKAOaeDdyvWrNqhQjufaraW4MxQj6VMyhSPLAX096ALdlkc+1bNnyqms2zjaQAqrHHWti0QLhfagC/aD94tdDCMRrWLZIC4OOldBGm0AHuMUARxpiUN3BxVuWLMJ46cU0IFIJHT9anY4j2g5DDOf6UAZ7gKo9KgQY61bcYH3TTAoZuaAInj3RYPBJqlPF8uADgVr4yhA6YqlOuFI7f0oAzrRcXakfw+9WXQDrt55yKfbwgSkgcAfnUkq4OME/hQBnGE72IyAx7d6TywNobLN2wOQatOG2/NyBwKrsShXsx7jtQAC2Tu7A/Wio959QfwooA+erVTkbeuauw8Kcde1UrXPyn0rQi5zQBcg+ZBjqOtX4iBGR3NZ9sMH2rSgXdQBCLZHfLD5e+OKtwy21v/d49qo3e9nKKMY6c1B5QQZLEtQBpajepPj7pUDArClUFiRU7c1C6ntQBXPfNRtyhPpVll9qhlGIyQOKAMmdtxOKquMnkVelQDNVnTNAFQoM8CnLCRgKu5m4CjqT6Vcgty8ikjgV0HgywafxTZuYTNHBKspTGQSD8oPtnBP0oA9Et/DM/g3wvb2QjRbrUWQ30yEmV+4hXsF9fpXT2kv/AAj1pJdSK8ks5HC5baOw9lFQ2Vtc6l4kvNR1e4MltCPLtxng45cntnd0NXoL4fbpGSEyo5VERP4jnhf6kUAbNi81zB5cwLzTLmQryEU9B+NaNjCdPKw2yGYvxjsePXt9ahVRp9nI0uFkdt0snRST/D7AUuj6otw4hIGxy2XU53Ec4I7D0oA2bEk5Rg29OMsOv09qw/GWuaP4eSO+vY1udSCn7LaKRvkI747L71Q8a+M7HwVp8tzeIbjU5x/o1ijbdwHRj/dQdz1PavmrWvEGo67rVxquoSK15OQS6DAUDoq+ijoBQB02va5f65qsmqa3N5k5+WOJeEiX+4o/zmsVJBKeBj2rJNzNJkOd2ehPWr9rKRjauM0Aa9oTHwc4PrWhBIVYeh61kxSEnJq7A/IzQBtx8Ae9WEb0qnbyBogfSrMZ5OKAN/Q7kxuFVhknGPQV1U9x5qmNTyFHXua4iwDmVdnLfyFdRpSs7MGOWx3FAEcqlpMsORVG+mWJ4Q2OE5z9a3jb+Y2FAziuX1mJ1mUOekaj8aAIEuUlmyuB+lXEypGOe4rGhBDtu6flVyEFB3wfegDXi/eHL8ei+lTFQwIxnIxWdBPIozkMfpUkd2xUllXA7g0AWycfKeDSbfMHy9M/jVBr9FI2oWJPrSi+JYK7hFPYdqALskyr8o5Pt3qhPMNx+UrjpznNK7k/MPmFQvtfccc9qALCTh1HyjmpYyjYyMZ45GaqQLlQOB7dKs7UVlUHFAFkW0TnG0Z6Uv2BRkeWMDvUSAqQ4zg02fUnThcccHNAEUunRLISFxnriohYw4DEA+tO+2GaTJ9KerKT1xQBYtDHHHsIAHp71bt4vMJPyjHTnrVK3Xdu2sevTFathDhh5h4PX6UAaGmW2WYkcVrbckHt0FNth+4AACrjnFSrCQVAB/CgCxaIpDFxTJT1IPtSiUR4Bz7+9VZXIZs8DsPWgCKeQY2imRHkD1ps3K7gOvX2p8a5U4GADy3egCVQc/41HcJnntjmp1HTOKlWMSZGOB37UAU44tsZPc1FMuWJHC1dlGM4A/wqtKpAIH5UAUmI3Hd07/41Cyq351M+c4HJFVJZVGMnOTgkdqAGFXBO3p9aKa0sRYkEY+lFAHzzbnPQYq9EaoQdRWhF90H3xQBdgB61pWv3gPWqEA+WrnmeSgfuaAH3CESHnjPSozBuXI60F96785PcUsMyK2Sw+lAFOZdrlcdKhfYo5bP0qzfuJzmMhSPSsd3cEgj8aALBlAPygt9aQvuQhlFVA59cU9WOaAI3gQ8kc0xbTLbu3vWjFGsmNwP1q2tiWX5GX6GgDLWFQvHWvQvB9oNP8C3mox28slze3GzzEUnyol+XI9yxrgr62niTcE4HUjpXstrqMWieD/C2jvEzs5hacrwELAvz69hQBW1t7jTfDlrpkZmZpDsVmOWIHrjuTW34NgubXTYXutzXDZZd45HOAT78U3U7SC81WGQu0U0ChkTPygk5BxXWvPHBazgqCbceWPduOfzNAHL+KNVuLo3FhbRFZIX8vDjiR+CfwH86g07UbLwjolzd3DRtqG0nAJIdwCcH2FVdCgvrvXTGpc28T+aQ5B3uD1z1rzj4w6xLdeM9W0/cFs7eQJHFH0Pygk/nQBxes6jc6peSXV9O81xKcu8jZY+g+g6Yqkq/KSPWo2JLfN19acmSwU5wTQBatoWdskcVoIvAwDTLbCoFGMCrsbDGMUAKm4AcCrUDEGmrsbAHH1qzCgBwOfpQBp6a+MqR2rUgUyEqinjqcVl2Y2yKMdeBnvXcadppQQLghmUbuOpoAueHNLHl+c6lmIwM1vWdmYpiSmM54Fbdlp8cFrDF0KgEj3NSz2/lkdD/ALI60Ac2ymOYjvn8KyNclt0vZVVCSMDpx0rfmjJuQD3POR3rm9UQySvIOrMaAMiWaMMMIPwFSx3CuACuT2qKW3ZTlxioM7TwM0AXTJuYpgjFVrgKAcAn1IqNpieNxzTV6nPJ6igBpByOSAOMinOu5xnBHfNO3fLknjuajwXII/nQA9Z2Rxg/IOoqZWE444I98VBIpwAgH1NJGHU5HHrigDQUEIoblvX2q1BFtcbgD9azoJmaQDHFaAuwcZjJHQYoAtTRMxX5CoHcVUkt3kcqsZI9T3qcXh288nsM5FCagUPMYx7dc0AU/wCzpEOduPrU4sjty5x9KmbU4+rxtnuaRdQiY/eGPTFADooYkkAyRjqRWpZlS4AB4qnGYiN7Zx2IqeGeNDlMZNAHSQhcAA5IGSKlU+UcKd/uxrGt7pt33iM1pq+UyDkfyoAdcnlWHGeagkIOGzwOtOZsAgkZ9qiZht5I/HvQBGzEnkAem6p1BUAjGD2qIIWPUEds1aigbjBCr6NQA9QXIABz1q7AojXBHJ61EqqvOQSO/wDSp8+3yjvmgCpMmx+eef8AJqnL8uckg+laV2pKA4PPFZ83fgH2HSgDOmVssOCHHOTis2dV2krk9gAK15lyOTjAwM1nToQuBz7igCp5fqgPuDRTwj9lIHoDRQB8/RfK3FX4xlRxWOt6hxsXjFSrek4GaAOghATBZhioby+QPiM5x3rLSZjyx4+tQzspduaALkl8/wDe49uKYt7zx1rNkHcGmx5zzQBuR3aMPm4NSErIO2KyIyPWpk68MRQBbMSZ6H86aUx1OBSBzjFRysQDzmgB3msGAQkY71ct79kUeaN3risyM1N24oA30u7aaBwsnVSNrdjXq2koJbeyuLuMmUiMIcZDJtwGFeEEfKc85GMV7LNaajd+DvD+q6fcFkjsYoPJVfm+Rstz78/lQBa8QW9yPGFmbVlETeUSG64B9a6EC+nW6KhgBcISQAeD/wDqrP1C3uJdQ0m4khAtwcO7nkcZH611D2vmqzQXKIZYjgA9W6g49QaAOP8Ahqt/cX09tqjMhkZ+Y8KVKluGHUE4rwrWfMub29urhCly9xIZIyeUO4jH5AV77o32fSPE63Du5kuSHdM9T3z+prx74kaZNaeN9d/dhPNn81F6ZVhkEeoNAHCs37z1FWI2GQfSoLmN0nMbAhu9LHwQPTigDVt2xnPerkRbruGKyI5cHFaNnHJLHK8YyI13HntQBdjODwc+tdBoFj/aDyKqKDsJGT/KufsFa5KpGoMjH15r0jRbD+ymjQqPN25I9z1oAd4X8N+bdKZ5JHgiO9lbn8Aa77RrYzXwkcBUUk8+g71BmGxtkaJdsUnzvz90Vlabqr3dzdTBvLijbZGmeMetAHa/2rZRs5MhbZ1IH86s2t1bahbGS1cSHnA74+lcJJdyNdrFDEhV8h2A5xT47n+zQJIG2CLhB79aAOlvFS3nDH5m2lqxZVtp1YggNnHPrUup3m/T1v8An98gZsHpxk/rXEtey7gQ/vQBuzwmJsEBh6msi5tNzs0Yw3U4p0WsMwCyncKsCcMm6E5z/CaAMcQSb/m5/CgnGN2Q1X5rm36SjYR144qK3eycsDMrDPc4oAhAJUbhx0p4iO4Bcbf5VuJbW/lKYgBxnI5FRyWmORg59RQBl7G2EYB9KUQjjcPyq6Iiv8Jx9KciksS3yqenFAFdIgv3F/Sgx4I3H5vSp1DIevy5601iWyV5oAibBPNRy+mCR7VIcRr8/DelQNMD2/KgBOowcY9KhkLDggmlLfNnH41HIS3BJIoAs288irtL8Vft5snmsdBjpVu3Y0AbiT8jB46gelbFlcb4dpP/ANauZiYnr09K1bCTEin0PHtQBugnAzjp6UN0II4xnGKULz9efpT2HrQAsAIJJ79D2FXoo2P8P51VhXJBUKD3PSrSN8mfbrQBNHYbjlZU3eh7VYSymRVwARnHXrVHLM4bHzdDirkU0ifewR0HqKAJDYyyAKFOD6nNUptPnUkGJgfpV77a6DCgjPPHSmvqdxjKv27jNAGJcWFwD8y4yfTqKrNpzliCGx9MVqXOs3vGZBgDgFf5VRfXbgZ3iNievFAFJtKjc5GcDjh6Kcdclz9xPwFFAHyBHIQqjdzU0M4z8x4zWcrdSKV5+MLj3oA1Dd5bAJC1LDOG+8awN7Z61bgmGMHrQB0cfluvFROmH+Ws62u/LkAfhfWthE3L5gOVI4xQBCCFO0ghqlVzgYptyPmDjtTEYDrQBZV271I+CtRBgcU/ORQA1cY4pUfDY7U0jHSmk7W5oAnBBbHavY/hhe/afAV7azzlY7O8UDDYKq6n+teL5w3tWx4f1K5tWuILad4ftCYBXuy8rx37/nQB7ppOopfWH2Y73khOw5XBPpW4kkFqxDQlmUBo8dQM5J/CvNvCtxfwPFq12sn2e4QBgVwFJ6k/jyK7jWJZ77RRPZlUmhGQ2eoAoAp+JIbaC8jvUgeWLzDJthGWB64/Hrisvxlpa+OfDE1zbQJb6tp8W6JQctJEOxA7g5FdTpV3a3elItjC5VQN/m/eHHKn2z3rkbW3ufDPidJY5GayuZBscHjJ/wCWZ9W9u4oA8PW0NxeTStuKQoBk9zVRLYtKe3c19D614G0bWftn/COsLa8Y+bPan7ue5X8e1eS6pov9my3MEpHnx5R06Mp96AOJQgP1Jrf0Js+ZuwMoePwrOgsz5j8Vq6XEUckjHymgC9oEINzGFGWZhyTjFd9p2qmS92TglAcK3cD3rjvCMO/VoVJG3k/pXR2lvi9Y9getAHX+LphbaXbxRt81wNx/CuT012R8qcY49jVvxPcO96sTuwjjjCop6DiqNgryShV4/GgDsrHIXz8AZXbx+tYms3JNz5IYuuRjHbNat5N9lsAq84TbgevesHTVFzqe+T7kY8xvw7UAdR9qhjtodOJBkCkBTzuyMkflXNalYJayFoWZon+YKedvtUz+YdbFy4K+VGSF9Wb/AOtVbUbuQy+UR8ic7vWgDNm2Imc/N/Sp7S5KkMcDI/Osu6uPPb5f4T2qMzsgwDgnt60AdLNHHfw7xgSDpisCcPGWDRgMp4OP5VJZ3Usfz78EelXJJo7yPEgAl7AdaALukSyiFf3hJ67Se1ayXDj73I96560/dqFDY/2s9fatW2k2geYQRQBpCYyKQuGPcelQygrjoe5XP61E8pLqoPHtS+bhWzgrnjPWgBzN2ySvXBpGdUj+XAYnB4xUasQeASp64OKjkYnJPJHQetADJTuP7wDPtVWTKNkdKkZgoz1+tVJpQoyWwvvQA951UgP1NODBjwcjtWaXEkme3SrULjKhfwoAtLx05qeEYPXr+lQJz0qaH7+PxoAvRHH+etatgFyPX1zWXEM4PatKy/1gB6UAdIvGzJ5FPJHTGT70w5KKoAzimnIB65HHrQBZjYH0H9amVcBfQdarQDkY7celWQTQBNGpwOOe/PWpU456Y/E1HGdwwPyp5JHIGfagBZCD7+p9aj5z605z8p7n+VMiDkrhSfUUAVbyMANznPpWLIGOc9K6S7iLQtkKOcYNYVxDluW4HXHrQBn7VHAVfzoqfyQCeSf0ooA+OFbg+lMJoJptADgaej4qKng8UAW423DmtTS70xAxSZ2dqxI2xxVpWG0etAHUZV0yOQahMTA5Tmsq1unjI3NuX0rWinV1G3k0AKvP1qUc9RimtllbaccdqbGT3BoAlPNRyDK+45qXOfao5OhNAESyZ608MVYFTgqQQfSopFPUDt0qGMsj7m5HpQB9E212vjPwfa6tE6RtbxiK8s4wBtdOAR/skc/jWbpfitY9RawY7YlymOiof7v/ANevJfCniW58N6slzB+9tZDsurbOBPGeCp98E812UR0C6jgNi7lWcRxSz5LDnhH9Gx0PegD0S+S7tp7W+tbgW9kTull25CqexHv0PpWhb6lpniOzlisgm7bie2c5Mbj+IZ6j0NZ2leJIbbULXSdahkj85SY2dRhgOAareLdMe1v4r/RFZJ0U7GXkMOysO49+1AFZND1PTtZhk0qaZrWI+bMhc7iB0Ct3yeoNS+I1svE96sV1Eo1BAFMiR7Zy5+6hX+ID1rttM1C3nsBZefHLchFe5ltmzuyOOD1weMdaopYx2N4L2URXLIx2XWM7A3YnqpoA8q8RfDvVvD8lxJPbtNaou4zQDev19q4yCTiQGJlGOa+hJ5r1UMNpdecs+d5D4cRjqAehJ6c1Fc6F4Y8SSNHrFoLG8IwssP7lyffHytQB414OlR9RjRIiWfgn2rspAi36kkKobOBWvqHwh1XSZlufDV5BqMSru8qY+TKPofut+lc5fw3sGEu4JbSfdhkmUqR/j+FAEviG7F1dQSRxAwBQFJ7nvmpNAs2a7WTaTGg3Htn0qK0gaeJo5WCr6k9DXU6Xp7w2SLt3Z+Yhfb2oAx/E0saMke/Oxcv2wetVbK5jsrJZmXMlw+cf7IP+NKdMm8Q+IVspJ1s7TndNKOuBnAHck1B4v02bQLiy+2PB5D8wGN8+Yi8E47c0AZut6pMb4MflBxgDuKDqSCPdJj7vSs7UZ472dWiICpwMnmsa/kYS+WD9PagDVN7CxOwYHc1GrLLN97A7e9YCefJIBhvQnOBWhCGEijdnHBxQBtRxuRgDHvSIrBw2/kdBVq1kQw7cEuR36Cq8qtuAY44wQBQBp20itGd7DIGTxU9uqSjKNkHrzWfZW+4bXYhcc4q7b23kttUkj+E+lAGlHMAMqMqOKUujdGwfSs+XzFbp8vtUbT+XhuBjigDTbA5JqJ5N3oAPQ1nNfMf4c0z7YD95dn48UAW5nADY/Cse6l3HaDwetTzyu3ygAr7VUKAE8UAPg64q3EwOMHBFU4wc1NHxigDThcgcqQatRAlcrzz+lUbcjafyq/CflHOccUAXYOMEjIPvWxpqB7hR2rJtvvj0rodIiAcyHkKOp4oA2AvzY9DRt5b60isNwBJz/OnjrxQAqLtqwqlsY/Woug4x+NTRHdgAn2PvQBMcqpyOMdhVm2tHlUNLmGM/iTSQzbGBCqD09qkuL6WRwoAXsB2oAkxax5Bhdm9WPWgfZz0VlPbuKpCVgOT/APWp8bZI4AHuKALbi1kDr82cYz2zWeNPtWBzuJ9qm8wh2BBAHWoUBEpGPf14oAkjspCvyIm3tkCiq11qvlzFUHA646ZooA+D6DRRQACloooAVfvVYWiigC1FV23JB4JoooA0YjxUq0UUAOfpTE5oooARutVj940UUAVl/wBY1dT4FJOsxoT8peAkdjiUYoooA9H+I3HjNCOsauEP935u3pXf+FSX0Ql/mIXgnmiigDJn/wBHuojB+6O9vufL29q34mK39iykgykCQj+Me/rRRQBVkVYvEkyxKEUsAQowDxWz5aOCHRWAAIBGcUUUAaBlkGmOBI4AcAAE+ta+q20Fz4Zl+0wxzbYyR5ihsHHbNFFAHj9tFGNVlQRpsAX5dox+VdGhKyvg4+btRRQByc7sdQuCWYkRuQSeled+JJZHvsO7MI0CoCc7R6D0oooAz0YiPgmlu+sR70UUATIATyB1p6ABgRwTRRQBs2PLrnnFWmA8w8UUUATqMLHjjPWtC3JPBPFFFADJOJFxWdKAS2QDRRQBmsTzyetLESVbJNFFAEtof3VOeiigCNSQetWIvuUUUAWYO/1rQtvuj6miigDRtf8AXJXVaX/x7t9aKKALwAAOABUg+6P900UUAOHf8KVSQpIPO2iigC1Dyxzz81Pk/wBYv+6KKKAHr0ofoaKKAEPCMRwcgVIOEkI60UUAZMYBXkDqaKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholangiogram showing a non-obstructed biliary system following clearance of a stone using intraductal lithotripsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15731=[""].join("\n");
var outline_f15_23_15731=null;
var title_f15_23_15732="Vascular malformation 9c";
var content_f15_23_15732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Coronal view of pelvic MR",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 467px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal view of pelvic MR shows flow void (arrow) in the uterine fundus suggesting a rapid arteriovenous connection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15732=[""].join("\n");
var outline_f15_23_15732=null;
var title_f15_23_15733="Laryngeal musculature";
var content_f15_23_15733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Intrinsic laryngeal musculature with relative positions of the thyroid, cricoid, and arytenoid cartilages",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Garrett, CG, Ossoff, RH. Hoarseness. Med Clin N Am 1999; 83:115. Copyright 1999 W.B. Saunders Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15733=[""].join("\n");
var outline_f15_23_15733=null;
var title_f15_23_15734="Amylin analogs for the treatment of diabetes mellitus";
var content_f15_23_15734=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Amylin analogs for the treatment of diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15734/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15734/contributors\">",
"     Kathleen Dungan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15734/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15734/contributors\">",
"     Irl B Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15734/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15734/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/23/15734/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advances in options for the treatment of diabetes, optimal glycemic control is often not achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/1\">",
"     1",
"    </a>",
"    ]. Hypoglycemia and weight gain associated with therapy may interfere with the implementation and long-term application of \"intensive\" therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Treatment of type 1 diabetes is directed at physiologic insulin replacement. Many patients with type 2 diabetes also ultimately require insulin therapy as a result of progressive beta cell dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/5\">",
"     5",
"    </a>",
"    ]. Starter insulin regimens (such as basal insulin monotherapy) for patients with type 2 diabetes commonly require repeated intensification over time to achieve even modest A1C reductions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/6\">",
"     6",
"    </a>",
"    ]. Therefore, other therapeutic approaches are needed.",
"   </p>",
"   <p>",
"    Glucose homeostasis is dependent on a complex interplay of multiple hormones that may be targets for a multi-faceted treatment approach: insulin and amylin, produced by pancreatic beta cells; glucagon, produced by pancreatic alpha cells; and gastrointestinal peptides, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP; gastric inhibitory polypeptide) (",
"    <a class=\"graphic graphic_figure graphicRef59551 \" href=\"UTD.htm?42/1/43025\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/7\">",
"     7",
"    </a>",
"    ]. Abnormal regulation of these substances may contribute to the clinical presentation of diabetes.",
"   </p>",
"   <p>",
"    The mechanism of action and therapeutic utility of amylin analogs will be reviewed here. GLP-1 based therapies and overviews of pharmacologic therapy for type 1 and type 2 diabetes are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=see_link\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AMYLIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amylin is a 37-amino acid peptide that is stored in pancreatic beta cells and is co-secreted with insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/8\">",
"     8",
"    </a>",
"    ]. Amylin and insulin levels rise and fall in a synchronous manner (",
"    <a class=\"graphic graphic_figure graphicRef74823 \" href=\"UTD.htm?1/12/1216\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/7\">",
"     7",
"    </a>",
"    ]. Amylin and insulin have complementary actions in regulating nutrient levels in the circulation. Amylin is deficient in type 1 diabetes and relatively deficient in insulin-requiring type 2 diabetes (",
"    <a class=\"graphic graphic_figure graphicRef74823 \" href=\"UTD.htm?1/12/1216\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amylin affects glucose control through several mechanisms, including slowed gastric emptying, regulation of postprandial glucagon, and reduction of food intake (",
"    <a class=\"graphic graphic_table graphicRef79703 \" href=\"UTD.htm?19/51/20283\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRAMLINTIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     Pramlintide",
"    </a>",
"    is a stable, soluble, nonaggregating, equipotent amylin analog that is administered by mealtime subcutaneous injection. It is available for use for both type 1 and insulin-treated type 2 diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     Pramlintide",
"    </a>",
"    regulates postmeal blood glucose levels by slowing gastric emptying, promoting satiety, and suppressing the abnormal postprandial rise of glucagon in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Thus, endogenous (liver-derived) and exogenous (meal-derived) glucose influx are better regulated, allowing exogenous insulin therapy to more easily match physiologic needs. These effects are glucose-dependent and are overridden as serum glucose levels fall [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/12\">",
"     12",
"    </a>",
"    ]. Pramlintide does not cause hypoglycemia in the absence of therapies that otherwise cause hypoglycemia. Supraphysiologic doses of pramlintide do not provoke hypoglycemia in normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/13\">",
"     13",
"    </a>",
"    ], and pramlintide does not interfere with recovery from insulin-induced hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     Pramlintide",
"    </a>",
"    has been studied in randomized controlled trials in both type 1 and type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. In type 1 diabetes, 30 to 60 mcg of pramlintide administered subcutaneously with meals resulted in sustained, albeit modest (&lt;1 percentage point) reductions in A1C over the 52-week trial (",
"    <a class=\"graphic graphic_figure graphicRef79842 graphicRef60521 \" href=\"UTD.htm?40/7/41073\">",
"     figure 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/16\">",
"     16",
"    </a>",
"    ]. More than twice as many patients (25 versus 11.3 percent) achieved an A1C of less than 7 percent in the treatment group than in the placebo group, with no increase in insulin dose or incidence of severe hypoglycemia. Modest reductions in body weight (mean of 0.5 kg) were seen in the treatment group, compared with weight gain in patients receiving insulin only.",
"   </p>",
"   <p>",
"    Similar results were found in a second large randomized trial evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     pramlintide",
"    </a>",
"    at 60 mcg three to four times per day [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/17\">",
"     17",
"    </a>",
"    ]. In this study, weight loss was more prevalent in obese patients compared with patients with normal body weight and was independent of reports of nausea.",
"   </p>",
"   <p>",
"    Placebo controlled trials in patients with type 2 diabetes showed similar results (",
"    <a class=\"graphic graphic_figure graphicRef79842 graphicRef60521 \" href=\"UTD.htm?40/7/41073\">",
"     figure 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. When added to existing insulin therapy with or without a sulfonylurea or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , reductions in A1C (mean 0.62 percentage points) and weight (1.4 kg) were seen with 120 mcg but not 90 mcg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     pramlintide",
"    </a>",
"    given twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/18\">",
"     18",
"    </a>",
"    ]. Pooled post hoc analyses showed that reductions in insulin requirements and body weight were greatest in more obese patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 24-week trial of patients with inadequately controlled type 2 diabetes, the addition of premeal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     pramlintide",
"    </a>",
"    to basal insulin with or without oral agents had similar glycemic efficacy as the addition of premeal rapid acting insulin analogs (A1C reduction of approximately one percentage point) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients randomly assigned to pramlintide maintained their weight, whereas those assigned to rapid acting insulin gained weight (mean 4.7 kg). Pramlintide was associated with fewer hypoglycemic events compared with prandial insulin.",
"   </p>",
"   <p>",
"    In addition to modest reductions in A1C and body weight,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     pramlintide",
"    </a>",
"    has been associated with reductions in postprandial glucose excursions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/23\">",
"     23",
"    </a>",
"    ] and in surrogate markers of cardiovascular risk and oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The clinical implications of these findings are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Side effects and adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate nausea is the most commonly reported side effect and generally dissipates by four weeks. Nausea can be minimized by slow upward dose titration and is less common in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe hypoglycemia in type 1 diabetes was increased fourfold during the first four weeks in one study when patients were started at full doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     pramlintide",
"    </a>",
"    at randomization without reduction in insulin dose [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/17\">",
"     17",
"    </a>",
"    ]. In a subsequent study, insulin dose was reduced by 25 percent at initiation of pramlintide therapy, which was titrated to the maximum dose over a period of one to two months. With this strategy, there was no increase in hypoglycemia. Premeal insulin doses stabilized at an average of 17 percent lower in pramlintide-treated patients compared with placebo by study end [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/26\">",
"     26",
"    </a>",
"    ]. Hypoglycemia was less frequent in studies of patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small studies suggest that the increased incidence of hypoglycemia observed in patients with type 1 diabetes is related to mismatched timing of prandial insulin relative to peak glucose levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     Pramlintide",
"    </a>",
"    delays gastric emptying, resulting in blunted but delayed post-meal peak glucose. Thus, rapid acting insulin analogs taken pre-meal may peak before the glucose peak occurs, increasing the risk of early hypoglycemia followed by delayed hyperglycemia. This is analogous to the pattern observed in patients with gastroparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/28\">",
"     28",
"    </a>",
"    ]. It is unknown whether regular human insulin or post-meal rapid acting insulin analogs ameliorate this problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dose and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     Pramlintide",
"    </a>",
"    is only approved for use in patients with type 1 and type 2 diabetes taking prandial insulin. Pramlintide precipitates above a pH of 5.5 and must be injected separately from insulin at a different site [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/29\">",
"     29",
"    </a>",
"    ]. The optimal timing for administration is immediately before a meal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. According to the approved labeling, premeal insulin doses (including premixed insulin) should be reduced by 50 percent, and should subsequently be titrated upward to achieve euglycemia once the target pramlintide dose is reached [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/32\">",
"     32",
"    </a>",
"    ]. However, as noted above, most patients require a smaller reduction in prandial insulin. Patients with near-optimal glycemic control on insulin pumps who utilize the extended wave bolus feature (square wave or dual wave) require minimal prandial insulin dose adjustments (&lt;10 percent) after initiation of pramlintide [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/27,33\">",
"     27,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     Pramlintide",
"    </a>",
"    should not be administered to patients with severe hypoglycemia unawareness. Pramlintide should only be administered before meals that contain at least 250 calories or 30 grams of carbohydrates. Patients may need to administer their prandial insulin after meals until they become familiar with the degree of satiety and resulting reduction of carbohydrate intake that may occur. Another strategy is to substitute human",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    for the rapid acting analogue. This strategy may better match insulin with food.",
"   </p>",
"   <p>",
"    The recommended starting dose for type 1 diabetes is 15 mcg before each meal, with increases of 15 mcg increments every three to seven days, as tolerated, to a goal of 60 mcg before each meal. Persistent nausea should prompt backward titration until resolved.",
"   </p>",
"   <p>",
"    The recommended initial dose for type 2 diabetes is 60 mcg, titrated upward as tolerated to 120 mcg with each meal.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     Pramlintide",
"    </a>",
"    slows gastric emptying and may delay the rate of absorption of oral medications. Patients with gastroparesis should not use pramlintide. Oral medications that require rapid absorption for effectiveness should be administered either one hour before or two hours after injection of pramlintide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     Pramlintide",
"    </a>",
"    reproduces the actions of the naturally occurring peptide hormone, amylin, and controls glucose without causing weight gain. Many questions remain unanswered regarding clinical use and long-term outcomes with this class of drug and, therefore, the exact role for amylin analogs among the myriad of other agents for diabetes management is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15734/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest an individualized approach to initiating these therapies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"       Pramlintide",
"      </a>",
"      is only approved for use in patients also taking prandial insulin. However, it requires injections with each meal in the setting of type 1 diabetes, and at least twice daily in type 2 diabetes. It cannot be mixed in a syringe with insulin. Pramlintide therapy requires careful patient education and monitoring to avoid severe hypoglycemia and should be instituted in collaboration with a diabetes educator experienced in its use. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pramlintide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"       Pramlintide",
"      </a>",
"      could be considered in motivated patients with type 1 diabetes suboptimally controlled with insulin therapy alone, particularly in patients taking multiple daily injections or insulin pump therapy who gain weight despite lifestyle intervention.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"       Pramlintide",
"      </a>",
"      may be considered for motivated patients with type 2 diabetes inadequately controlled on insulin who are overweight or experience weight gain refractory to lifestyle measures.",
"     </li>",
"     <li>",
"      There are inadequate data to support the following uses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"       pramlintide",
"      </a>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"       Pramlintide",
"      </a>",
"      in patients not requiring insulin",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"       Pramlintide",
"      </a>",
"      in patients with a history of severe hypoglycemia or hypoglycemia unawareness",
"     </li>",
"     <li>",
"      Combination therapy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"       pramlintide",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      or other GLP-1 based therapies",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/1\">",
"      Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/2\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/3\">",
"      Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/4\">",
"      Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001; 24:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/5\">",
"      U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/6\">",
"      Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/7\">",
"      Buse, JB, Weyer, C, Maggs, DG. Amylin replacement with Pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 2002; 20:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/8\">",
"      Johnson KH, O'Brien TD, Hayden DW, et al. Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. Am J Pathol 1988; 130:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/9\">",
"      Kong MF, Stubbs TA, King P, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998; 41:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/10\">",
"      Fineman MS, Koda JE, Shen LZ, et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002; 51:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/11\">",
"      Woerle HJ, Albrecht M, Linke R, et al. Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide. Diabetes Care 2008; 31:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/12\">",
"      Kolterman OG, Schwartz S, Corder C, et al. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 1996; 39:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/13\">",
"      Bretherton-Watt D, Gilbey SG, Ghatei MA, et al. Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab 1992; 74:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/14\">",
"      Heise T, Heinemann L, Heller S, et al. Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. Metabolism 2004; 53:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/15\">",
"      Amiel SA, Heller SR, Macdonald IA, et al. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabetes Obes Metab 2005; 7:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/16\">",
"      Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002; 25:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/17\">",
"      Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 2004; 21:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/18\">",
"      Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/19\">",
"      Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002; 4:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/20\">",
"      Riddle M, Frias J, Zhang B, et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 2007; 30:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/21\">",
"      Riddle M, Pencek R, Charenkavanich S, et al. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 2009; 32:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/22\">",
"      Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004; 12:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/23\">",
"      Kovatchev BP, Crean J, McCall A. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes. Diabetes Technol Ther 2008; 10:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/24\">",
"      Ceriello A, Lush CW, Darsow T, et al. Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes. Diabetes Metab Res Rev 2008; 24:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/25\">",
"      Wysham C, Lush C, Zhang B, et al. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. Curr Med Res Opin 2008; 24:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/26\">",
"      Levetan C, Want LL, Weyer C, et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 2003; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/27\">",
"      King AB. Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used. Endocr Pract 2009; 15:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/28\">",
"      Ishii M, Nakamura T, Kasai F, et al. Altered postprandial insulin requirement in IDDM patients with gastroparesis. Diabetes Care 1994; 17:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/29\">",
"      Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 2004; 53 Suppl 3:S233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/30\">",
"      Creutzfeldt W. The [pre-] history of the incretin concept. Regul Pept 2005; 128:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/31\">",
"      Maggs DG, Fineman M, Kornstein J, et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev 2004; 20:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/32\">",
"      Weyer C, Gottlieb A, Kim DD, et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care 2003; 26:3074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/33\">",
"      King AB. Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients. Diabetes Technol Ther 2010; 12:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15734/abstract/34\">",
"      Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006; 29:435.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1758 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15734=[""].join("\n");
var outline_f15_23_15734=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AMYLIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRAMLINTIDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Side effects and adverse events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dose and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1758\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1758|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/1/43025\" title=\"figure 1\">",
"      Multihormonal regulation of glucose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/12/1216\" title=\"figure 2\">",
"      24h plasma amylin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/29/5599\" title=\"figure 3A\">",
"      A1C pramlin vs Pbo A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/45/3807\" title=\"figure 3B\">",
"      A1C pramlin vs Pbo B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1758|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/51/20283\" title=\"table 1\">",
"      Amylin and gluc homeostasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=related_link\">",
"      Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_23_15735="Clinical manifestations and diagnosis of inclusion body myositis";
var content_f15_23_15735=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of inclusion body myositis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15735/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15735/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15735/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15735/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15735/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15735/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15735/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/23/15735/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporadic inclusion body myositis (IBM) is classified along with polymyositis and dermatomyositis as one of the idiopathic inflammatory myopathies. However, despite some histologic similarities, the clinicopathologic manifestations of IBM are clearly distinct from the other two disorders (",
"    <a class=\"graphic graphic_table graphicRef74076 \" href=\"UTD.htm?27/13/27867\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histopathologic changes in IBM were first described in the mid-1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], although the disorder was not distinguished from polymyositis and named until 1971 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/3\">",
"     3",
"    </a>",
"    ]. The subsequent recognition of amyloid deposits in IBM was helpful in further differentiating this disorder from other idiopathic inflammatory myopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of IBM will be reviewed here. Treatment is considered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28133?source=see_link\">",
"     \"Treatment and prognosis of inclusion body myositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H383299\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that IBM is present in 15 to 28 percent of patients with idiopathic inflammatory myositis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, the true frequency may be higher and may even exceed that of polymyositis, since some patients who previously had a diagnosis of polymyositis almost certainly had other muscle diseases, including IBM.",
"   </p>",
"   <p>",
"    Although inclusion body myositis may be more frequently diagnosed now than in the past, it is a relatively rare disease. The prevalence is estimated at 5 to 9 cases per million adults, but estimates of the prevalence range from 4.9 to 70 per million population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. There is a paucity of data on the annual incidence; the reported range in two studies is from one to 7.9 per million [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, it may be the most common acquired idiopathic inflammatory myopathy in individuals over the age of 50.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several published series have documented the clinical characteristics of IBM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The disease affects men more often than women.",
"     </li>",
"     <li>",
"      The mean age at onset of symptoms is approximately 60 years, with a range from the third to the ninth decade.",
"     </li>",
"     <li>",
"      Patients with IBM present with the",
"      <strong>",
"       insidious onset",
"      </strong>",
"      of weakness. The average duration of symptoms before diagnosis is about six years.",
"     </li>",
"     <li>",
"      Proximal lower extremity weakness is usually the first sign with subsequent involvement of upper extremity and distal muscle groups. Proximal muscle weakness is typically more pronounced although distal weakness is predominant in some patients. The facial muscles may be involved, but the oculomotor muscles are spared.",
"     </li>",
"     <li>",
"      Symmetric weakness is the rule in IBM, as it is in the other inflammatory myopathies. However, asymmetric involvement occurs in IBM in about 10 to 15 percent of cases.",
"     </li>",
"     <li>",
"      Weakness is accompanied by myalgias in about 40 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Muscle atrophy usually progresses in parallel with the duration and severity of weakness. Some patients, however, have profound atrophy of the upper arms or quadriceps, greater than would be expected for the same degree of weakness in polymyositis. Deep tendon reflexes decrease, usually in parallel with the degree of weakness.",
"     </li>",
"     <li>",
"      Dysphagia due to involvement of the cricopharyngeal muscle occurs in about one-third to one-half of patients. It is the presenting complaint in some cases, preceding the onset of extremity weakness by up to seven years [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/15-17\">",
"       15-17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who are untreated or who do not respond to treatment become gradually weaker over a period of years. The older the age at onset of the disease, the more rapid is the loss of strength and function.",
"   </p>",
"   <p>",
"    Patients presenting before age 60 progress to the use of a walker after an average of 10.2 years, and those presenting after age 60 require a walker after only 5.7 years of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/18\">",
"     18",
"    </a>",
"    ]. By 15 years, most patients require assistance with basic daily activities, and some become wheelchair bound or bedridden. IBM can be an indirect cause of death due to respiratory failure or infection, particularly respiratory tract infections. Rare cases of respiratory failure due to respiratory muscle weakness have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients have a progressive loss of strength. However, in one small study, approximately one-third (4 of 11) remained stable or improved when observed for a period of six months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle enzymes are typically normal or mildly elevated in IBM, with creatine kinase (CK) levels generally being less than 10 times normal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/12\">",
"     12",
"    </a>",
"    ]. Markers of systemic inflammation, such as elevation of the sedimentation rate and anemia, are usually absent. There is no association with antinuclear antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromyography (EMG) in IBM reveals myopathic patterns with increased insertional activity, fibrillations, and polyphasic potentials. These findings are not specific for IBM and are present in other inflammatory myopathies. In some cases, however, a mixed pattern of myopathic and neurogenic changes are seen that is more typical of IBM than polymyositis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/5,12-14\">",
"     5,12-14",
"    </a>",
"    ]. Nerve conduction studies are usually normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) may aid in establishing the diagnosis and in distinguishing IBM from polymyositis. MRI abnormalities in IBM tend to be localized to anterior muscle groups and are more distal and asymmetrical than in polymyositis although there is significant overlap in the MRI findings of the two disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/21\">",
"     21",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Muscle biopsy abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in other inflammatory muscle diseases, muscle biopsy is helpful for diagnosis and may be obtained using open or percutaneous approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .) IBM is associated with a variety of light microscopic and ultrastructural features, which are of varying diagnostic utility [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is endomysial inflammation in over 90 percent of patients. The location of the inflammatory infiltrate, which tends to be more intense in early disease, and the CD8+ T lymphocyte predominance of the inflammatory cells resemble the findings in polymyositis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Basophilic-rimmed vacuoles within the muscle fiber sarcoplasm are characteristic of IBM. These vacuoles are destroyed by paraffin fixation and must be identified from flash-frozen biopsy specimens. Our experience suggests that they may be absent in the initial biopsy in up to 30 percent of patients later diagnosed with the disease (unpublished observation). They are not specific for IBM, also being present in familial distal myopathies and oculopharyngeal dystrophy.",
"     </li>",
"     <li>",
"      Eosinophilic inclusions may be found adjacent to the basophilic-rimmed vacuoles. These inclusions are more specific for IBM but are present in only about 50 percent of patients.",
"     </li>",
"     <li>",
"      There is fiber size variation with groups of atrophic fibers and occasional hypertrophic fibers.",
"     </li>",
"     <li>",
"      The definitive diagnostic feature of IBM is the presence in over 90 percent of patients of filamentous",
"      <strong>",
"       inclusions",
"      </strong>",
"      and vacuoles on electron microscopy. The inclusions resemble myxovirus or paramyxovirus particles, although definitive evidence for a viral etiology of IBM is lacking [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/25\">",
"       25",
"      </a>",
"      ]. The inclusions are found in both the sarcoplasm and less often in the nucleus. The vacuoles contain the products of muscle degradation including myeloid bodies, membrane fragments, and debris. Filamentous inclusions are not a feature of the other inflammatory myopathies but are seen in some cases of familial distal myopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of the filaments bind to antibodies directed against &szlig;-amyloid and prion proteins:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &szlig;-amyloid proteins are formed",
"      <strong>",
"       locally",
"      </strong>",
"      within the muscle rather than being derived from circulating amyloid precursors [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/26\">",
"       26",
"      </a>",
"      ]. The amyloid deposits in IBM are similar to those found in the senile plaques of Alzheimer disease [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/27\">",
"       27",
"      </a>",
"      ] and cardiac amyloidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/28\">",
"       28",
"      </a>",
"      ], raising the possibility of similar pathogenetic mechanisms [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prion protein is encoded by the prion (PRNP) gene. Studies in animal models and humans suggest a pathogenic link exists between the PRNP gene, IBM, and Creutzfeldt-Jakob disease. As an example, enhanced expression of the PRNP gene in transgenic mice results in a degenerative muscle disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/29\">",
"       29",
"      </a>",
"      ]. In addition, a study of 22 patients with inclusion body myositis reported a significant excess of methionine homozygosity at codon 129 of the PRNP gene, a defect also observed in patients with Creutzfeldt-Jakob disease [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=see_link\">",
"       \"Creutzfeldt-Jakob disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis of sporadic inclusion body myositis is suspected on the basis of a combination of muscle weakness, elevated serum levels of muscle enzymes, myopathic features noted on clinical electrophysiologic studies, and the presence of vacuoles and characteristic filamentous inclusions within myocytes.",
"   </p>",
"   <p>",
"    IBM should be considered in patients who present with otherwise unexplained progressive muscle weakness with or without an elevated serum CK, particularly those over the age of 50. A general approach to the evaluation of a patient with muscle weakness, including a discussion of the initial medical history, physical examination, laboratory tests, imaging techniques, and electrophysiologic studies, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link\">",
"     \"Approach to the patient with muscle weakness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history serves to identify clinical manifestations of IBM. It may also identify other possible causes of a patient's symptoms (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Differential diagnosis'",
"    </a>",
"    below) such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug exposure - Exposure to a variety of prescription and illicit drugs may cause myopathy, myositis, neuropathy, or other disorders that cause muscle weakness. Among the drug exposures that should be specifically sought are antimalarial drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      , glucocorticoids, cholesterol lowering drugs (eg, HMG-CoA reductase inhibitors [statins]), alcohol, and cocaine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"       \"Drug-induced myopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Predisposing illness - A prior diagnosis or symptoms suggestive of connective tissue diseases (eg, systemic lupus erythematosus, systemic sclerosis, mixed connective tissue disease), malignancy, or endocrine disorder (eg, hyper- or hypothyroidism, Cushing syndrome, etc) should be sought.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination helps to determine the distribution of muscle weakness and atrophy. Findings of quadriceps and finger flexor weakness and wasting and of foot drop due to tibialis anterior weakness are often noted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no diagnostic laboratory test for IBM. Moderate elevations of plasma muscle enzyme levels (less than 10-fold higher than normal) are compatible with IBM, while levels greater than this suggest other causes.",
"   </p>",
"   <p>",
"    Laboratory tests that may be useful in the evaluation of weakness include serum electrolytes, calcium, magnesium, phosphate, creatine kinase, aldolase, lactate dehydrogenase, serum aminotransferases, and thyroid stimulating hormone. If there are clinical features that suggest a systemic rheumatic or collagen disease, then serologic studies are warranted, including: antinuclear antibodies (ANA). A positive urine test for blood in the absence of red cells in the sediment suggests myoglobinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the patient with muscle weakness\", section on 'Laboratory studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no findings on imaging studies that are diagnostic for IBM. If available, and if cost is not a limiting factor, MRI may help to identify regions of affected muscle appropriate for biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle biopsy is the definitive test in idiopathic inflammatory myopathies, including IBM, dermatomyositis, and polymyositis. Muscle biopsy is particularly important in distinguishing IBM from amyopathic dermatomyositis and polymyositis.",
"   </p>",
"   <p>",
"    Immunohistologic and electron-microscopic evaluation of the tissue require freshly frozen muscle and special fixatives. A discussion of the technical aspects of muscle biopsy, including selection of a site, preferred technique, specimen handling, staining, and other testing, is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best diagnostic information can be expected from a laboratory that frequently processes muscle biopsy specimens and whose staff is provided with detailed clinical information. This may be facilitated by a discussion between the clinician requesting the biopsy, the surgeon, and pathologist prior to the procedure, or by referral of the patient to a center with the necessary laboratory facilities. A set of detailed instructions for handling of muscle biopsy specimens is available at the following Internet site:",
"    <a class=\"external\" href=\"file://www.medicine.uiowa.edu/Path_Handbook/Appendix/AnatomicPath/ex_muscle_biopsy.html\">",
"     www.medicine.uiowa.edu/Path_Handbook/Appendix/AnatomicPath/ex_muscle_biopsy.html",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The presence of all three of the following on muscle biopsy confirms IBM and effectively excludes other idiopathic inflammatory myopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vacuolated muscle fibers",
"     </li>",
"     <li>",
"      Muscle fiber inclusions that have staining characteristics of beta-amyloid deposits",
"     </li>",
"     <li>",
"      Demonstration of paired helical fibers by electron microscopy or immunohistologic staining",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other methods are used in some laboratories or are being actively investigated. One example is immunohistochemical staining using antibodies to paired phosphorylated tau protein [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IBM resembles polymyositis when the distribution of weakness is predominantly proximal, and there are patients in whom two disorders cannot be distinguished by clinical presentation, CK level, or EMG. In such cases, muscle biopsy may distinguish between the two disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Muscle biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are a number of other disorders that can resemble IBM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several kindreds with slowly progressive muscle weakness (variously labeled familial distal myopathy, hereditary inclusion body myopathies, and distal myopathy with rimmed vacuole formation) have been described in which there is progressive muscle weakness, usually with marked distal muscle group involvement, and the muscle biopsy shows a vacuolar myopathy with inclusions [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/31-34\">",
"       31-34",
"      </a>",
"      ]. In contrast to sporadic IBM, the onset of weakness is in early adulthood. The family history and a paucity of inflammation on histologic examination help to distinguish these rare heritable disorders from sporadic IBM.",
"      <br/>",
"      <br/>",
"      The autosomal recessive form of inclusion body myopathy appears to involve the gene for UDP-N-acetylglucosamine",
"      <span class=\"nowrap\">",
"       2-epimerase/N-acetylmannosamine",
"      </span>",
"      kinase (GNE) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. Some endomysial inflammation was noted in two patients with this disorder, both of whom had compound heterozygous mutations in their GNE genes [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vacuolar changes are also present in drug-induced myopathy due to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      . The more acute presentation and drug history differentiate these conditions from IBM. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"       \"Drug-induced myopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with IBM who have predominantly distal or asymmetric involvement may resemble motor neuron disease or peripheral neuropathies with predominantly motor involvement. Electrophysiologic testing and muscle biopsy may be necessary to establish the correct diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23450?source=see_link\">",
"       \"Epidemiology and pathogenesis of amyotrophic lateral sclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Typical histopathologic changes of IBM are seen in a rare autosomal dominant disorder that is due to mutations in the gene for valosin containing protein [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/37\">",
"       37",
"      </a>",
"      ]. This disease has features of IBM, early-onset Paget disease of bone, and 'premature' frontotemporal dementia (MIM 605382) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15735/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. This disorder, which is known as inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia (IBMPFD), presents in adulthood. There is currently no effective therapy, and it is ultimately fatal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=see_link\">",
"       \"Patient information: Myositis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sporadic inclusion body myositis (IBM) is a rare disorder affecting from five to nine adults per million that causes muscle weakness with an insidious onset. Proximal muscle weakness is present initially in many patients, but distal weakness may be an early feature in some. Asymmetric weakness and myalgias each occur in a minority of patients. Dysphagia is common and occurs in from one-third to one-half of patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no diagnostic laboratory or imaging tests for IBM. Moderate CK elevation is typically seen (&lt;10-fold greater than normal). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Laboratory abnormalities'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Muscle biopsy findings may be diagnostic when typical rimmed vacuoles and eosinophilic muscle fiber inclusions are present. However, these features may not be apparent on the initial biopsy in some patients. The definitive feature of IBM is the presence of filamentous inclusions demonstrated by electron microscopy. Filaments bind antibodies with affinity for &szlig;-amyloid. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Muscle biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical diagnosis of sporadic inclusion body myositis is suspected on the basis of a combination of muscle weakness, elevated plasma levels of muscle enzymes, myopathic features noted on clinical electrophysiologic studies, and the presence in a muscle biopsy of vacuoles and characteristic filamentous inclusions within myocytes. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes other idiopathic inflammatory myopathies (eg, dermatomyositis, polymyositis), drug-induced myopathy, and heritable inclusion body myopathies. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/1\">",
"      Adams RD, Kakulas BA, Samaha FA. A myopathy with cellular inclusions. Trans Am Neurol Assoc 1965; 90:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/2\">",
"      Chou SM. Myxovirus-like structures in a case of human chronic polymyositis. Science 1967; 158:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/3\">",
"      Yunis EJ, Samaha FJ. Inclusion body myositis. Lab Invest 1971; 25:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/4\">",
"      Mendell JR, Sahenk Z, Gales T, Paul L. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol 1991; 48:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/5\">",
"      Kula RW, Sawchak JA, Sher JH. Inclusion body myositis. Curr Opin Rheumatol 1989; 1:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/6\">",
"      Mhiri C, Gherardi R. Inclusion body myositis in French patients. A clinicopathological evaluation. Neuropathol Appl Neurobiol 1990; 16:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/7\">",
"      Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000; 55:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/8\">",
"      Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 2000; 23:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/9\">",
"      Wilson FC, Ytterberg SR, St Sauver JL, Reed AM. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol 2008; 35:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/10\">",
"      Kaipiainen-Sepp&auml;nen O, Aho K. Incidence of rare systemic rheumatic and connective tissue diseases in Finland. J Intern Med 1996; 240:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/11\">",
"      Ringel SP, Kenny CE, Neville HE, et al. Spectrum of inclusion body myositis. Arch Neurol 1987; 44:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/12\">",
"      Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain 1989; 112 ( Pt 3):727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/13\">",
"      Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol 1992; 19:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/14\">",
"      Beyenburg S, Zierz S, Jerusalem F. Inclusion body myositis: clinical and histopathological features of 36 patients. Clin Investig 1993; 71:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/15\">",
"      Felice KJ, North WA. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Medicine (Baltimore) 2001; 80:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/16\">",
"      Wintzen AR, Bots GT, de Bakker HM, et al. Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry 1988; 51:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/17\">",
"      Riminton DS, Chambers ST, Parkin PJ, et al. Inclusion body myositis presenting solely as dysphagia. Neurology 1993; 43:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/18\">",
"      Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology 2000; 55:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/19\">",
"      Voermans NC, Vaneker M, Hengstman GJ, et al. Primary respiratory failure in inclusion body myositis. Neurology 2004; 63:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/20\">",
"      Rose MR, McDermott MP, Thornton CA, et al. A prospective natural history study of inclusion body myositis: implications for clinical trials. Neurology 2001; 57:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/21\">",
"      Dion E, Cherin P, Payan C, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 2002; 29:1897.",
"     </a>",
"    </li>",
"    <li>",
"     Mikol J, Engel AG. Inclusion body myositis. In: Myology, 2nd, Engel AG, Franzini-Armstrong C (Eds), McGraw-Hill, New York 1994. p.1385.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/23\">",
"      Engel WK, Askanas V. Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology 2006; 66:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/24\">",
"      Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/25\">",
"      Nishino H, Engel AG, Rima BK. Inclusion body myositis: the mumps virus hypothesis. Ann Neurol 1989; 25:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/26\">",
"      Askanas V, Engel WK. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Curr Opin Rheumatol 1998; 10:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/27\">",
"      Askanas V, Engel WK. Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 2001; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/28\">",
"      Askanas V, Engel WK, McFerrin J, Vattemi G. Transthyretin Val122Ile, accumulated Abeta, and inclusion-body myositis aspects in cultured muscle. Neurology 2003; 61:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/29\">",
"      Westaway D, DeArmond SJ, Cayetano-Canlas J, et al. Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins. Cell 1994; 76:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/30\">",
"      Lampe J, Kitzler H, Walter MC, et al. Methionine homozygosity at prion gene codon 129 may predispose to sporadic inclusion-body myositis. Lancet 1999; 353:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/31\">",
"      Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/32\">",
"      Askanas V. New developments in hereditary inclusion body myopathies. Ann Neurol 1997; 41:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/33\">",
"      Ranque-Francois B, Maisonobe T, Dion E, et al. Familial inflammatory inclusion body myositis. Ann Rheum Dis 2005; 64:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/34\">",
"      Nishino I, Noguchi S, Murayama K, et al. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology 2002; 59:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/35\">",
"      Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001; 29:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/36\">",
"      Yabe I, Higashi T, Kikuchi S, et al. GNE mutations causing distal myopathy with rimmed vacuoles with inflammation. Neurology 2003; 61:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/37\">",
"      Kimonis VE, Kovach MJ, Waggoner B, et al. Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Genet Med 2000; 2:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15735/abstract/38\">",
"      Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004; 36:377.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5163 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.100-DA0D917308-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15735=[""].join("\n");
var outline_f15_23_15735=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H383299\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Electromyography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Muscle biopsy abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5163\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5163|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/13/27867\" title=\"table 1\">",
"      IBM versus polymyositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=related_link\">",
"      Approach to the patient with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=related_link\">",
"      Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23450?source=related_link\">",
"      Epidemiology and pathogenesis of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=related_link\">",
"      Patient information: Myositis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28133?source=related_link\">",
"      Treatment and prognosis of inclusion body myositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_23_15736="Effect of antidepressants on suicide risk in children and adolescents";
var content_f15_23_15736=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Effect of antidepressants on suicide risk in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15736/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15736/contributors\">",
"     C Scott Moreland, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15736/contributors\">",
"     Liza Bonin, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15736/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15736/contributors\">",
"     David Brent, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15736/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15736/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/23/15736/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is concern that selective serotonin reuptake inhibitors (SSRIs) and other antidepressants may increase the risk of suicidal ideation and behavior in children, adolescents, and adults younger than 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In early 2004, the United States Food and Drug Administration (FDA) asked manufacturers of a number of antidepressants to make labeling changes to include a warning about a possible increased risk of suicidal ideation or behavior, particularly at the initiation of therapy or at the time of dose changes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/4\">",
"     4",
"    </a>",
"    ]. After further analysis, in October 2004, the FDA directed manufacturers of all antidepressants (including tricyclic antidepressants [TCAs] and monoamine oxidase inhibitors) to include a warning stating that antidepressants may increase the risk of suicidal ideation and behavior in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Establishing the causal association is difficult because of the clear associations between severe depression and suicide and between severe depression and the need for antidepressant therapy. Because suicide is uncommon, it also is difficult to demonstrate the negative, which is that antidepressants do not cause suicide. Risk factors for suicidal behavior in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link&amp;anchor=H7#H7\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\", section on 'Psychiatric disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic discusses the evidence regarding antidepressants and the risk of suicide in children and adolescents. The use of antidepressants in adolescent depression is discussed separately, as is the association between antidepressants and suicide risk in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=see_link\">",
"     \"Psychopharmacological treatment for adolescent depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVIDENCE OF ASSOCIATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence for and against an association between antidepressant therapy and suicidal thoughts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    behaviors in children, adolescents, and young adults comes from randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/6-10\">",
"     6-10",
"    </a>",
"    ], observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], and population-based studies comparing the rates of suicide and antidepressant use over time [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. Each of these study designs has limitations in demonstrating a causal association [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suicide is rare in randomized, controlled trials of antidepressants. Thus, individual trials typically lack the power to detect a relationship between antidepressants and suicidal ideation or behavior.",
"     </li>",
"     <li>",
"      Observational studies can more easily detect rare events such as suicide. However, causality is difficult to establish because of the association between severe depression and the use of antidepressants.",
"     </li>",
"     <li>",
"      Population-based studies have examined rates of antidepressant use and suicide over time. These studies have generally found lower rates of suicide with increasing rates of antidepressant use [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/14-18\">",
"       14-18",
"      </a>",
"      ]. Accordingly, the consensus has been that increases in prescribing likely yield lower rates of suicide. However, rare antidepressant-induced suicides could be masked by secular trends [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/21\">",
"       21",
"      </a>",
"      ]. In addition, the use of newer antidepressants (eg, SSRIs) may be a marker for better overall quality of health care [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/18\">",
"       18",
"      </a>",
"      ]. Thus, it is not clear that increased rates of antidepressant prescribing are the cause of decreasing rates of suicide [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials of antidepressants in children and adolescents were not designed to determine whether these medications increase suicidal behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/22\">",
"     22",
"    </a>",
"    ]. Most of the studies excluded subjects with suicidal ideation and did not have enough power to detect rare adverse events such as suicide. Suicidal behavior, if it occurred, was reported as an adverse event, but was not uniformly defined [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systematic reviews of randomized trials, subject to the limitations described above, have yielded different conclusions about the association between antidepressants and increased risk of suicidal ideation and behavior, as illustrated below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The FDA convened an advisory panel to reexamine analyses of published and unpublished data regarding suicidal thoughts and behaviors and antidepressants in children and adolescents. The advisory panel's combined analysis of 24 short-term (4 to 16 weeks), placebo-controlled trials of nine antidepressant medications in more than 4400 children and adolescents being treated for major depressive disorder (MDD) and other psychiatric disorders yielded the following results [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/10\">",
"       10",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      78 patients (2 percent) experienced adverse events representing suicidal ideation or behavior, collectively termed suicidality; adverse events are reports made by the research clinician if a patient or parent spontaneously shares thoughts about suicidality [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among the adverse events that were reported, patients on antidepressant medication had an increased risk of suicidality during the first few months of treatment compared with those on placebo (4 percent versus 2 percent).",
"     </li>",
"     <li>",
"      In 17 of 23 studies, standardized forms were used to ask each patient about suicidality at each visit. The data revealed that medication neither increased the suicidality that was present before treatment, nor induced suicidality in patients who were not thinking about suicide at the start of the study. Over the course of treatment, all studies combined showed a slight reduction in suicidality.",
"     </li>",
"     <li>",
"      No completed suicides occurred during any of the studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The FDA advisory panel concluded that there is a small increased risk of suicidal thoughts or behavior in children taking antidepressants compared with placebo (risk ratio 2.0, 95% CI 1.3-3.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/10\">",
"       10",
"      </a>",
"      ]. The risk appears to be greatest in the first few weeks after initiating therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/10,24\">",
"       10,24",
"      </a>",
"      ]. Similar results were found in a 2007 meta-analysis that included seven studies not examined by the FDA when using a fixed-effects model (which assumes homogeneity across studies) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/25\">",
"       25",
"      </a>",
"      ]. However, using a random effects model, the 2007 meta-analysis found only a 0.7 percent increase in the risk of suicidal ideation or behavior in children taking antidepressants, a difference that was not statistically significant. The ratio of patients who responded to an antidepressant compared to those who experienced a suicidal event was around 11:1.",
"     </li>",
"     <li>",
"      A meta-analysis of 17 trials (3229 children and adolescents) compared antidepressants (SSRIs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ) with placebo and found that suicidal ideation or behavior occurred in more patients who received antidepressants (RR=1.58, 95% CI 1.02-2.45) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/26\">",
"       26",
"      </a>",
"      ]. The authors estimated that this translated to an increase in suicidal events of around 1.5 percent, in contrast to an increase in remission of 6.8 percent, so that the rate of remission was over 4.5 more frequent than the rate of suicidal events.",
"     </li>",
"     <li>",
"      The preliminary report of the American College of Neuropsychopharmacology (ACNP) Task Force on SSRIs and Suicidal Behavior in Youth included published and unpublished evidence from 15 trials regarding the safety and effectiveness of five antidepressants (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/9\">",
"       9",
"      </a>",
"      ]. Among 15 clinical trials, including more than 2000 patients, there were no completed suicides. The rate of suicidal behavior and ideation was similar between those treated with antidepressants and placebo.",
"     </li>",
"     <li>",
"      Analysis of FDA summary reports of randomized trials of nine second-generation antidepressants found 77 suicides among 48,277 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/6\">",
"       6",
"      </a>",
"      ]. Rates of suicide based on patient exposure years were similar among those receiving an SSRI (0.59 percent [95% CI 0.31-0.87 percent]), a different antidepressant (a combination of the newer antidepressants being studied and the older antidepressants used in the active control arms of the studies) (0.76 percent [95% CI 0.49-1.03 percent]), and placebo (0.45 percent [95% CI 0.01-0.89 percent]).",
"     </li>",
"     <li>",
"      A meta-analysis of four randomized trials (708 children and adolescents with major depression), including the Treatment for Adolescents with Depression Study, found that the risk of suicidal thoughts and behavior was comparable for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      and placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/27\">",
"       27",
"      </a>",
"      ]. Although the meta-analysis found that antidepressants did not provide a protective effect against suicidality in youth, in older patients, suicidal thoughts and behavior decreased with antidepressants. The effect of antidepressants upon suicidality in adults is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=see_link\">",
"       \"Effect of antidepressants on suicide risk in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Treatment for Adolescents With Depression Study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Treatment for Adolescents with Depression Study (TADS) is one of the first studies to track suicidal thoughts and behaviors in the context of adolescent depression treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/8,28\">",
"     8,28",
"    </a>",
"    ]. TADS compared the short-term (12-week) efficacy of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    (an SSRI), cognitive behavioral therapy (CBT), fluoxetine plus CBT, and pill placebo in 439 adolescents with major depressive disorder (MDD). The second phase of TADS compared the long-term (36-week) safety and effectiveness of the three active treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients at high risk for suicide (suicide attempt requiring medical attention within six months, clear intent or active plan to commit suicide, or suicidal ideation with a family unable to guarantee safety) were excluded. However, approximately 30 percent of patients had some evidence of suicidality at entry (as measured by the Suicidal Ideation Questionnaire-Junior High School Version [SIQ-Jr], on which a score of &ge;31 indicates a level of suicidality requiring prompt clinical attentions).",
"   </p>",
"   <p>",
"    After 12 weeks of therapy, patients in all four groups had a significant decrease in suicidal thinking from baseline (from adjusted mean total score of 20 to 30 to an adjusted mean total score of 11 to 15, depending upon the treatment group). The proportion of patients with scores &ge;31 (indicating a level of suicidality requiring prompt attention) decreased from 30 percent at baseline to 10 percent after 12 weeks of therapy. Improvement in suicidal thinking was greatest for patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    with CBT and least for those receiving fluoxetine alone, suggesting that CBT is protective against suicidal thinking. Treatment with fluoxetine did not appear to increase suicidal thinking.",
"   </p>",
"   <p>",
"    Among the 439 subjects in the acute-phase of TADS, 24 (5.5 percent) had a suicide-related adverse event (worsening suicidal ideation, suicide attempt, or both). Seven patients attempted suicide (four in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    plus CBT group, two in the fluoxetine monotherapy group, and one in the CBT monotherapy group) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/8\">",
"     8",
"    </a>",
"    ]. There were no completed suicides. A subsequent analysis did not include two of the suicide attempts in the combination group (one occurred after the patient prematurely terminated from the assigned treatment, and one was not coded as a suicide attempt according to the Columbia-Classification Algorithm for Suicidal Assessment) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the long-term phase, suicidal ideation decreased with treatment in all groups, but less so in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    group [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/28\">",
"     28",
"    </a>",
"    ]. Suicide events were more frequent in the fluoxetine group than in the other two groups (15 percent versus 8 percent for combination and 6 percent for CBT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Observational studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of eight observational studies (&gt;200,000 patients) found that exposure to SSRIs in adolescents with moderate or severe depression was associated with an increased risk for attempted or completed suicide (OR 1.92, CI 1.51-2.44) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/13\">",
"     13",
"    </a>",
"    ]. However, adolescents who received treatment with SSRIs may have been more severely depressed than those who did not receive SSRIs. Nonetheless, these results are similar to the findings of the FDA analysis of randomized controlled trials described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taken together, the data suggest that compared with placebo, antidepressant medications in some children and adolescents may result in a small increase in the risk of suicidality. However, studies of antidepressants found that response occurred 11 times more often than a suicidal event, and remission (a more stringent outcome than response) occurred 4.5 times more often than a suicidal event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF VARIOUS GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In response to concerns about the increased risk of suicidality with antidepressant therapy, various regulatory and clinical groups have taken a closer look at the data, and based upon their conclusions, made recommendations regarding the use of antidepressants in children and adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     FDA black box warning",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2004, the FDA directed manufacturers of antidepressants (",
"    <a class=\"graphic graphic_table graphicRef80584 \" href=\"UTD.htm?0/46/749\">",
"     table 1",
"    </a>",
"    ) to revise the labeling of their products to include a boxed warning and expanded warning statements about the risks of suicidality in children and adolescents being treated with these drugs (",
"    <a class=\"graphic graphic_table graphicRef54498 \" href=\"UTD.htm?35/56/36748\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/5,30\">",
"     5,30",
"    </a>",
"    ]. In May 2007, the FDA extended the warning to include adults younger than 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/20,31\">",
"     20,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The FDA also updated the medication guide and product labeling to remind healthcare providers that depression and certain other serious psychiatric disorders are themselves the most important causes of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The warning applies to any and all use of antidepressant drugs in children and adolescents. The warning requires any clinician prescribing antidepressant medication to clearly warn the patient and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    family about the potential risks associated with these medications. In addition, the FDA has determined that all patients receiving these medications should be given a Patient Medication Guide (MedGuide) to advise them of the risk and precautions that can be taken (",
"    <a class=\"graphic graphic_table graphicRef77780 \" href=\"UTD.htm?27/22/28013\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/33\">",
"     33",
"    </a>",
"    ]. MedGuides are intended to be distributed by the pharmacist with each new prescription or refill of antidepressant medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other regulatory and clinical groups have come to differing conclusions regarding the safety and efficacy of antidepressants in children, as illustrated below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) found only",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      to have a favorable risk-benefit profile [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/34\">",
"       34",
"      </a>",
"      ]. It recommends against the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      for the treatment of MDD in children [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American College of Neuropsychopharmacology (ACNP) Task Force on SSRIs and Suicidal Behavior in Youth concluded that, because depression is one of the largest risk factors for suicide, diagnosis and treatment of depression in children and adolescents require urgent attention [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/35\">",
"       35",
"      </a>",
"      ]. The Task Force found that among the antidepressants, only",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      has demonstrated strong statistical evidence of efficacy. The Task Force also concluded that, based on the FDA meta-analysis, SSRI and other antidepressants are associated with a small increase in the risk of suicidality. However, other lines of evidence (eg, population-based studies comparing the rates of suicide and antidepressant use over time [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/14-18\">",
"       14-18",
"      </a>",
"      ], toxicology studies of completed suicides [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/36,37\">",
"       36,37",
"      </a>",
"      ], and cohort studies [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]) indicated a possible beneficial effect of antidepressant therapy on the risk of suicide. The Task Force recommends the continued use of fluoxetine as an effective and readily available treatment for major depression in children and adolescents.",
"     </li>",
"     <li>",
"      The American Academy of Child and Adolescent Psychiatry (AACAP) supported the conclusions of the ACNP Task Force. The AACAP Work Group recommended that its members continue to treat depression with all of the effective means available. Effective treatment, based on available research, includes treatment with an antidepressant only, an antidepressant with CBT, or CBT alone. The AACAP supports a combined treatment approach as the most efficacious [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/23,40\">",
"       23,40",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      has the most evidence of efficacy and is considered the first-line medication [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/23\">",
"       23",
"      </a>",
"      ]. However, because 30 to 40 percent of patients may not respond to fluoxetine and others will be unable to tolerate it because of side effects, alternative medications are necessary; other SSRIs are most appropriate. The treating clinician, in conjunction with the patient and family, must determine the best treatment option for the individual patient.",
"     </li>",
"     <li>",
"      The Society for Adolescent Medicine (SAM) strongly supports the appropriate use of antidepressant medications in the treatment for adolescents with depression [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/41\">",
"       41",
"      </a>",
"      ]. When using such medications, the risk of suicidality must be balanced with the clinical need.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MONITORING FOR SUICIDALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are treated with antidepressants must be closely monitored by the clinician and family. Details of monitoring, including frequency and parameters, are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     IMPACT OF THE FDA ADVISORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Integrated claims data from national managed care plans in the United States were used to evaluate patterns of diagnosis and treatment of depression in children and adolescents before and after the FDA advisory on risk of suicidality with SSRIs in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/32,42-44\">",
"     32,42-44",
"    </a>",
"    ]. Between 1999 and 2004, the rates of diagnosis of new episodes of pediatric depression and of treatment with SSRIs were increasing. After the FDA advisory, there was a reversal in both of these trends, without evidence of a significant increase in other treatment modalities. In addition, care and treatment of children and adolescents with depression shifted from generalists to psychiatrists.",
"   </p>",
"   <p>",
"    The aforementioned studies did not evaluate the possible underlying causes of the shifts in diagnosis of depression and prescribing of antidepressants for children and adolescents. One possibility is that the original increase in depression rates and use of antidepressants in children reflected over-diagnosis and misuse of medication. If this is correct, then the decrease after the FDA warnings is an appropriate outcome. Alternatively, current practice could reflect a substantial problem with under-diagnosis and undertreatment of depression.",
"   </p>",
"   <p>",
"    What is clear is that since the FDA warnings, general practitioners are diagnosing less pediatric depression and prescribing fewer antidepressants to children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/32,42,43\">",
"     32,42,43",
"    </a>",
"    ]. While psychiatrists are treating slightly more youth depression, it is not enough to compensate for the observed decline in primary care. The observed rates of diagnosis after the FDA advisory (0.3 to 0.5 percent) are substantially lower than previously published incidences of child (0.4 to 2.5 percent) and adolescent depression (0.4 to 8.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/42\">",
"     42",
"    </a>",
"    ]. It is still too soon to know the impact and meaning of these trends on the treatment and prognosis of depression in children and adolescents.",
"   </p>",
"   <p>",
"    According to the United States Centers for Disease Control and Prevention (CDC), 1985 suicides occurred among children and adolescents aged 10 through 19 years in 2004, compared with 1737 in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. This was the first increase in the suicide rate in this age group in more than ten years. Similarly, in the Netherlands, the suicide rate in children and adolescents increased by 49 percent between 2003 and 2005; during the same time period, SSRI prescriptions for children and adolescents decreased by 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results were found in a 2008 Canadian study which examined data 9 years before and 2 years after Health Canada&rsquo;s regulatory warning on prescribing antidepressants to children and adolescents (which occurred in June 2003, 4 months before the FDA&rsquo;s October warning). Suicide deaths in children and adolescents increased significantly by 25 percent, corresponding to a significant decrease in antidepressant prescriptions of 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, changes were found in treatment that was not directly targeted by the warning: antidepressant prescriptions for young adults (18 to 24 years) decreased significantly, as did follow up visits for depression for children, adolescents, and young adults.",
"   </p>",
"   <p>",
"    The black box warning was intended to bring attention to and close monitoring of antidepressants in children and adolescents, not to decrease the amount of prescriptions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment for depression. The apparent unexpected effect of the regulatory actions on clinician's prescribing practices is a cause for significant concern, particularly in the context of evidence that antidepressant treatment in children and adolescents is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The debate concerning risk for suicidality with antidepressants compared to the risk of suicide in untreated or undertreated depression has significant consequences. Beyond working to clarify the nature of the relationship between suicide and antidepressants, systemic monitoring of the consequences of regulatory warnings is an ongoing need. Approximately two-thirds of children and adolescents with a mental disorder do not receive adequate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15736/abstract/50\">",
"     50",
"    </a>",
"    ]. Anything that significantly interferes with access to care should be a cause for concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"       \"Patient information: Depression in adolescents (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=see_link\">",
"       \"Patient information: Depression treatment options for adolescents (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There appears to be a slightly increased risk of suicidal thoughts and behaviors (but not completed suicide) among a small group of children and adolescents who are treated with antidepressant medications compared with placebo. However, the evidence is inadequate to conclusively establish this association. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Summary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The FDA has directed manufacturers of antidepressants (",
"      <a class=\"graphic graphic_table graphicRef80584 \" href=\"UTD.htm?0/46/749\">",
"       table 1",
"      </a>",
"      ) to include a boxed warning label regarding the increased risk of suicidality (",
"      <a class=\"graphic graphic_table graphicRef54498 \" href=\"UTD.htm?35/56/36748\">",
"       table 2",
"      </a>",
"      ), thus requiring the prescribing clinician to discuss the warning with the patient and family. In addition, all patients receiving antidepressants should be given a Patient Medication Guide (MedGuide) to advise them of the risk and precautions that can be taken (",
"      <a class=\"graphic graphic_table graphicRef77780 \" href=\"UTD.htm?27/22/28013\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'FDA black box warning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When considering the use of antidepressants in children and adolescents, the risk of antidepressant-related suicidality must be weighed against the beneficial effects of treatment and the long-term risk of suicide in untreated depression. When considering this balance, the consensus among most mental health specialists is that the benefits of antidepressant therapy outweigh the risks. The ratio of response to suicidal events is approximately 11:1, and for remission to suicidal events is 4.5:1 (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Other groups'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Randomized trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children and adolescents who are treated with antidepressants be closely monitored by the clinician and family for increasing suicidal thoughts or behaviors.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/1\">",
"      Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003; 72:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/2\">",
"      Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/3\">",
"      Jureidini JN, Doecke CJ, Mansfield PR, et al. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004; 328:879.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. FDA. Public Health Advisory. Worsening Depression and Suicidality in Patients Being Treated with Antidepressant Medications. March 22, 2004. Available at www.fda.gov/cder/drug/antidepressants/AntidepressanstPHA.htm (Accessed on June 29, 2006).",
"    </li>",
"    <li>",
"     U.S. FDA. Public Health Advisory. Suicidality in children and adolescents being treated with antidepressant medications. October 15, 2004. Available at www.fda.gov/cder/drug/antidepressants/SSRIPHA200410.htm (Accessed on June 29, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/6\">",
"      Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/7\">",
"      Beasley CM Jr, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/8\">",
"      March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292:807.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Neuropsychopharmacology, Preliminary Report of the Task Force on SSRI's and Suicidal Behavior in Youth. January 21, 2004. Available at: www.acnp.org (Accessed on September 13, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/10\">",
"      Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/11\">",
"      Fux M, Taub M, Zohar J. Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors. Acta Psychiatr Scand 1993; 88:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/12\">",
"      Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study. Arch Gen Psychiatry 2006; 63:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/13\">",
"      Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ 2009; 180:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/14\">",
"      Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ 2003; 326:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/15\">",
"      Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/16\">",
"      Carlsten A, Waern M, Ekedahl A, Ranstam J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf 2001; 10:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/17\">",
"      Isacsson G, Holmgren P, Druid H, Bergman U. The utilization of antidepressants--a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992-1994. Acta Psychiatr Scand 1997; 96:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/18\">",
"      Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005; 62:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/19\">",
"      Vitiello B, Swedo S. Antidepressant medications in children. N Engl J Med 2004; 350:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/20\">",
"      Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. N Engl J Med 2007; 356:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/21\">",
"      Gunnell D, Ashby D. Antidepressants and suicide: what is the balance of benefit and harm. BMJ 2004; 329:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/22\">",
"      Rappaport N, Prince JB, Bostic JQ, Association of Medical School Pediatric Department Chairs, Inc. Lost in the black box: juvenile depression, suicide, and the FDA's black box. J Pediatr 2005; 147:719.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Child and Adolescent Psychiatry. Supplementary talking points for child and adolescent psychiatrists regarding the FDA black box warning on the use of antidepressants for pediatric patients. November, 2004. Available at www.aacap.org/announcements/psychiatricmeds.htm (Accessed on June 29, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/24\">",
"      Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/25\">",
"      Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/26\">",
"      Hetrick SE, McKenzie JE, Cox GR, et al. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2012; 11:CD004851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/27\">",
"      Gibbons RD, Brown CH, Hur K, et al. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/28\">",
"      March JS, Silva S, Petrycki S, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007; 64:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/29\">",
"      Emslie G, Kratochvil C, Vitiello B, et al. Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry 2006; 45:1440.",
"     </a>",
"    </li>",
"    <li>",
"     Labeling change request letter for antidepressant medications. Available at www.fda.gov/cder/drug/antidepressants/SSRIlabelChange.htm (Accessed on June 29, 2006).",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Antidepressant use in children, adolescents, and adults. Available at: www.fda.gov/cder/drug/antidepressants/default.htm. Accessed on May 2, 2007.",
"    </li>",
"    <li>",
"     FDA Revised Talk Paper: FDA Proposes new warnings about suicidial thinking, behavior in young adults who take antidepressant medications. May 2, 2007. Available at: www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html (Accessed on July 26, 2008).",
"    </li>",
"    <li>",
"     FDA proposed medication guide: about using antidepressants in children for teenagers. Available at www.fda.gov/cder/drug/antidepressants/SSRIMedicationGuide.htm (Accessed on June 29, 2006).",
"    </li>",
"    <li>",
"     Selective serotonin reuptake inhibitors (SSRIs): Overview of regulatory status and CSM advice relating to major depressive dosorder (MDD) in children and adolescents including a summary of available safety and efficacy data. Available at www.mhra.gov.uk (Accessed on June 29, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/35\">",
"      Mann JJ, Emslie G, Baldessarini RJ, et al. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 2006; 31:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/36\">",
"      Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand 2005; 111:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/37\">",
"      Leon AC, Marzuk PM, Tardiff K, Teres JJ. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiatry 2004; 65:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/38\">",
"      Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/39\">",
"      Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004; 18:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/40\">",
"      Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007; 46:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/41\">",
"      Lock J, Walker LR, Rickert VI, et al. Suicidality in adolescents being treated with antidepressant medications and the black box label: position paper of the Society for Adolescent Medicine. J Adolesc Health 2005; 36:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/42\">",
"      Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007; 164:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/43\">",
"      Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007; 64:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/44\">",
"      Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009; 66:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/45\">",
"      Centers for Disease Control and Prevention (CDC). Suicide trends among youths and young adults aged 10-24 years--United States, 1990-2004. MMWR Morb Mortal Wkly Rep 2007; 56:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/46\">",
"      Hamilton BE, Mini&ntilde;o AM, Martin JA, et al. Annual summary of vital statistics: 2005. Pediatrics 2007; 119:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/47\">",
"      Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/48\">",
"      Katz LY, Kozyrskyj AL, Prior HJ, et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ 2008; 178:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15736/abstract/49\">",
"      Mosholder AD, Pamer CA. Postmarketing surveillance of suicidal adverse events with pediatric use of antidepressants. J Child Adolesc Psychopharmacol 2006; 16:33.",
"     </a>",
"    </li>",
"    <li>",
"     National Mental Health Information Center, Center for Mental Health Services. Children and Mental Health Fast Facts, 2000. Available at: mentalhealth.samhsa.gov/publications/allpubs/fastfact5/default.asp (Accessed on July 25, 2008).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1225 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15736=[""].join("\n");
var outline_f15_23_15736=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVIDENCE OF ASSOCIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Randomized trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Treatment for Adolescents With Depression Study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Observational studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RECOMMENDATIONS OF VARIOUS GROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FDA black box warning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MONITORING FOR SUICIDALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      IMPACT OF THE FDA ADVISORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1225\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1225|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/46/749\" title=\"table 1\">",
"      Black box antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/56/36748\" title=\"table 2\">",
"      Antidepressant warning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/22/28013\" title=\"table 3\">",
"      Med guide antidepressants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=related_link\">",
"      Effect of antidepressants on suicide risk in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=related_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=related_link\">",
"      Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=related_link\">",
"      Psychopharmacological treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_23_15737="Prenatal sonographic diagnosis of cystic renal disease";
var content_f15_23_15737=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prenatal sonographic diagnosis of cystic renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15737/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15737/contributors\">",
"     Tulin Ozcan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15737/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15737/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15737/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15737/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15737/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/23/15737/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital cystic renal diseases may become clinically apparent in the fetus, child, or adult. Congenital cystic renal diseases that can be diagnosed by antenatal ultrasound examination will be reviewed here. The diagnosis, clinical manifestations, and prognosis of renal cysts and cystic disorders in children and adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=see_link\">",
"     \"Renal cystic diseases in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=see_link\">",
"     \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link\">",
"     \"Genetics and pathogenesis of nephronophthisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=see_link&amp;anchor=H341953331#H341953331\">",
"     \"Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)\", section on 'Mucin 1 mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29937733\">",
"    <span class=\"h1\">",
"     ULTRASOUND APPEARANCE OF THE KIDNEY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal renal cortex is as echogenic as the liver or spleen, while the medulla is relatively hypoechogenic. By definition, a hyperechogenic kidney has a renal cortex more echogenic than the liver and spleen. It is important to note that normal fetal kidneys can be physiologically hyperechogenic in the first and second trimester.",
"   </p>",
"   <p>",
"    Ultrasound examination of fetuses with hyperechoic kidneys includes assessment of [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Amniotic fluid volume",
"     </li>",
"     <li>",
"      Kidney size",
"     </li>",
"     <li>",
"      Corticomedullary differentiation",
"     </li>",
"     <li>",
"      Level of renal echogenicity",
"     </li>",
"     <li>",
"      Location and size of renal cysts (if present)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Corticomedullary differentiation can be absent or present and, if present, is further classified as normal, increased, or reversed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/2\">",
"     2",
"    </a>",
"    ]. Normal corticomedullary differentiation is defined according to the echogenicity of the cortex and medulla. The combination of renal cortex as echogenic as liver or spleen and relatively hypoechogenic medulla is characteristic of well-defined, normal corticomedullary differentiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29937740\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several classification systems for congenital cystic renal disease have been proposed, taking into account the pathologic, clinical, and genetic features of these disorders. For clinical purposes, it is useful to classify cystic renal diseases that present in the prenatal period in the following way:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Autosomal recessive polycystic kidney disease",
"     </li>",
"     <li>",
"      Autosomal dominant polycystic kidney disease",
"     </li>",
"     <li>",
"      Renal cysts seen with",
"      <span class=\"nowrap\">",
"       syndromes/sequences",
"      </span>",
"      (glomerulocystic and medullary cystic dysplasia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonhereditary disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Renal dysplasia",
"     </li>",
"     <li>",
"      Multicystic kidney disease",
"     </li>",
"     <li>",
"      Obstructive cystic dysplasia",
"     </li>",
"     <li>",
"      Nondysplastic renal cystic tumors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nondysplastic nonhereditary renal cysts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Renal cystic tumors",
"     </li>",
"     <li>",
"      Simple renal cysts",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12017265\">",
"    <span class=\"h1\">",
"     HEREDITARY DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Autosomal recessive polycystic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal recessive polycystic kidney disease (ARPKD) is a rare disorder, occurring in 1:20,000 live births. Fetal death may occur because of severe oligohydramnios, and neonatal death may occur because of pulmonary insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ARPKD is caused by mutations in the PKHD1 gene (polycystic kidney and hepatic disease gene) on chromosome 6p, which encodes the protein fibrocystin. Fibrocystin is normally expressed in the primary cilia and the basal body of renal and bile duct epithelial cells. Its exact function is not known; however, fibrocystin likely acts as a membrane receptor, interacting with extracellular protein ligands and transducing intracellular signals to the nucleus involved in collecting-duct and biliary differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link&amp;anchor=H88678691#H88678691\">",
"     \"Autosomal recessive polycystic kidney disease in children\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal pathology in ARPKD is characterized by nonobstructive dilatation or ectasia of the collecting tubules located in the renal medulla, resulting in microcysts up to 2 mm in diameter. The cysts may expand into the cortex in severe cases. The outer renal cortex remains normal since there are no tubules in this area. The severity of the renal disease is proportional to the percentage of nephrons affected by cysts and is correlated with the severity of the PHKD1 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/5\">",
"     5",
"    </a>",
"    ]. All affected individuals have some degree of liver involvement with biliary dysgenesis and hepatic fibrosis.",
"   </p>",
"   <p>",
"    ARPKD has been subclassified into perinatal, neonatal, and juvenile groups. Renal involvement is more common in cases with perinatal presentation, whereas liver involvement is more typical of later diagnosis of ARPKD.",
"   </p>",
"   <p>",
"    The pathogenesis, pathology, and clinical manifestations of ARPKD are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"     \"Autosomal recessive polycystic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Ultrasound appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant prenatal ultrasound feature of ARPKD is uniform, massive enlargement of the kidneys with preservation of the reniform shape (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69859 graphicRef79653 \" href=\"UTD.htm?31/38/32357\">",
"     image 1A-B",
"    </a>",
"    ) with diffuse hyperechogenicity of both cortex and medulla, and loss of corticomedullary differentiation.",
"   </p>",
"   <p>",
"    The sonographic features of ARPKD can initially appear anytime during gestation. Elongated hyperechogenic kidneys with normal transverse and anteroposterior diameters may be the only ultrasound finding before the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/6\">",
"     6",
"    </a>",
"    ]. Serial ultrasound examinations with measurement of kidney dimensions that confirm progressive enlargement and reduction in amniotic fluid volume help establish the diagnosis. This is particularly important before 24 weeks of gestation when the diagnosis is less certain. The presence of severe oligohydramnios, especially when there is a family history of ARPKD, increases the probability that the presumptive diagnosis is accurate.",
"   </p>",
"   <p>",
"    The kidney size is typically 4 to 15 standard deviations above the mean size for gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/7\">",
"     7",
"    </a>",
"    ]. Due to the large kidney size, the abdominal circumference is larger than expected for menstrual dates. Late in pregnancy, isolated macroscopic cysts are visible in the renal medulla in one third of cases. The massive enlargement of the kidneys is often associated with oligohydramnios and a small or absent bladder due to the drastic reduction in urine production. Pulmonary hypoplasia can occur when oligohydramnios is present early in gestation. However, oligohydramnios is not always present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/888?source=see_link\">",
"     \"Physiology of amniotic fluid volume regulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A relatively hypoechoic peripheral rim representing the normal peripheral cortex may be present and can be a key finding in differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/7\">",
"     7",
"    </a>",
"    ]. Pyramidal hyperechogenicity resembling medullary nephrocalcinosis (calcium deposits) with reversal of corticomedullary differentiation has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/8\">",
"     8",
"    </a>",
"    ]. This finding is important since there are very few other causes of reversed corticomedullary differentiation. Amniotic fluid volume is preserved and these patients have a better prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/7\">",
"     7",
"    </a>",
"    ]. By comparison, in children and adults, the kidney size is less prominent and a hypoechoic outer cortical rim with reversed corticomedullary differentiation, medullary macrocysts, or echoic nonshadowing foci in the medulla is usually seen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of associated structural fetal abnormalities is not increased, except, as discussed above, the liver may be involved and pulmonary hypoplasia may be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Obstetric management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ARPKD is likely when there are bilateral enlarged echogenic kidneys, a small or absent bladder, and oligohydramnios; however, a precise prenatal diagnosis cannot be made with certainty by ultrasound alone. Echogenic kidneys without cysts and with normal amniotic fluid volume represent a variant of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/10\">",
"     10",
"    </a>",
"    ]. Fetuses with very large kidneys and severe oligohydramnios are likely to have a poor outcome (eg, pulmonary hypoplasia), whereas when amniotic fluid volume remains normal and the kidneys are moderately enlarged, there is a higher likelihood of survival without significant morbidity.",
"   </p>",
"   <p>",
"    ARPKD is not associated with an increased frequency of abnormal karyotype; therefore, chromosome studies are not helpful for confirming the diagnosis, but can be useful for excluding other disorders in the differential diagnosis associated with an abnormal karyotype. Additionally, amniocentesis or chorionic villus sampling can be performed so molecular diagnostic tests can be done on fetal DNA, which can sometimes confirm the diagnosis of ARPKD. Prenatal diagnosis is possible using haplotype analysis or direct mutation analysis on the PKHD1 gene. Direct mutation analysis has been reported to detect 47 to 83 percent of phenotypically diverse and 85 percent of severe phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/11\">",
"     11",
"    </a>",
"    ]. Molecular genetic testing is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link&amp;anchor=H172118677#H172118677\">",
"     \"Autosomal recessive polycystic kidney disease in children\", section on 'Molecular genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic siblings of affected children should be evaluated for hepatic fibrosis and renal lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link&amp;anchor=H25824024#H25824024\">",
"     \"Autosomal recessive polycystic kidney disease in children\", section on 'Counseling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Survival of individuals with ARPKD depends upon the subtype: perinatal (hours), neonatal (months), infantile (up to 10 years), and juvenile (decades). Perinatal death is related to both renal and pulmonary insufficiency. However, if pulmonary hypoplasia is not life threatening, dialysis and renal transplantation have been reported to prolong survival [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/12\">",
"     12",
"    </a>",
"    ]. Pregnancy interruption is an option due to reduced life expectancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link&amp;anchor=H9#H9\">",
"     \"Autosomal recessive polycystic kidney disease in children\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autosomal dominant polycystic renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal cystic disease. Although the typical age of clinical onset is in the third to fifth decade of life, rarely (&lt;1 percent of cases) ADPKD can present in utero or in the neonatal period with ultrasound changes, similar to ARPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/13\">",
"     13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    ADPKD is characterized by the slow development (over decades) of large spherical cystic dilatation in all parts of the nephron, although the initial differentiation to nephrons and the collecting system are normal. The renal pathology is focal with areas of abnormal nephrons scattered among areas of abnormal nephrons. The tubule wall, which is lined by a single layer of epithelial cells, expands and then rapidly closes off from the tubule of origin. This is different from ARPKD in which cysts are derived from collecting tubules and remain connected to the nephron of origin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/3\">",
"     3",
"    </a>",
"    ]. Initially, cysts may be localized to the distal nephron and the collecting duct; in later stages, they are spread to both the cortex and medulla. As the cysts enlarge, they severely compromise the functional integrity of the remaining normal parenchyma. Approximately 50 percent of ADPKD patients will progress to end stage renal disease, requiring transplant or dialysis by late middle age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link\">",
"     \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extrarenal abnormalities include cysts in other organs, such as the liver, seminal vesicles (in males), pancreas, and arachnoid membrane. There may also be noncystic abnormalities, such as intracranial and coronary artery aneurysms and dolichoectasias, aortic root dilatation and aneurysms, mitral valve prolapse, and abdominal wall hernias [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estimated incidence at birth is 1:400 to 1000 deliveries; however, this disorder is rarely identified prenatally [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/14\">",
"     14",
"    </a>",
"    ]. ADPKD is inherited as an autosomal dominant trait with complete penetrance. The disease is caused by mutations in either of the two genes encoding plasma membrane&ndash;spanning polycystin 1 and polycystin 2 (PKD1 on chromosome 16p13.3) and PKD2 (on chromosome 4q21), respectively. The polycystins regulate tubular and vascular development in the kidneys and other organs (liver, brain, heart, and pancreas) and interact to increase the flow of calcium through a cation channel formed in plasma membranes. Mutations of PKD1 are more common than mutations of PKD2 (accounting for 85 percent of cases), are likely to be associated with more renal cysts, and lead to earlier development of renal insufficiency (on average 20 years earlier) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link\">",
"     \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a small number of families with classic presentations of polycystic kidney disease whose members appear to have mutations at loci distinct from those of PKD1 and PKD2, suggesting that a third locus may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The renal manifestations, ex-utero diagnosis, and course of this disorder are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28584?source=see_link\">",
"     \"Autosomal dominant polycystic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Ultrasound appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, the kidneys appear normal prenatally. The rarely seen prenatal presentation of ADPKD is characterized by moderately enlarged kidneys (1 to 2 standard deviations above the mean size for gestational age) with a hyperechogenic cortex. The medulla can be hypoechogenic or hyperechogenic. A hypoechogenic medulla resulting in increased corticomedullary differentiation was reported in 25 of 27 (77 percent) prenatally diagnosed cases; absent or decreased corticomedullary differentiation with hyperechoic medulla was less frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/16\">",
"     16",
"    </a>",
"    ]. Cysts are seen in approximately 15 percent of prenatal cases, and are usually in a cortical location. Very rarely, one kidney may be larger than the other, suggesting unilateral disease.",
"   </p>",
"   <p>",
"    The ultrasonographic appearance of the kidneys may not allow differentiation of autosomal recessive from autosomal dominant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, a negative (normal) ultrasound in a fetus at risk provides no reassurance of absence of ADPKD because of the variability in ultrasound findings, de novo mutations in 10 percent of cases, and late presentation of this disorder. However, if either parent has ADPKD, the finding of enlarged echogenic kidneys with or without cysts in the fetus strongly supports the diagnosis.",
"   </p>",
"   <p>",
"    Amniotic fluid volume is usually normal since normal nephrons are present; this is an important distinction from ARPKD. In a report of 27 prenatally diagnosed cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/16\">",
"     16",
"    </a>",
"    ], amniotic fluid volume was normal in 89 percent, slightly diminished in 7 percent, and increased initially, but with secondary normalization in one case (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Associated structural abnormalities, such as cysts in the liver and spleen, have not been identified prenatally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Obstetric management",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADPKD is associated with a normal karyotype; therefore, chromosome studies are not useful for confirming the diagnosis. The disease is unknown to the family in over 50 percent of parents at the time of obstetric ultrasound. If fetal ADPKD is suspected and not known to be inherited in the family, then the parents should be assessed by ultrasound evaluation of their kidneys and liver, as renal compromise may not occur until later in life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=see_link\">",
"     \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Confirmation of the diagnosis is possible by molecular DNA studies, which can be obtained from fetal DNA either through amniocentesis or chorionic villus sampling. The majority of cases (approximately 90 percent) are inherited; few cases are due to de novo mutations. Although linkage-based diagnostic approaches are feasible in large families, direct mutation screening is generally more applicable. As ADPKD displays a high level of allelic heterogeneity, complete screening of both genes is required. Screening of individuals with ADPKD detects mutations in up to 91 percent of cases. However, only approximately 65 percent of patients have definite mutations, with approximately 26 percent having indefinite changes that require further evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\", section on 'Genetic testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\", section on 'Prenatal and preimplantation genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In prenatal presentations, the amniotic fluid volume remains normal with preserved renal function; however, prenatal presentation may be associated with more rapid progression of the disease after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/19\">",
"     19",
"    </a>",
"    ]. In one study of patients diagnosed prenatally, 43 percent died within the first year of life, 3 percent developed renal failure by age three years, and 67 percent developed hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/20\">",
"     20",
"    </a>",
"    ]. Another study of 26 children with a mean follow-up of 76 months reported a more favorable prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/19\">",
"     19",
"    </a>",
"    ]. In this study, 19 children were asymptomatic, 5 had hypertension, 2 had proteinuria, and 2 had chronic renal insufficiency. A high proportion of siblings developed early renal cysts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28584?source=see_link&amp;anchor=H91671647#H91671647\">",
"     \"Autosomal dominant polycystic kidney disease in children\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4533929\">",
"    <span class=\"h2\">",
"     Renal cysts seen with syndromes/sequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many syndromes present with hyperechoic cystic kidneys. The distinction between the medullary and glomerulocystic forms requires examination of renal histopathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4533936\">",
"    <span class=\"h3\">",
"     Glomerulocystic kidney disease (GCKD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerulocystic kidney disease is characterized by cysts resulting from dilation of Bowman&rsquo;s space. At least 5 percent of the glomeruli are involved. These cysts do not become very large; thus, the kidney size tends to remain normal or only moderately enlarged (2 to 8 standard deviations above the mean for gestational age). Although glomerulocystic disease can be a feature of some syndromes and dysplastic kidneys, it can also originate from nonsyndromic inherited disorders such as ADPKD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=see_link&amp;anchor=H7#H7\">",
"     \"Renal cystic diseases in children\", section on 'Glomerular cortical cysts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4533943\">",
"    <span class=\"h4\">",
"     Ultrasound appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In glomerulocystic kidney disease, the kidneys are moderately enlarged and hyperechogenic with loss of corticomedullary differentiation. Subcapsular cysts are diagnostic, but are not always present. Combining the information obtained from a thorough family genetic history and comprehensive sonographic fetal anatomic survey helps to narrow the differential diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       ADPKD glomerulocystic type",
"      </strong>",
"      &mdash; The cysts in ADPKD are usually isolated and located in the cortex [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/17\">",
"       17",
"      </a>",
"      ]. Prevalence is 1:400 to 1000 and family history reveals autosomal dominant inheritance.",
"     </li>",
"     <li>",
"      <strong>",
"       Oral facial digital syndrome type 1 (OFD1)",
"      </strong>",
"      &mdash; Findings include median cleft lip or palate, hypertelorism, micrognathia, brachydactyly, syndactyly, clinodactyly of the fifth finger, duplicated hallux, preaxial or postaxial polydactyly, intracerebral cysts, agenesis of the corpus callosum, and cerebellar agenesis with or without Dandy-Walker malformation. Prevalence is 1:50,000 to 1:250,000 and inheritance is X linked recessive. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/44/20169?source=see_link&amp;anchor=H27#H27\">",
"       \"Etiology, prenatal diagnosis, obstetrical management, and recurrence of orofacial clefts\", section on 'Oral-facial-digital syndrome, type I (CL/P)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Short rib-polydactyly syndromes",
"      </strong>",
"      &mdash; Findings include median cleft lip or palate, narrow thorax with short ribs, shortening of all bones, proportionately small head, polydactyly, and small cerebellar vermis. This is a rare autosomal recessive lethal skeletal dysplasia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42585?source=see_link&amp;anchor=H2348360#H2348360\">",
"       \"Prenatal diagnosis of the lethal skeletal dysplasias\", section on 'Short-rib polydactyly syndromes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Trisomy 18",
"      </strong>",
"      &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H11#H11\">",
"       \"Congenital cytogenetic abnormalities\", section on 'Trisomy 18 syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Trisomy 13",
"      </strong>",
"      &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H14#H14\">",
"       \"Congenital cytogenetic abnormalities\", section on 'Trisomy 13 syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tuberous sclerosis complex",
"      </strong>",
"      &mdash; Findings include facial angiofibromas, ungual fibromas, cortical tubers, glomerulocystic kidney disease, angiolipomas in the kidney, and cardiac rhabdomyomas. Prevalence is 1:5800 and inheritance is autosomal dominant, but two thirds of cases result from a de novo mutation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link\">",
"       \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Jeune syndrome (asphyxiating thoracic dysplasia)",
"      </strong>",
"      &mdash; Findings include skeletal dysplasia characterized by narrow thorax with short ribs, shortening of long bones, polydactyly, brachydactyly, and renal and hepatic anomalies. Prevalence is 1:100,000 to 130,000 and inheritance is autosomal recessive. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42585?source=see_link\">",
"       \"Prenatal diagnosis of the lethal skeletal dysplasias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Zellweger syndrome (cerebrohepatorenal syndrome)",
"      </strong>",
"      &mdash; Findings include growth restriction, muscular hypotonia, increased nuchal translucency, abnormal head shape, micrognathia, hydrocephalus, periventricular cysts, ventriculomegaly, hypoplastic corpus callosum or agenesis, hepatomegaly, cardiac anomalies, simian crease, and extremity contractures. Prevalence is 1:50,000 to 100,000 and inheritance is autosomal recessive. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link&amp;anchor=H17#H17\">",
"       \"Peroxisomal disorders\", section on 'Zellweger syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Ivemark II syndrome",
"      </strong>",
"      &mdash; Findings include renal-hepatic-pancreatic dysplasia, asplenia-polysplenia; cystic liver, kidney and pancreas; agenesis of corpus callosum, and renal cortical cysts. This is a rare autosomal recessive syndrome, usually diagnosed by fetopathologic examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4534040\">",
"    <span class=\"h3\">",
"     Medullary cystic dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medullary cystic dysplasia is characterized by tubular cysts. Meckel Gruber, Bardet Biedl, and Beckwith Wiedemann syndromes should be considered in the differential diagnosis of ARPCKD, as they mainly involve renal medulla:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Meckel Gruber syndrome",
"      </strong>",
"      &mdash; Findings include occipital encephalocele, Dandy-Walker malformation, bilateral polycystic kidneys with medullary cysts, and post-axial polydactyly. Prevalence is 1:32,500 to 40,000 and inheritance is autosomal recessive. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16744?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical manifestations, diagnosis, and treatment of nephronophthisis\", section on 'Meckel-Gruber syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bardet Biedl syndrome",
"      </strong>",
"      &mdash; Findings include moderately enlarged hyperechogenic kidneys with absent corticomedullary differentiation, medullary cysts, normal amniotic fluid volume, postaxial polydactyly, and hypogonadism. Prevalence is 1:125,000 to 160,000 and inheritance is autosomal recessive. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical manifestations and causes of nephrogenic diabetes insipidus\", section on 'Bardet-Biedl syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Beckwith Wiedemann syndrome",
"      </strong>",
"      &mdash; Findings include macroglossia, macrosomia, omphalocele, hemihyperplasia, renal medullary dysplasia (later development of medullary sponge kidney), polyhydramnios, and enlargement of the placenta and liver. Prevalence is approximately 1:14,000 births. It is an imprinting disorder, which follows a predominantly sporadic inheritance pattern in 85 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=see_link\">",
"       \"Beckwith-Wiedemann syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12017537\">",
"    <span class=\"h1\">",
"     NONHEREDITARY DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4534087\">",
"    <span class=\"h2\">",
"     Renal dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysplastic kidneys are common malformations affecting up to 2 to 4 in 1000 births. They are part of the spectrum of Congenital Abnormalities of the Kidney and Urinary Tract (CAKUT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link\">",
"     \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal dysplasia is a continuum that has many subtypes, ranging from hypoplasia to renal agenesis to massive cystic kidneys, and is the leading etiology of end stage renal disease in children. It is characterized by structural disorganization of the renal tissue, poorly",
"    <span class=\"nowrap\">",
"     branched/differentiated",
"    </span>",
"    nephrons and collecting ducts, increased stroma, and, occasionally, cysts and metaplastic tissues, such as cartilage. Renal dysplasia originates from abnormal interaction between the ureteral bud and metanephric blastema.",
"   </p>",
"   <p>",
"    Dysplastic kidneys may occur randomly or secondary to genetic defects, lower urinary tract obstruction (obstructive dysplasia), or teratogen exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/21\">",
"     21",
"    </a>",
"    ]. Approximately 10 percent of affected fetuses have a family history of significant",
"    <span class=\"nowrap\">",
"     renal/urinary",
"    </span>",
"    tract malformation. Monogenic causes include mutations in individual genes, such as",
"    <span class=\"nowrap\">",
"     TCF2/hepatocyte",
"    </span>",
"    nuclear factor 1&szlig; (HNF1b), PAX2, and uroplakins. Compound heterozygote mutations in several",
"    <span class=\"nowrap\">",
"     renal/urinary",
"    </span>",
"    tract developmental genes have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TCF2 gene encodes the protein hepatocyte nuclear factor 1beta (HNF1b) which is involved in early renal development. Mutations of TCF2 are reported in cystic renal",
"    <span class=\"nowrap\">",
"     hypoplasia/dysplasia",
"    </span>",
"    and occasionally immaturity-onset diabetes of the young type 5 and genital tract abnormalities. PAX2 is a central nephrogenic molecule involved in the outgrowth and branching of the ureteric bud and is also expressed during the development of the eye, ear, and nervous system, as well as the urogenital tract. PAX2 is involved in the renal-coloboma syndrome characterized by renal hypoplasia. Uroplakins are molecules distributed in the apical surface of the urothelium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Multicystic dysplastic kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multicystic dysplastic kidney (MCDK) is a severe form of renal dysplasia in which the kidney consists of multiple noncommunicating cysts of various sizes separated by dysplastic parenchyma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79332 graphicRef80361 \" href=\"UTD.htm?31/7/31861\">",
"     image 2A-B",
"    </a>",
"    ). Primitive nephrons filled with urine are the basis of the multiple cysts, which are seen initially at the periphery of the kidney. The kidney is enlarged and the overall shape is abnormal. The affected kidney is nonfunctional and frequently undergoes involution when the cysts shrink from absence of urine production. This leads to a picture similar to renal agenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16296?source=see_link\">",
"     \"Prenatal diagnosis of renal agenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cases of MCDK are unilateral. The prevalence is 1:4300 births, with the left kidney and males slightly more often affected. Associated anomalies of the kidney are present in one third of cases, most commonly vesicoureteral reflux (20 percent) and obstruction of the ureteropelvic junction. Bilateral MCKD is less common; the prevalence is 1:10,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extrarenal malformations are noted in 15 to 25 percent of MCKD cases. The most common abnormalities are heart defects, esophageal or intestinal atresia, spinal abnormalities, and VATER association. The risk of aneuploidy is as high as 3 to 10 percent; the majority of these fetuses also have associated extrarenal anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ultrasound appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic presentation of MCDK is a multiloculated abdominal mass consisting of multiple noncommunicating thin-walled cysts that are distributed randomly. No normal renal tissue is apparent on ultrasound. The appearance of multiple large cysts in the paravertebral area has been likened to a cluster of grapes. The kidney is usually enlarged with an irregular nonreniform outline, and no visible renal pelvis. The ureter is atretic or absent. The renal artery is small or absent in MCDK and the Doppler waveform, when present, is markedly abnormal with reduced systolic peak and absent diastolic flow.",
"   </p>",
"   <p>",
"    Amniotic fluid volume is normal with unilateral disease. Bilateral disease results in absent urine production, absence of bladder filling, and severe oligohydramnios that leads to pulmonary hypoplasia. The kidneys may be enlarged early in pregnancy, but often there is a decrease in size as pregnancy progresses; the kidneys can become severely shrunken (terminal phase). In severe bilateral cases, the condition can mimic renal agenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16296?source=see_link\">",
"     \"Prenatal diagnosis of renal agenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, only a portion of the kidney is affected. This is called segmental multicystic dysplastic kidney, and is seen in 4 percent of MCKD cases, but rarely in the fetus. Most cases occur in the upper pole of a duplex kidney and often involute spontaneously without significant complication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/9,27\">",
"     9,27",
"    </a>",
"    ]. Parenchymal tissue between the cysts is often hyperechogenic.",
"   </p>",
"   <p>",
"    Rare cases of Wilms tumor, multilocular cyst, or cystic mesoblastic nephroma can present in a similar manner to MCDK. From its ultrasound appearance, MCDK may also be confused with severe hydronephrosis; however, the cysts do not communicate in MCDK while they do with hydronephrosis. The renal parenchyma can still be seen with hydronephrosis, but is not seen in MCKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Obstetric management",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough fetal survey should be performed to assess for additional structural anomalies that could suggest another disorder or a specific syndrome. Bilateral MCKD or associated nonrenal abnormalities should prompt consideration of aneuploidy or inherited conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Careful examination of the contralateral kidney is important in determining the prognosis. In unilateral disease, conservative management with periodic ultrasound assessment is sufficient. Children with isolated unilateral MCKD with a normal contralateral kidney have good long-term outcomes with normal renal function, infrequent urinary tract infections, and compensatory contralateral renal hypertrophy. Routine removal of the multicystic kidney is no longer recommended because the long-term risks of hypertension and infection are low and the risk of malignancy is not increased [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/28\">",
"     28",
"    </a>",
"    ]. Sixty percent of the affected kidneys will atrophy and disappear over a period of five years, obviating the issue of prophylactic surgical removal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=see_link&amp;anchor=H3#H3\">",
"     \"Renal cystic diseases in children\", section on 'Multicystic dysplastic kidney'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants with complex disease, bilateral MCKD, or contralateral urological abnormalities have a worse outcome, with a high incidence of chronic renal insufficiency or failure. The prognosis is poor in bilateral disease with anhydramnios. The option of pregnancy termination should be discussed in these cases. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4534535\">",
"    <span class=\"h2\">",
"     Obstructive dysplasia (ORD) or cystic renal dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive dysplasia occurs secondary to fetal urinary tract obstruction or vesicoureteral reflux. The kidneys are hyperechogenic, with or without subcapsular cysts. The kidney size may be normal with preserved corticomedullary differentiation, or diffusely hyperechoic with small subcortical cysts, megacystis, and dilated ureters. The mild form of ORD is associated with partial lower tract obstruction. Severe ORD with complete lower tract obstruction (urethral atresia, posterior ureteral valve) is characterized by marked cystic dysplasia with increased corticomedullary differentiation. Segmental ORD occurs in a duplex kidney and is typically confined to the upper moiety [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal cystic diseases in children\", section on 'Nonhereditary renal malformation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ORD can also be seen in prune-belly syndrome, which consists of a distended abdomen with redundant skin and defective abdominal wall musculature, accompanied by megacystis, megaureters, hydronephrotic dysplastic kidneys, and bilateral cryptorchidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44407?source=see_link\">",
"     \"Prune-belly syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4534546\">",
"    <span class=\"h3\">",
"     Ultrasound appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enlarged or small hyperechogenic kidneys with or without cortical cysts are noted on ultrasound. Serial sonograms may document the delayed visibility of renal cysts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduction in size of an initially enlarged kidney with compensatory hypertrophy of the contralateral kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4534568\">",
"    <span class=\"h1\">",
"     NONDYSPLASTIC NONHEREDITARY RENAL CYSTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4534576\">",
"    <span class=\"h2\">",
"     Renal cystic tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal tumors of infancy are usually solid; if there is a cystic component, differential diagnosis should include cystic congenital mesoblastic nephroma, cystic nephroma, cystic partially differentiated nephroblastoma (CPDN), adrenal hemorrhage, clear cell sarcoma (formerly called &lsquo;&lsquo;anaplastic subtype of Wilms&rsquo;&rsquo;), and cystic renal cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/9,29\">",
"     9,29",
"    </a>",
"    ]. Wilms tumor may contain cysts, which are caused by hemorrhage and necrosis. Cystic nephroma and CPDN are characterized by a solitary, well circumscribed, multiseptated mass of noncommunicating locules with thin septations. Ossifying renal tumor of infancy can also present as multilocular cystic masses; however, most cases have minor nodular solid components associated with the cystic components [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4534583\">",
"    <span class=\"h2\">",
"     Simple renal cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple renal cysts can be identified by ultrasonography early in gestation, but in contrast to multicystic disease, the majority of simple cysts resolve during pregnancy without any sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4534637\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC WORK-UP AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic work-up of fetal hyperechogenic kidneys with or without renal cysts should include a thorough fetal anatomic survey, review of the family&rsquo;s genetic history, and ultrasound examination of the kidneys of the parents and grandparents. The increased risk of an abnormal fetal karyotype should be discussed and prenatal chromosome analysis offered if nonrenal malformations are detected or the findings are bilateral.",
"   </p>",
"   <p>",
"    Uniformly echogenic fetal kidneys without visible macrocysts are not an uncommon incidental finding on obstetric ultrasound examination. It is essential to differentiate significant renal disease from normal variants, which are characterized by normal kidney size, moderately bright cortex, visible corticomedullary differentiation (after 20 weeks gestational age), normal bladder size, and normal amniotic fluid volume [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of enlarged hyperechogenic kidneys, with or without cysts, includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ARPKD (significantly enlarged kidneys with reniform shape, loss of corticomedullary differentiation, subcortical hypoechoic rim, cysts [if present] predominantly in the medulla, reduced amniotic fluid volume)",
"     </li>",
"     <li>",
"      ADPKD (kidneys moderately enlarged, amniotic fluid volume usually normal, cysts [if present] usually in cortical location, but rarely presents in the prenatal period)",
"     </li>",
"     <li>",
"      Obstructive dysplasia (hyperechogenic kidneys, renal cortical cysts with dilated upper or lower urinary tract)",
"     </li>",
"     <li>",
"      Multicystic dysplasia (usually unilateral, reniform shape not preserved, kidney enlarged by randomly distributed large size cysts).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Syndromes that present with hyperechoic kidneys",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal cysts are differentiated by the associated anomalies. In one study, the final diagnosis in 93 fetuses presenting with hyperechogenic kidneys who went on to develop nephropathy was ARPKD",
"    <span class=\"nowrap\">",
"     (31/93),",
"    </span>",
"    ADPKD",
"    <span class=\"nowrap\">",
"     (28/93),",
"    </span>",
"    Bardet-Biedl syndrome",
"    <span class=\"nowrap\">",
"     (11/93),",
"    </span>",
"    Meckel-Gruber syndrome",
"    <span class=\"nowrap\">",
"     (9/93),",
"    </span>",
"    Ivemark II syndrome",
"    <span class=\"nowrap\">",
"     (6/93),",
"    </span>",
"    trisomy 18",
"    <span class=\"nowrap\">",
"     (5/93),",
"    </span>",
"    Jarcho-Levin syndrome (spondylothoracic dysplasia)",
"    <span class=\"nowrap\">",
"     (1/93),",
"    </span>",
"    Beemer syndrome (narrow ribs, micromelia, with or without polydactyly)",
"    <span class=\"nowrap\">",
"     (1/93),",
"    </span>",
"    and Meckel-like syndrome",
"    <span class=\"nowrap\">",
"     (1/93)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal magnetic resonance imaging (MRI) can help in differentiating ARPKD from congenital renal cystic diseases without medullary involvement. For example, in one study, MRI of two fetuses with enlarged hyperechoic kidneys showed localized medullary hyperintense lesions suggesting ARPKD in one fetus and medullary cystic dysplasia in the other fetus with Jeune's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15737/abstract/32\">",
"     32",
"    </a>",
"    ]. Medullary involvement is visualized as hyperintense lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polycystic kidney disease is one of the major causes of end stage renal disease in children and adults. Bilateral polycystic kidneys in a fetus should prompt investigation of the kidneys in the rest of the family. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Autosomal recessive polycystic kidney disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Autosomal dominant polycystic renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The predominant prenatal ultrasound feature of autosomal recessive polycystic kidney disease (ARPKD) is uniform, massive enlargement of the kidneys bilaterally with preservation of the reniform shape and loss of corticomedullary differentiation. The sonographic features can initially appear at any time during gestation, including the third trimester. A hyperechogenic appearance of the kidneys with normal amniotic fluid volume in the first trimester may be an early indication of this disorder. In the second trimester, there is usually massive uniform echogenic enlargement of the kidneys bilaterally associated with oligohydramnios and a small or absent bladder (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69859 graphicRef79653 \" href=\"UTD.htm?31/38/32357\">",
"       image 1A-B",
"      </a>",
"      ). Serial ultrasound examinations that confirm progressive enlargement and reduction in amniotic fluid volume help establish the diagnosis. However, hyperechogenicity and elongation of the kidney may be the only ultrasound finding until the third trimester in rare cases. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Ultrasound appearance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical clinical presentation of autosomal dominant kidney disease (ADPKD) is in the third to fifth decade of life. The kidneys appear normal prenatally in most cases. Rarely, the fetal kidneys appear enlarged and echogenic with a reniform shape and usually increased corticomedullary differentiation. If either parent has ADPKD, the finding of enlarged echogenic kidneys in the fetus strongly suggests the diagnosis. A negative (normal) ultrasound in a fetus at risk provides only limited reassurance of the absence of ADPKD because of the variability in ultrasound findings and late presentation of this disorder. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Ultrasound appearance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multicystic dysplastic kidney (MCKD) can be unilateral or bilateral and presents with randomly located renal cysts that do not connect. The contralateral kidney has an abnormality in one third of unilateral cases. Extrarenal malformations are noted in 15 to 25 percent of MCKD cases. Fetal karyotyping is recommended in bilateral MCKD and when associated extrarenal abnormalities are present. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Multicystic dysplastic kidney'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obstructive dysplasia is secondary to urinary tract obstruction or reflux and presents with hyperechogenic kidneys with or without cysts and a dilated urinary tract. (See",
"      <a class=\"local\" href=\"#H4534535\">",
"       'Obstructive dysplasia (ORD) or cystic renal dysplasia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic work-up of fetal hyperechogenic kidneys with or without renal cysts should include a thorough fetal anatomic survey, review of the family&rsquo;s genetic history, and ultrasound examination of the kidneys of the parents and grandparents. The increased risk of an abnormal fetal karyotype should be discussed and prenatal testing offered if nonrenal malformations are detected or in bilateral MCKD. (See",
"      <a class=\"local\" href=\"#H4534637\">",
"       'Diagnostic work-up and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/1\">",
"      Cohen HL, Cooper J, Eisenberg P, et al. Normal length of fetal kidneys: sonographic study in 397 obstetric patients. AJR Am J Roentgenol 1991; 157:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/2\">",
"      Chaumoitre K, Brun M, Cassart M, et al. Differential diagnosis of fetal hyperechogenic cystic kidneys unrelated to renal tract anomalies: A multicenter study. Ultrasound Obstet Gynecol 2006; 28:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/3\">",
"      Wilson PD. Polycystic kidney disease. N Engl J Med 2004; 350:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/4\">",
"      Ward CJ, Hogan MC, Rossetti S, et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 2002; 30:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/5\">",
"      Denamur E, Delezoide AL, Alberti C, et al. Genotype-phenotype correlations in fetuses and neonates with autosomal recessive polycystic kidney disease. Kidney Int 2010; 77:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/6\">",
"      Bronshtein M, Bar-Hava I, Blumenfeld Z. Clues and pitfalls in the early prenatal diagnosis of 'late onset' infantile polycystic kidney. Prenat Diagn 1992; 12:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/7\">",
"      Avni FE, Garel L, Cassart M, et al. Perinatal assessment of hereditary cystic renal diseases: the contribution of sonography. Pediatr Radiol 2006; 36:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/8\">",
"      Okumura M, Bunduki V, Shiang C, et al. Unusual sonographic features of ARPKD. Prenat Diagn 2006; 26:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/9\">",
"      Garel L. Renal Cystic Disease. Ultrasound Clin 2010; 5:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/10\">",
"      Tsatsaris V, Gagnadoux MF, Aubry MC, et al. Prenatal diagnosis of bilateral isolated fetal hyperechogenic kidneys. Is it possible to predict long term outcome? BJOG 2002; 109:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/11\">",
"      Sharp AM, Messiaen LM, Page G, et al. Comprehensive genomic analysis of PKHD1 mutations in ARPKD cohorts. J Med Genet 2005; 42:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/12\">",
"      Guay-Woodford LM, Desmond RA. Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 2003; 111:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/13\">",
"      Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/14\">",
"      Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/15\">",
"      Rossetti S, Harris PC. Genotype-phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease. J Am Soc Nephrol 2007; 18:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/16\">",
"      Brun M, Maugey-Laulom B, Eurin D, et al. Prenatal sonographic patterns in autosomal dominant polycystic kidney disease: a multicenter study. Ultrasound Obstet Gynecol 2004; 24:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/17\">",
"      Zerres K. Genetics of cystic kidney diseases. Criteria for classification and genetic counselling. Pediatr Nephrol 1987; 1:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/18\">",
"      Harris PC, Rossetti S. Molecular diagnostics for autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2010; 6:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/19\">",
"      Boyer O, Gagnadoux MF, Guest G, et al. Prognosis of autosomal dominant polycystic kidney disease diagnosed in utero or at birth. Pediatr Nephrol 2007; 22:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/20\">",
"      MacDermot KD, Saggar-Malik AK, Economides DL, Jeffery S. Prenatal diagnosis of autosomal dominant polycystic kidney disease (PKD1) presenting in utero and prognosis for very early onset disease. J Med Genet 1998; 35:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/21\">",
"      Winyard P, Chitty LS. Dysplastic kidneys. Semin Fetal Neonatal Med 2008; 13:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/22\">",
"      Weber S, Moriniere V, Kn&uuml;ppel T, et al. Prevalence of mutations in renal developmental genes in children with renal hypodysplasia: results of the ESCAPE study. J Am Soc Nephrol 2006; 17:2864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/23\">",
"      Martinovic-Bouriel J, Benachi A, Bonni&egrave;re M, et al. PAX2 mutations in fetal renal hypodysplasia. Am J Med Genet A 2010; 152A:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/24\">",
"      Schreuder MF, Westland R, van Wijk JA. Unilateral multicystic dysplastic kidney: a meta-analysis of observational studies on the incidence, associated urinary tract malformations and the contralateral kidney. Nephrol Dial Transplant 2009; 24:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/25\">",
"      Lazebnik N, Bellinger MF, Ferguson JE 2nd, et al. Insights into the pathogenesis and natural history of fetuses with multicystic dysplastic kidney disease. Prenat Diagn 1999; 19:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/26\">",
"      Aubertin G, Cripps S, Coleman G, et al. Prenatal diagnosis of apparently isolated unilateral multicystic kidney: implications for counselling and management. Prenat Diagn 2002; 22:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/27\">",
"      Lin CC, Tsai JD, Sheu JC, et al. Segmental multicystic dysplastic kidney in children: clinical presentation, imaging finding, management, and outcome. J Pediatr Surg 2010; 45:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/28\">",
"      Hains DS, Bates CM, Ingraham S, Schwaderer AL. Management and etiology of the unilateral multicystic dysplastic kidney: a review. Pediatr Nephrol 2009; 24:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/29\">",
"      Murthi GV, Carachi R, Howatson A. Congenital cystic mesoblastic nephroma. Pediatr Surg Int 2003; 19:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/30\">",
"      Ko HS, Graf N, Brambs HJ, et al. Clinical Quiz. A patient with hematuria and cystic renal mass. Pediatr Nephrol 2006; 21:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/31\">",
"      Blazer S, Zimmer EZ, Blumenfeld Z, et al. Natural history of fetal simple renal cysts detected in early pregnancy. J Urol 1999; 162:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15737/abstract/32\">",
"      Cassart M, Massez A, Metens T, et al. Complementary role of MRI after sonography in assessing bilateral urinary tract anomalies in the fetus. AJR Am J Roentgenol 2004; 182:689.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6748 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15737=[""].join("\n");
var outline_f15_23_15737=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29937733\">",
"      ULTRASOUND APPEARANCE OF THE KIDNEY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29937740\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12017265\">",
"      HEREDITARY DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Autosomal recessive polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Ultrasound appearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Obstetric management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autosomal dominant polycystic renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Ultrasound appearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Obstetric management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4533929\">",
"      Renal cysts seen with syndromes/sequences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4533936\">",
"      - Glomerulocystic kidney disease (GCKD)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4533943\">",
"      Ultrasound appearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4534040\">",
"      - Medullary cystic dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12017537\">",
"      NONHEREDITARY DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4534087\">",
"      Renal dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Multicystic dysplastic kidney",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ultrasound appearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Obstetric management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4534535\">",
"      Obstructive dysplasia (ORD) or cystic renal dysplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4534546\">",
"      - Ultrasound appearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4534568\">",
"      NONDYSPLASTIC NONHEREDITARY RENAL CYSTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4534576\">",
"      Renal cystic tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4534583\">",
"      Simple renal cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4534637\">",
"      DIAGNOSTIC WORK-UP AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6748\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6748|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/6/107\" title=\"diagnostic image 1A\">",
"      Prenatal ultrasound ARKPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/43/19121\" title=\"diagnostic image 1B\">",
"      Prenatal ultrasound of ARKPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/10/37024\" title=\"diagnostic image 2A\">",
"      Prenatal ultrasound bilateral MCDK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/3/20528\" title=\"diagnostic image 2B\">",
"      Prenatal ultrasound of unilateral MCDK",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=related_link\">",
"      Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28584?source=related_link\">",
"      Autosomal dominant polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=related_link\">",
"      Autosomal recessive polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=related_link\">",
"      Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16744?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=related_link\">",
"      Diagnosis of and screening for autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/44/20169?source=related_link\">",
"      Etiology, prenatal diagnosis, obstetrical management, and recurrence of orofacial clefts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=related_link\">",
"      Genetics and pathogenesis of nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=related_link\">",
"      Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/888?source=related_link\">",
"      Physiology of amniotic fluid volume regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16296?source=related_link\">",
"      Prenatal diagnosis of renal agenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42585?source=related_link\">",
"      Prenatal diagnosis of the lethal skeletal dysplasias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44407?source=related_link\">",
"      Prune-belly syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=related_link\">",
"      Renal cystic diseases in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_23_15738="Primary drugs in pediatric resuscitation";
var content_f15_23_15738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary drugs in pediatric resuscitation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15738/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15738/contributors\">",
"     Pamela Bailey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15738/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15738/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/23/15738/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/23/15738/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/23/15738/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children undergoing pediatric advanced life support (PALS), medications are of secondary importance to the prompt treatment of hypoxemia and respiratory impairment, initiation of high quality cardiopulmonary resuscitation, and early defibrillation in pulseless patients with ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link&amp;anchor=H4#H4\">",
"     \"Basic life support in infants and children\", section on 'Basic life support sequence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=see_link\">",
"     \"Guidelines for pediatric advanced life support\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary drugs used in advanced pediatric life support (APLS) and pediatric resuscitation are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef70539 \" href=\"UTD.htm?23/54/24430\">",
"     table 1",
"    </a>",
"    ). Among these drugs, oxygen and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    are the only ones with proven benefit in childhood cardiopulmonary arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucose should be provided to children with hypoglycemia. Adenosine,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"     procainamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    are indicated for treatment of tachyarrhythmias. (See",
"    <a class=\"local\" href=\"#H5952713\">",
"     'Recommended drugs by clinical condition'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The indications for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19446?source=see_link\">",
"     calcium chloride",
"    </a>",
"    are limited, and the use of these drugs should be considered secondary to establishment of an airway, oxygen delivery, attainment of vascular access, and administration of adequate volume [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of these medications in pediatric resuscitation is reviewed here.",
"   </p>",
"   <p>",
"    Pediatric basic life support, pediatric advanced life support, and the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/4/20551?source=see_link\">",
"     naloxone",
"    </a>",
"    in children with opioid intoxication are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link\">",
"       \"Basic life support in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=see_link\">",
"       \"Guidelines for pediatric advanced life support\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=see_link&amp;anchor=H27#H27\">",
"       \"Opioid intoxication in children and adolescents\", section on 'Naloxone'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5952713\">",
"    <span class=\"h1\">",
"     RECOMMENDED DRUGS BY CLINICAL CONDITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children undergoing pediatric advanced life support (PALS), medications are of secondary importance to the prompt treatment of hypoxemia and respiratory impairment, initiation of high quality cardiopulmonary resuscitation, and early defibrillation in pulseless patients with ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link&amp;anchor=H4#H4\">",
"     \"Basic life support in infants and children\", section on 'Basic life support sequence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=see_link\">",
"     \"Guidelines for pediatric advanced life support\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary drugs used in pediatric advanced life support (PALS) and pediatric resuscitation according to clinical presentation are as follows (",
"    <a class=\"graphic graphic_table graphicRef70539 \" href=\"UTD.htm?23/54/24430\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asystole or pulseless electrical activity &ndash; Oxygen,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"       algorithm 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ventricular fibrillation or ventricular tachycardia without a pulse &ndash; Oxygen,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      as adjuncts to high quality cardiopulmonary resuscitation and defibrillation (",
"      <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"       algorithm 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bradycardia &ndash; Oxygen,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef52446 \" href=\"UTD.htm?20/4/20545\">",
"       algorithm 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Uncomplicated supraventricular tachycardia (SVT) &ndash; Oxygen, adenosine (",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Possible ventricular tachycardia or aberrant SVT &ndash; Oxygen, adenosine,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"       procainamide",
"      </a>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypomagnesemia or torsades de pointes &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"     </li>",
"     <li>",
"      Hypocalcemia, hypermagnesemia, hyperkalemia or calcium channel blocker overdose &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19446?source=see_link\">",
"       Calcium chloride",
"      </a>",
"     </li>",
"     <li>",
"      Hypoglycemia &ndash; Glucose",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4897046\">",
"    <span class=\"h1\">",
"     SUBSTRATE DELIVERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fundamental goal of basic and advanced life support is to support cerebral, myocardial, and systemic oxygenation before irreversible injury occurs. Because respiratory compromise is the leading cause of cardiac arrests in children, 100 percent oxygen should be administered, to any child who is suspected of being hypoxemic using a nonrebreathing face mask or bag-mask ventilation. The potential negative effects of high concentrations of oxygen are not a consideration in the setting of cardiopulmonary arrest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=see_link\">",
"     \"Continuous oxygen delivery systems for infants, children, and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=see_link\">",
"     \"Oxygen toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia may accompany trauma, respiratory failure, shock, sepsis, and many other illnesses that result in cardiopulmonary arrest. Small infants are particularly prone to developing hypoglycemia because of inadequate glycogen stores. In addition, acute illness may have caused decreased caloric intake or excessive losses (eg, from diarrhea and vomiting). A rapid bedside glucose test should be performed in all infants who are clinically unstable because the clinical signs of hypoglycemia and hypoxemia are similar (eg, altered mental status, poor perfusion, tachycardia, hypotension). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link\">",
"     \"Approach to hypoglycemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mechanisms",
"      </strong>",
"      &ndash; Glucose is the primary metabolic substrate for the neonatal myocardium, and hypoglycemia may contribute to myocardial dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2\">",
"       2",
"      </a>",
"      ]. Glucose also is a significant energy source in older infants and children during periods of ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2\">",
"       2",
"      </a>",
"      ]. Whether glucose administration improves cardiac function or survival in hypoglycemic children with cardiac arrest is not known [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Indications and contraindications",
"      </strong>",
"      &ndash; During pediatric resuscitation, documented hypoglycemia (eg, serum glucose concentration less than 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.2",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      should be corrected, but routine administration of glucose without evaluation of the serum glucose is not recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2\">",
"       2",
"      </a>",
"      ]. Empiric treatment with glucose may be appropriate if bedside glucose determination is not available and the infant or child has symptoms of hypoglycemia or is at risk for developing hypoglycemia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link\">",
"       \"Approach to hypoglycemia in infants and children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The routine administration of glucose during pediatric resuscitation is",
"      <strong>",
"       not",
"      </strong>",
"      recommended because of the absence of data demonstrating benefit and the potential harm of hyperglycemia. Large volumes of dextrose-containing fluids should not be given to normoglycemic children during resuscitation because they can cause hyperglycemia, which can induce osmotic diuresis, produce or aggravate hypokalemia, or worsen ischemic brain injury [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2,6-8\">",
"       2,6-8",
"      </a>",
"      ]. Evidence for the harm of empiric glucose administration is less convincing for neonates. As an example, in a newborn animal model, administration of glucose improved survival in hypoxic rat pups and did not increase the extent of hypoxic-ischemic brain damage [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Dose and administration",
"      </strong>",
"      &ndash; The dose of glucose is 0.5 to 1",
"      <span class=\"nowrap\">",
"       g/kg.",
"      </span>",
"      It should be administered via intravenous (IV) or intraosseous (IO) infusion. The maximum concentration of glucose that can be administered through a peripheral vein is 25 percent dextrose in water (D25W); higher concentrations cause sclerosis of peripheral veins. Thus, 50 percent solutions of dextrose in water (D50W) must be diluted 1:1 with sterile water before peripheral administration in children. However, in infants and children younger than five years of age, 10 percent dextrose in water is typically used.",
"      <br/>",
"      <br/>",
"      The volume of solution necessary to achieve the desired dose varies depending upon the dextrose concentration of the solution. Each of the following alternatives provides 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      of glucose [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2\">",
"       2",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      2 to 4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of D25W",
"     </li>",
"     <li>",
"      5 to 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 10 percent dextrose in water (D10W)",
"     </li>",
"     <li>",
"      A bolus of 10 to 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 5 percent dextrose in normal saline or lactated Ringer's solution",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4897086\">",
"    <span class=\"h1\">",
"     CARDIAC ARREST",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    is the intervention most likely to be of benefit when basic life support and volume resuscitation do not restore effective circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mechanisms",
"      </strong>",
"      &ndash; The actions of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      include both alpha- and beta-adrenergic stimulation. The alpha-mediated peripheral arterial vasoconstriction is the beneficial action of epinephrine in cardiac arrest. Peripheral arterial vasoconstriction elevates systemic vascular resistance, thereby increasing the aortic-right atrial pressure gradient during the decompression phase of cardiopulmonary resuscitation (CPR). This gradient, also called the coronary perfusion pressure, correlates directly with myocardial blood flow in animal models, and is a good predictor of return of spontaneous circulation (ROSC) in animals and humans [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. In addition, increased systemic vascular tone raises the arterial pressure during the compression phase of CPR, thereby raising the cerebral perfusion pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/13\">",
"       13",
"      </a>",
"      ]. Thus, the administration of epinephrine increases blood flow to both the heart and the brain. Additional alpha-adrenergic vasoconstrictor effects of epinephrine include reduced blood flow to the splanchnic, renal, mucosal, and dermal vascular beds [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Beta-adrenergic stimulation increases myocardial contractility and heart rate and relaxes smooth muscle in the coronary arteries, cerebral arteries, skeletal muscle vascular beds, and bronchi [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2,14\">",
"       2,14",
"      </a>",
"      ]. Other effects of epinephrine include stimulation of spontaneous cardiac contraction in asystole and enhanced ability to terminate ventricular fibrillation by electrical defibrillation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Indications and contraindications",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       Epinephrine",
"      </a>",
"      is indicated for the treatment of cardiac arrest, symptomatic bradycardia not responsive to oxygen and ventilation, and hypotension not responsive to fluid administration [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2\">",
"       2",
"      </a>",
"      ]. Asystole and bradyarrhythmias are the most common rhythms in pediatric cardiac arrests [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2\">",
"       2",
"      </a>",
"      ]. The administration of epinephrine to children with these rhythms may generate a perfusing pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/16\">",
"       16",
"      </a>",
"      ]. In addition, the use of epinephrine in children with ventricular fibrillation, an uncommon rhythm in pediatric arrest, may render the rhythm more susceptible to electrical defibrillation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/10\">",
"       10",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Contraindications to the use of epinephrine are extremely rare in children and consist of hypersensitivity to epinephrine or one of its components and narrow angle glaucoma.",
"     </li>",
"     <li>",
"      <strong>",
"       Dose and administration",
"      </strong>",
"      &ndash; The dose of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      varies depending on the route of administration. Although it can be given endotracheally, the intravenous (IV) or intraosseous (IO) route is preferred [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"       5",
"      </a>",
"      ]. Epinephrine should be administered through a secure intravascular line because infiltration into the tissues may cause local ischemia, which may lead to tissue injury and ulceration [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/16\">",
"       16",
"      </a>",
"      ]. Epinephrine is inactivated by alkaline solutions and should not be added to solutions containing",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Parenteral",
"      </strong>",
"      &ndash; The IV or IO dose of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      is 0.01",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      given as 0.1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of the 0.1",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      (1:10,000) solution. Repeated doses may be given every three to five minutes as needed [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Endotracheal",
"      </strong>",
"      &ndash; The recommended dose of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      when given by the endotracheal route is 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      given as 0.1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of the 1",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      (1:1000) solution, which can also be repeated every three to five minutes as needed [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"       5",
"      </a>",
"      ]. The endotracheal dosing of epinephrine in neonates is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link&amp;anchor=H24#H24\">",
"       \"Neonatal resuscitation in the delivery room\", section on 'Epinephrine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Higher doses of epinephrine are required for endotracheal administration because peak levels achieved via this route are less than 10 percent of those achieved with IV administration [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/17\">",
"       17",
"      </a>",
"      ]. In addition, studies in animals using endotracheal epinephrine at doses of 0.01 to 0.02",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      demonstrated no discernible effect on systolic or diastolic blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Optimal endotracheal drug absorption depends upon delivery of the drug as deeply as possible into the airway [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/19\">",
"       19",
"      </a>",
"      ]. The epinephrine dose should be diluted with normal saline to a volume of 3 to 5 mL and instilled into the endotracheal tube. It also may be delivered beyond the tip of the endotracheal tube with a suction catheter followed by a 3 to 5 mL saline flush. Several positive-pressure breaths should be given after endotracheal administration of epinephrine.",
"     </li>",
"     <li>",
"      <strong>",
"       High-dose",
"      </strong>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; High-dose epinephrine (HDE) is no longer recommended for use in pediatric resuscitation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"       5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      HDE (0.1 to 0.2",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      had been previously recommended for second and subsequent doses for infants and children with unresponsive asystole or pulseless electrical activity (PEA) on the basis of animal and adult studies that demonstrated improved cerebral and cardiac perfusion with higher doses of epinephrine [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/16,20-22\">",
"       16,20-22",
"      </a>",
"      ]. In addition, several studies reported an increase in return of spontaneous circulation in children who received HDE after failing to respond to two standard doses (SDE) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/11,23\">",
"       11,23",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, subsequent large, multi-institutional, adult trials, well controlled animal outcome studies, and retrospective pediatric reviews failed to show any benefit of HDE in terms of survival to discharge and neurologic outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/24-28\">",
"       24-28",
"      </a>",
"      ]. Finally, a controlled trial evaluated children with in-hospital cardiac arrest who were randomly assigned to receive HDE or SDE after failure of an initial dose of SDE [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/29\">",
"       29",
"      </a>",
"      ]. Although return of spontaneous circulation was similar in both groups, HDE was associated with increased risk of death (adjusted OR 7.9, 95% CI 0.9-72.5).",
"      <br/>",
"      <br/>",
"      HDE is not indicated for symptomatic bradycardia unresponsive to oxygen and ventilation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension unresponsive to fluid therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2,14,19\">",
"       2,14,19",
"      </a>",
"      ]. In these situations, a continuous epinephrine infusion should be administered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link&amp;anchor=H13#H13\">",
"       \"Hypovolemic shock in children: Initial evaluation and management\", section on 'Fluid resuscitation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the recognized benefits of increasing coronary and cerebral perfusion pressures, evidence has shown a negative safety profile of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    , due to its ability to increase myocardial workload, decrease subendocardial perfusion, and induce ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/30\">",
"     30",
"    </a>",
"    ]. Most of the evidence on the toxicity of epinephrine has been described in hemodynamically intact animals and adults. Whether these results can be applied to the low flow state present during cardiac arrest is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/11,19\">",
"     11,19",
"    </a>",
"    ]. Very high doses of epinephrine have been associated with a pattern of myocardial injury called \"contraction band necrosis\" [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/31\">",
"     31",
"    </a>",
"    ]. Damage to the arterial vascular endothelium also may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/32\">",
"     32",
"    </a>",
"    ]. One study found that adult patients receiving more than 15 mg cumulative-dose epinephrine had an increased mortality rate at 24 hours after arrest compared with patients receiving less than 15 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6659759\">",
"    <span class=\"h2\">",
"     Vasopressin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopressin, a nonadrenergic endogenous peptide that induces peripheral, coronary, and renal vasoconstriction via stimulation of Vasopression1 receptors, lacks the adverse effects of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    and has gained much attention as a replacement vasopressor [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/34\">",
"     34",
"    </a>",
"    ]. Another possible advantage of vasopressin is that Vasopressin2 receptor stimulation induces vasodilation and may lessen the end-organ hypoperfusion thought to occur with epinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small pediatric case series suggest that vasopressin, or its long-acting analog, terlipressin, may be effective in refractory cardiac arrest when standard therapy fails [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. These reports include patients with prolonged return of spontaneous circulation (ROSC) and intact neurologic survival. However, a large NRCPR (National Registry of Cardiopulmonary Resuscitation) retrospective observational study found that vasopressin was associated with a lower frequency of ROSC, and a trend toward lower 24-hour and discharge survival [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, vasopressin is not included in the consensus pediatric cardiac arrest algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The use of vasopressin in adult resuscitation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link&amp;anchor=H18#H18\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\", section on 'Vasopressin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4897154\">",
"    <span class=\"h1\">",
"     TACHYARRHYTHMIAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4895863\">",
"    <span class=\"h2\">",
"     Adenosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine is the drug of choice for uncomplicated supraventricular tachycardia (SVT) in children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mechanisms",
"      </strong>",
"      &ndash; Adenosine interacts with Adenosine1 receptors on the surface of cardiac cells; the resulting effects include slowing of the sinus rate and an increase in the atrioventricular node conduction delay. These actions interrupt the reentrant circuit of tachycardias that require the atrioventricular node for reentry, which account for the great majority of cases of SVT in children. While adenosine is effective in terminating SVT associated with atrioventricular (AV) node reentry, AV reentry tachycardia associated with an accessory pathway, sinus node reentry, and automatic atrial tachycardia, it is",
"      <strong>",
"       not",
"      </strong>",
"      effective for atrial flutter, atrial fibrillation, atrial tachycardia or VT that is not caused by reentry at the AV node. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link&amp;anchor=H9#H9\">",
"       \"Management of supraventricular tachycardia in children\", section on 'Adenosine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Indication and contraindications",
"      </strong>",
"      &ndash; Adenosine is the drug of choice for the acute medical conversion of SVT unresponsive to vagal maneuvers (",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef53559 \" href=\"UTD.htm?21/42/22189\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef70842 \" href=\"UTD.htm?11/63/12272\">",
"       waveform 1",
"      </a>",
"      ). However, in children with Wolff-Parkinson-White syndrome, adenosine administration for SVT can cause atrial fibrillation with progression to ventricular fibrillation. As a result, caution should be used when giving adenosine if WPW is a possible mechanism, and emergency resuscitation equipment should be available.",
"      <br/>",
"      <br/>",
"      Adenosine should be avoided in patients with a wide QRS complex tachycardia since it can provoke severe hemodynamic deterioration in those who have ventricular tachycardia rather than an SVT. Adenosine is also contraindicated in patients with pre-existing second or third degree heart block or sinus node disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link&amp;anchor=H9#H9\">",
"       \"Management of supraventricular tachycardia in children\", section on 'Adenosine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Although adenosine is considered to be the drug of choice for conversion of uncomplicated SVT in children, there are some children with frequently recurrent or refractory SVT poorly responsive to adenosine. These patients commonly have impaired ventricular function or are recovering from surgery for congenital heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/40\">",
"       40",
"      </a>",
"      ].",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"       Procainamide",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      are suggested agents for such patients if they do not respond to adenosine. (See",
"      <a class=\"local\" href=\"#H4895234\">",
"       'Procainamide'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H8196866\">",
"       'Amiodarone'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Dose and administration",
"      </strong>",
"      &ndash; The initial dose of adenosine for SVT is 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      rapid IV push (maximum first dose 6 mg) followed immediately with a 5 mL saline flush to promote drug entry into the systemic circulation. Because the elimination half-life of adenosine is 10 seconds, it should be given in an intravenous line as close to the heart as possible. If adenosine is given too slowly or with an inadequate saline flush, then less drug may reach the heart and decrease efficacy. The use of two syringes (one with adenosine and the other with normal saline flush) connected to a T-connector or a stopcock is a useful way of ensuring rapid and effective drug delivery.",
"      <br/>",
"      <br/>",
"      A systematic review of five case series (232 infants and children) suggests that an adenosine dose of 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      will successfully reverse SVT in 20 to 65 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/41\">",
"       41",
"      </a>",
"      ]. Subsequent doses may be increased by 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      to a maximum single dose of 0.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum total single dose 12 mg). In children &gt;50 kg, the initial adult dose of 6 mg should be given with subsequent doses being the maximum single dose of 12 mg. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link&amp;anchor=H9#H9\">",
"       \"Management of supraventricular tachycardia in children\", section on 'Adenosine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The most common side effects reported after adenosine administration are flushing, chest discomfort, nausea and headache. Transient sinus bradycardia or heart block may occur, usually lasting between 10 and 40 seconds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8196866\">",
"    <span class=\"h2\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     Amiodarone",
"    </a>",
"    has largely replaced",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    for the treatment of pulseless ventricular arrhythmias and is also potentially useful for supraventricular and stable ventricular arrhythmias.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mechanisms",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       Amiodarone",
"      </a>",
"      is a class III antiarrhythmic agent that slows atrioventricular (AV) node conduction, prolongs the AV node refractory period and QT interval, and slows ventricular conduction (widens the QRS). These actions are mediated through effects on sodium, potassium, and calcium channels as well as blocking alpha- and beta-adrenergic receptors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link&amp;anchor=H27142119#H27142119\">",
"       \"Clinical uses of amiodarone\", section on 'Pharmacokinetics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Indications and contraindications",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       Amiodarone",
"      </a>",
"      is effective in treating both ventricular and supraventricular arrhythmias that are resistant to other therapies. In children, amiodarone is recommended for the treatment of pulseless ventricular arrhythmias (",
"      <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"       algorithm 1",
"      </a>",
"      ) or stable ventricular tachycardia (",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 3",
"      </a>",
"      ). Amiodarone is also used for supraventricular tachycardia that is refractory to adenosine. However,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"       procainamide",
"      </a>",
"      may be more effective in this situation. (See",
"      <a class=\"local\" href=\"#H4895234\">",
"       'Procainamide'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H4895863\">",
"       'Adenosine'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link&amp;anchor=H12#H12\">",
"       \"Management of supraventricular tachycardia in children\", section on 'Amiodarone'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Amiodarone should not be administered together with another drug that causes QT prolongation, such as procainamide, without expert consultation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"       5",
"      </a>",
"      ]. It is contraindicated in patients with congenital prolonged QT syndrome because it can exacerbate ventricular arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/42\">",
"       42",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Evidence supporting the use of amiodarone in children with ventricular arrhythmias is primarily based upon experience in adult patients which indicate that amiodarone is more effective than",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      for patients with pulseless or refractory ventricular arrhythmias. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link&amp;anchor=H8#H8\">",
"       \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\", section on 'Amiodarone'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In addition, a small pediatric case series reported an 80 percent success rate for intravenous amiodarone in the treatment of critical tachyarrhythmias (eg, atrial or ventricular tachyarrhythmias, junctional ectopic tachycardia) in 40 children who did not respond to standard therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/43\">",
"       43",
"      </a>",
"      ]. Most of these patients developed this arrhythmias after cardiac surgery.",
"     </li>",
"     <li>",
"      <strong>",
"       Dose and administration",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       Amiodarone",
"      </a>",
"      may be given via rapid intravenous or intraosseous bolus in a dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum single dose: 300 mg). The 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      dose may be repeated up to a maximum daily dose of 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum recommended daily dose 2.2 grams).",
"      <br/>",
"      <br/>",
"      Amiodarone should",
"      <strong>",
"       not",
"      </strong>",
"      be administered through an endotracheal tube.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4895234\">",
"    <span class=\"h2\">",
"     Procainamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"     Procainamide",
"    </a>",
"    is a class IA antiarrhythmic that is an alternative to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    for the treatment of supraventricular tachycardia (SVT) refractory to adenosine or stable ventricular tachycardia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mechanisms",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"       Procainamide",
"      </a>",
"      is a sodium channel blocker that prolongs the refractory period of both the atria and ventricles and slows conduction velocity. Unlike adenosine, procainamide does not block reentry at the atrioventricular node and can be safely used in patients with Wolff-Parkinson-White syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link&amp;anchor=H11#H11\">",
"       \"Management of supraventricular tachycardia in children\", section on 'Procainamide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Indications and contraindications",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"       Procainamide",
"      </a>",
"      is suggested for the treatment SVT that is unresponsive to adenosine or stable ventricular tachycardia (",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 3",
"      </a>",
"      ). Procainamide may be more effective than",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      in patients with refractory supraventricular arrhythmias. As an example, an observational study of 37 patients (24 with congenital heart disease) found that procainamide was significantly more effective than amiodarone in terminating refractory supraventricular tachycardia without an observed difference in adverse effects [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/40\">",
"       40",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Procainamide should be",
"      <strong>",
"       avoided",
"      </strong>",
"      in patients who have received amiodarone. It is contraindicated for patients with allergy to procainamide or related drugs (eg, procaine penicillin), heart block (eg, complete or second degree heart block), or torsades de pointes.",
"     </li>",
"     <li>",
"      <strong>",
"       Dose and administration",
"      </strong>",
"      &ndash; The intravenous (IV) loading dose in children younger than one year of age is 7 to 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      given over 30 to 60 minutes. Children older than one year should receive a loading dose of 15",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      The loading dose should be followed by a continuous IV infusion starting at 40-50",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per minute with measurement of plasma levels four hours after the loading dose. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link&amp;anchor=H11#H11\">",
"       \"Management of supraventricular tachycardia in children\", section on 'Procainamide'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"       Procainamide",
"      </a>",
"      should be given by slow infusion to avoid heart block, negative inotropic effects and prolongation of the QT interval (which will predispose to torsade de pointes) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6659945\">",
"    <span class=\"h2\">",
"     Lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     Lidocaine",
"    </a>",
"    may be used for the treatment of pulseless ventricular arrhythmias if",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    is not available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mechanisms",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       Lidocaine",
"      </a>",
"      is a class IB antiarrhythmic that blocks sodium channels in cardiac conductive tissue when they are in the inactivated state at the end of depolarization and during early repolarization. This action results in inhibition of electrical conduction and automaticity, particularly in ischemic tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"       5",
"      </a>",
"      ]. Lidocaine is not as effective as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      in promoting the return of spontaneous circulation in adults.",
"     </li>",
"     <li>",
"      <strong>",
"       Indication and contraindications",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       Lidocaine",
"      </a>",
"      is suggested for the treatment of pulseless ventricular arrhythmias that are refractory to high quality cardiopulmonary resuscitation, defibrillation, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      when",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      is not available.",
"      <br/>",
"      <br/>",
"      Lidocaine is contraindicated in patients with Wolff-Parkinson-White syndrome and those who are allergic to amide-type local anesthetics (",
"      <a class=\"graphic graphic_table graphicRef57120 \" href=\"UTD.htm?17/47/18171\">",
"       table 3",
"      </a>",
"      ). It may also cause seizures and myocardial and circulatory depression, especially in children with poor cardiac output and those with renal or liver failure [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=see_link\">",
"       \"Major side effects of class I antiarrhythmic drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dose and administration",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       Lidocaine",
"      </a>",
"      should be initially given as a single intravenous (IV) or intraosseous (IO) bolus dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      followed by an IV infusion of 20 to 50",
"      <span class=\"nowrap\">",
"       mcg/kg/minute.",
"      </span>",
"      If the start of the infusion will be delayed longer than 15 minutes, then a second IV or IO bolus dose of 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      may be given.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8196901\">",
"    <span class=\"h2\">",
"     Magnesium sulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    is the primary agent recommended for the treatment of torsades de pointes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mechanisms",
"      </strong>",
"      &ndash; Magnesium is a crucial cofactor in the sodium-potassium-ATPase enzyme system. It stabilizes the motor membrane by reducing the sensitivity of the motor end plate to acetylcholine. A decreased intracellular magnesium level promotes myocardial excitability but, even in the absence of a low magnesium level, a bolus of IV magnesium will suppress ectopic ventricular beats. At high levels, magnesium acts as a calcium channel blocker and can produce bradycardia with atrioventricular block and cardiac arrest. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=see_link&amp;anchor=H3#H3\">",
"       \"Symptoms of hypermagnesemia\", section on 'Cardiovascular effects'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Indications and contraindications",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"      is indicated in the treatment of torsades de pointes (polymorphic VT with long QT interval) or documented hypomagnesemia. Patients with hypokalemia and arrhythmias frequently have associated hypomagnesemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link&amp;anchor=H10#H10\">",
"       \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\", section on 'Magnesium sulfate'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=see_link&amp;anchor=H3#H3\">",
"       \"Signs and symptoms of magnesium depletion\", section on 'Hypokalemia'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients who receive magnesium sulfate require monitoring of serum magnesium concentrations. Magnesium should be administered with caution to patients with myasthenia gravis or other neuromuscular disease and patients with renal impairment. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Dose and administration",
"      </strong>",
"      &ndash; For torsades de pointes,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      should be diluted in 5 percent dextrose (D5W) to a 20 percent solution or less and given as an intravenous or intraosseous infusion at a dose of 25 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose: 2 grams). The rate of infusion depends upon the clinical situation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with pulseless arrest &ndash; infuse over 1 to 2 minutes.",
"     </li>",
"     <li>",
"      Perfusing patients &ndash; infuse over 15 minutes because rapid infusion is associated with hypotension and asystole.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4897390\">",
"    <span class=\"h1\">",
"     LIMITED INDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Atropine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     Atropine",
"    </a>",
"    is no longer routinely recommended in patients with cardiac arrest and is primarily indicated for vasovagal induced bradycardia or the treatment of primary atrioventricular block.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mechanisms",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       Atropine",
"      </a>",
"      is a parasympatholytic drug that increases heart rate by accelerating the sinus and atrial pacemaker and improving conduction through the AV node. Although the dominant cardiac response is tachycardia, the heart rate may decrease transiently when small doses are administered [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/45\">",
"       45",
"      </a>",
"      ]. This decrease is thought to occur because atropine, at low doses, blocks the M1 muscarinic postganglionic receptors that provide feedback inhibition for synaptic acetylcholine release [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/46\">",
"       46",
"      </a>",
"      ]; the resulting increase in acetylcholine inhibits spontaneous impulse generation in the SA node.",
"     </li>",
"     <li>",
"      <strong>",
"       Indications and contraindications",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       Atropine",
"      </a>",
"      is indicated for the prevention of bradycardia during endotracheal intubation in infants younger than one year of age, patients younger than five years of age who also receive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      , and children older than five years of age who are administered a second dose of succinylcholine. Atropine is also recommended for children with bradycardia caused by increased vagal tone or primary atrioventricular block or unresponsive to oxygen, airway support, and administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef52446 \" href=\"UTD.htm?20/4/20545\">",
"       algorithm 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Sinus tachycardia may occur after administration of atropine but it usually is well tolerated in children. The development of hypoxia-induced bradycardia may be masked if atropine is given to block vagal-induced bradycardia during intubation. In these cases, the use of pulse oximetry is recommended to monitor oxygenation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H12#H12\">",
"       \"Rapid sequence intubation (RSI) in children\", section on 'Atropine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Fixed and dilated pupils should not be attributed to atropine because atropine causes dilation of the pupils but does not eliminate the pupil constrictive response to light [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/47\">",
"       47",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      When not being used in a resuscitation situation, atropine is contraindicated in patients with obstructive gastrointestinal or genitourinary conditions (eg, surgical abdomen, paralytic ileus, posterior urethral valves), and myasthenia gravis (unless treating side effects of acetylcholinesterase inhibition) because it may exacerbate the underlying condition [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/48\">",
"       48",
"      </a>",
"      ]. Atropine may cause additional tachycardia in patients with thyrotoxicosis and mucous plugging in patients with asthma. It should also be used with caution in patients with hyperthermia and delirium.",
"     </li>",
"     <li>",
"      <strong>",
"       Dose and administration",
"      </strong>",
"      &ndash; The dose of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      varies depending on the route of administration. Although it can be given endotracheally, administration by the intravenous (IV) or the intraosseous route (IO) is preferred [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        IV/IO",
"       </strong>",
"      </span>",
"      <strong>",
"       route",
"      </strong>",
"      &ndash; The recommended IV or IO dose of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      is 0.02",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      The maximum single dose is 1 mg. The dose may be repeated once, if needed [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"       5",
"      </a>",
"      ]. Higher doses probably are not routinely necessary because a total dose of 2 mg is sufficient to produce full vagal blockade in an adult [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/49\">",
"       49",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients with poisoning from cholinesterase inhibiting agents may require much higher doses of atropine to dry bronchial secretions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=see_link&amp;anchor=H12#H12\">",
"       \"Organophosphate and carbamate poisoning\", section on 'Atropine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A minimum parenteral dose of 0.1 mg has been suggested based upon a study that showed that very low doses of atropine (0.0036",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      were associated with a mild slowing of heart rate [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/45\">",
"       45",
"      </a>",
"      ]. This low dose effect was most evident in school-aged children. However, in neonates who weigh less than 5 kilograms, this minimum dose can lead to anticholinergic toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. Thus, some experts advocate that all patients should receive the weight-based dose of 0.02",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      with no minimum dose [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Endotracheal route",
"      </strong>",
"      &ndash; Studies evaluating the absorption of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      by the endotracheal route are lacking. The recommended dose for endotracheal administration is 0.04 to 0.06",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      which may also be repeated once [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"       5",
"      </a>",
"      ]. When given endotracheally, the atropine dose should be diluted with normal saline to a volume of 3 to 5 mL and instilled into the endotracheal tube. It may also be delivered beyond the tip of the endotracheal tube with a suction catheter, followed by a 3 to 5 mL saline flush. Several positive-pressure breaths should be given after endotracheal administration of atropine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sodium bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combined respiratory and metabolic acidosis develops during cardiopulmonary arrest. Hypoxia-induced anaerobic metabolism generates lactic acid, and ventilatory failure causes carbon dioxide retention. In addition, during shock or cardiac arrest, metabolic acid excretion is diminished because renal perfusion is inadequate. The severity of the acidosis worsens as the arrested state continues [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most effective means of correcting the acidosis in cardiac arrest is to provide adequate oxygenation, ventilation, and tissue perfusion. Because most pediatric cardiac arrests are secondary to respiratory failure, support of ventilation through early intubation is the primary treatment, followed by support of the circulation with fluids and inotropic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. The routine use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    is not recommended because of lack of convincing evidence of beneficial effects and potential adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mechanisms",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      increases blood pH by buffering excess blood hydrogen ion as long as the patient has adequate ventilation to excrete carbon dioxide.",
"     </li>",
"     <li>",
"      <strong>",
"       Indications and contraindications",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      The AHA recommends that",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      be considered only in children with prolonged cardiac arrest and documented severe metabolic acidosis who fail to respond to oxygenation, ventilation, fluids, and chest compressions combined with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      in recommended doses [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/16\">",
"       16",
"      </a>",
"      ]. Sodium bicarbonate also may be considered when shock is associated with documented metabolic acidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link&amp;anchor=H13#H13\">",
"       \"Hypovolemic shock in children: Initial evaluation and management\", section on 'Fluid resuscitation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In children without cardiac arrest or shock, metabolic acidosis typically resolves with adequate volume replacement and ventilatory support. Additional indications for the administration of sodium bicarbonate include hyperkalemia, hypermagnesemia, tricyclic antidepressant overdose, or overdose from other sodium channel blocking agents [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2,16,52,53\">",
"       2,16,52,53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"       \"Treatment and prevention of hyperkalemia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=see_link\">",
"       \"Tricyclic antidepressant poisoning\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Sodium bicarbonate administration should",
"      <strong>",
"       not",
"      </strong>",
"      be given to children with inadequate ventilation because inadequate respiratory excretion of carbon dioxide will lead to retention and worsening respiratory acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/16\">",
"       16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Excess administration of sodium bicarbonate during resuscitation has been associated with the following effects and should be avoided:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypertonicity",
"     </li>",
"     <li>",
"      Worsening of intracellular acidosis with impairment of myocardial contractility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35448?source=see_link&amp;anchor=H18#H18\">",
"       \"Therapies of uncertain benefit in basic and advanced cardiac life support\", section on 'Sodium bicarbonate therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extreme metabolic alkalosis with reduced oxygen delivery to the tissues, hypokalemia, and decreased plasma ionized calcium concentration. All of these adverse effects increase the risk for cardiac arrhythmias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dose and administration",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      is administered by the intravenous (IV) or intraosseous (IO) route. It should not be given endotracheally because it is irritating to the airways, destroys lung surfactant, and can produce massive atelectasis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The initial dose of sodium bicarbonate is 1",
"      <span class=\"nowrap\">",
"       mEq/kg",
"      </span>",
"      (1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 8.4 percent solution or 2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 4.2 percent solution [recommended for children younger than six months of age]). The usual maximum single dose of sodium bicarbonate is 50 mEq for a child to 100 mEq for an adult patient.",
"      <br/>",
"      <br/>",
"      During prolonged arrests, subsequent doses of 0.5",
"      <span class=\"nowrap\">",
"       mEq/kg",
"      </span>",
"      each may be given every 10 minutes by slow (one to two minutes) infusion or based upon blood gas analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2,5\">",
"       2,5",
"      </a>",
"      ]. However, arterial blood gas analysis taken during cardiac arrest or severe shock may overestimate tissue and venous pH. Thus, central venous blood gas measurements, if possible, are advised to accurately assess acid-base status during resuscitation",
"      <span class=\"nowrap\">",
"       [",
"       <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/54,55\">",
"        54,55",
"       </a>",
"       ].",
"       <br/>",
"       <br/>",
"       IV/IO",
"      </span>",
"      tubing must be irrigated with normal saline before and after giving infusions of sodium bicarbonate to prevent inactivation of administered",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      or, in hypocalcemic or hyperkalemic patients, precipitation with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19446?source=see_link\">",
"       calcium chloride",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Epinephrine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4895656\">",
"       'Calcium'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Repeated doses of sodium bicarbonate can also produce symptomatic hypernatremia and hyperosmolarity [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. Compared with plasma, the standard 8.4 percent sodium bicarbonate solution is hyperosmolar (2000",
"      <span class=\"nowrap\">",
"       mOsm/L",
"      </span>",
"      versus 289",
"      <span class=\"nowrap\">",
"       mOsm/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2\">",
"       2",
"      </a>",
"      ]. Use of hypertonic solutions in premature infants has been associated with an increased risk of developing periventricular-intraventricular hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/58\">",
"       58",
"      </a>",
"      ]. For this reason, a more dilute solution (4.2 percent) should be used in infants younger than six months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2,4,14\">",
"       2,4,14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The administration of sodium bicarbonate may sclerose small veins and produce a chemical burn if extravasated into subcutaneous tissues [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/2\">",
"       2",
"      </a>",
"      ]. Transient vasodilation and hypotension can occur with rapid infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4895656\">",
"    <span class=\"h2\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium has limited uses in pediatric resuscitation which include the treatment of hypocalcemia or hypermagnesemia, hyperkalemia, or calcium channel blocker overdose.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mechanisms",
"      </strong>",
"      &ndash; Calcium increases cardiac inotropy. Influx and efflux of calcium ions are important for the maintenance of normal conductivity and rhythm.",
"     </li>",
"     <li>",
"      <strong>",
"       Indications and contraindications",
"      </strong>",
"      &ndash; Calcium has a very specific indication in cardiac arrests as emergency protection against the arrhythmogenic effects of hypocalcemia, hyperkalemia, hypermagnesemia, or calcium channel blocker overdose [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"       5",
"      </a>",
"      ]. It is otherwise not recommended for pediatric cardiopulmonary arrest because of an observed association with decreased survival and poor neurologic outcomes after pediatric arrests [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Dose and administration",
"      </strong>",
"      &ndash; The optimum dose of calcium is based upon extrapolation from adult data and limited pediatric data.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19446?source=see_link\">",
"       Calcium chloride",
"      </a>",
"      is preferred over",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"       calcium gluconate",
"      </a>",
"      because it provides greater bioavailability of calcium but should only be given if central venous access is available because administration through a peripheral intravenous line is associated with skin necrosis and sloughing [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/61\">",
"       61",
"      </a>",
"      ]. Calcium gluconate is less irritating to the veins and may be administered by peripheral or central venous access.",
"      <br/>",
"      <br/>",
"      The recommended dose of elemental calcium is 5 to 7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"       5",
"      </a>",
"      ]. Dosing in this range can be achieved by giving 0.2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of calcium chloride 10 percent which provides 5.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <strong>",
"       elemental",
"      </strong>",
"      calcium or 0.6",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of calcium gluconate 10 percent which provides 5.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <strong>",
"       elemental",
"      </strong>",
"      calciums. The maximum single dose is 540 mg of",
"      <strong>",
"       elemental",
"      </strong>",
"      calcium. Calcium chloride or calcium gluconate should be administered by slow intravenous push over 10 to 20 seconds in cardiac arrest and more slowly (eg, over 5 to 10 minutes) in perfusing patients.",
"      <br/>",
"      <br/>",
"      Rapid administration may cause bradycardia or asystole. If",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      is being given through the same intravenous line, the tubing must be thoroughly flushed before and after calcium administration. Otherwise an insoluble precipitate can form in the catheter lumen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5953323\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children undergoing pediatric advanced life support (PALS), medications are of secondary importance to the prompt treatment of hypoxemia and respiratory impairment, initiation of high quality cardiopulmonary resuscitation, and, in pulseless patients with ventricular arrhythmias, early defibrillation. (See",
"    <a class=\"local\" href=\"#H5952713\">",
"     'Recommended drugs by clinical condition'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link\">",
"     \"Basic life support in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21272?source=see_link\">",
"     \"Defibrillation and cardioversion in children (including automated external defibrillation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary drugs used in pediatric advanced life support (PALS), according to clinical presentation, are as follows (",
"      <a class=\"graphic graphic_table graphicRef70539 \" href=\"UTD.htm?23/54/24430\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"       5",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Asystole or pulseless electrical activity &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       Epinephrine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"       algorithm 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Epinephrine'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Ventricular fibrillation or ventricular tachycardia without a pulse &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       Epinephrine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      as adjuncts to high quality cardiopulmonary resuscitation and defibrillation (",
"      <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"       algorithm 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Epinephrine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8196866\">",
"       'Amiodarone'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Bradycardia &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       Epinephrine",
"      </a>",
"      and, in patients with vagally-mediated bradycardia or primary atrioventricular block,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef52446 \" href=\"UTD.htm?20/4/20545\">",
"       algorithm 2",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Epinephrine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Atropine'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Uncomplicated supraventricular tachycardia (SVT) &ndash; Adenosine (",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 3",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H4895863\">",
"       'Adenosine'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Possible ventricular tachycardia or aberrant or refractory SVT &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       Amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"       procainamide",
"      </a>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 3",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H8196866\">",
"       'Amiodarone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4895234\">",
"       'Procainamide'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hypomagnesemia or torsades de pointes &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H8196901\">",
"       'Magnesium sulfate'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hypocalcemia, hypermagnesemia, hyperkalemia or calcium channel blocker overdose &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19446?source=see_link\">",
"       Calcium chloride",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H4895656\">",
"       'Calcium'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hypoglycemia &ndash; Glucose (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Glucose'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to these agents, all critically ill children should receive 100 percent inspired oxygen. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Oxygen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      administration should be restricted to patients with prolonged cardiac arrest and documented severe metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Sodium bicarbonate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/1\">",
"      Goetting MG. Mastering pediatric cardiopulmonary resuscitation. Pediatr Clin North Am 1994; 41:1147.",
"     </a>",
"    </li>",
"    <li>",
"     Pediatric Advanced Life Support Provider Manual. Ralston, M, et al (Eds), American Heart Association, Subcommittee on Pediatric Resuscitation, Dallas, 2006, p.221.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/3\">",
"      Patterson MD. Resuscitation update for the pediatrician. Pediatr Clin North Am 1999; 46:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/4\">",
"      Ushay HM, Notterman DA. Pharmacology of pediatric resuscitation. Pediatr Clin North Am 1997; 44:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/5\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/6\">",
"      Michaud LJ, Rivara FP, Longstreth WT Jr, Grady MS. Elevated initial blood glucose levels and poor outcome following severe brain injuries in children. J Trauma 1991; 31:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/7\">",
"      D'Alecy LG, Lundy EF, Barton KJ, Zelenock GB. Dextrose containing intravenous fluid impairs outcome and increases death after eight minutes of cardiac arrest and resuscitation in dogs. Surgery 1986; 100:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/8\">",
"      Nakakimura K, Fleischer JE, Drummond JC, et al. Glucose administration before cardiac arrest worsens neurologic outcome in cats. Anesthesiology 1990; 72:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/9\">",
"      Voorhies TM, Rawlinson D, Vannucci RC. Glucose and perinatal hypoxic-ischemic brain damage in the rat. Neurology 1986; 36:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/10\">",
"      Paradis NA, Koscove EM. Epinephrine in cardiac arrest: a critical review. Ann Emerg Med 1990; 19:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/11\">",
"      Goetting MG, Paradis NA. High-dose epinephrine improves outcome from pediatric cardiac arrest. Ann Emerg Med 1991; 20:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/12\">",
"      Paradis NA, Martin GB, Rivers EP, et al. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. JAMA 1990; 263:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/13\">",
"      Michael JR, Guerci AD, Koehler RC, et al. Mechanisms by which epinephrine augments cerebral and myocardial perfusion during cardiopulmonary resuscitation in dogs. Circulation 1984; 69:822.",
"     </a>",
"    </li>",
"    <li>",
"     Ludwig, S, Lavell, e, JM. Resuscitation-pediatric basic and advanced life support. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/15\">",
"      Otto CW, Yakaitis RW, Blitt CD. Mechanism of action of epinephrine in resuscitation from asphyxial arrest. Crit Care Med 1981; 9:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/16\">",
"      Kleinman ME, de Caen AR, Chameides L, et al. Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Pediatrics 2010; 126:e1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/17\">",
"      Guidelines for cardiopulmonary resuscitation and emergency cardiac care. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Part VII. Neonatal resuscitation. JAMA 1992; 268:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/18\">",
"      Orlowski JP, Gallagher JM, Porembka DT. Endotracheal epinephrine is unreliable. Resuscitation 1990; 19:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/19\">",
"      Zaritsky A. Pediatric resuscitation pharmacology. Members of the Medications in Pediatric Resuscitation Panel. Ann Emerg Med 1993; 22:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/20\">",
"      Brown CG, Werman HA, Davis EA, et al. Comparative effect of graded doses of epinephrine on regional brain blood flow during CPR in a swine model. Ann Emerg Med 1986; 15:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/21\">",
"      Brown CG, Werman HA, Davis EA, et al. The effects of graded doses of epinephrine on regional myocardial blood flow during cardiopulmonary resuscitation in swine. Circulation 1987; 75:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/22\">",
"      Gonzalez ER, Ornato JP, Garnett AR, et al. Dose-dependent vasopressor response to epinephrine during CPR in human beings. Ann Emerg Med 1989; 18:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/23\">",
"      Goetting MG, Paradis NA. High dose epinephrine in refractory pediatric cardiac arrest. Crit Care Med 1989; 17:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/24\">",
"      Dieckmann RA, Vardis R. High-dose epinephrine in pediatric out-of-hospital cardiopulmonary arrest. Pediatrics 1995; 95:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/25\">",
"      Brown CG, Martin DR, Pepe PE, et al. A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. The Multicenter High-Dose Epinephrine Study Group. N Engl J Med 1992; 327:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/26\">",
"      Stiell IG, Hebert PC, Weitzman BN, et al. High-dose epinephrine in adult cardiac arrest. N Engl J Med 1992; 327:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/27\">",
"      Berg RA, Otto CW, Kern KB, et al. A randomized, blinded trial of high-dose epinephrine versus standard-dose epinephrine in a swine model of pediatric asphyxial cardiac arrest. Crit Care Med 1996; 24:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/28\">",
"      Carpenter TC, Stenmark KR. High-dose epinephrine is not superior to standard-dose epinephrine in pediatric in-hospital cardiopulmonary arrest. Pediatrics 1997; 99:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/29\">",
"      Perondi MB, Reis AG, Paiva EF, et al. A comparison of high-dose and standard-dose epinephrine in children with cardiac arrest. N Engl J Med 2004; 350:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/30\">",
"      American Heart Association. Management of cardiac arrest. Circulation 2005; 112:IV.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/31\">",
"      Haft JI. Cardiovascular injury induced by sympathetic catecholamines. Prog Cardiovasc Dis 1974; 17:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/32\">",
"      Rivers EP, Wortsman J, Rady MY, et al. The effect of the total cumulative epinephrine dose administered during human CPR on hemodynamic, oxygen transport, and utilization variables in the postresuscitation period. Chest 1994; 106:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/33\">",
"      Guidelines for cardiopulmonary resuscitation and emergency cardiac care. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Part VI. Pediatric advanced life support. JAMA 1992; 268:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/34\">",
"      Stroumpoulis K, Xanthos T, Rokas G, et al. Vasopressin and epinephrine in the treatment of cardiac arrest: an experimental study. Crit Care 2008; 12:R40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/35\">",
"      Jing XL, Li X, Li H, et al. Vasopressin and epinephrine versus epinephrine in management of patients with cardiac arrest: a meta-analysis. Signa Vitae 2010; 5:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/36\">",
"      Mann K, Berg RA, Nadkarni V. Beneficial effects of vasopressin in prolonged pediatric cardiac arrest: a case series. Resuscitation 2002; 52:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/37\">",
"      Gil-Ant&oacute;n J, L&oacute;pez-Herce J, Morteruel E, et al. Pediatric cardiac arrest refractory to advanced life support: is there a role for terlipressin? Pediatr Crit Care Med 2010; 11:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/38\">",
"      Yilidzda D, Horoz OO, Erdem S. Beneficial effects of terlipressin in pediatric cardiac arrest. Pediatr Emerg Care 2011; 27:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/39\">",
"      Duncan JM, Meaney P, Simpson P, et al. Vasopressin for in-hospital pediatric cardiac arrest: results from the American Heart Association National Registry of Cardiopulmonary Resuscitation. Pediatr Crit Care Med 2009; 10:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/40\">",
"      Chang PM, Silka MJ, Moromisato DY, Bar-Cohen Y. Amiodarone versus procainamide for the acute treatment of recurrent supraventricular tachycardia in pediatric patients. Circ Arrhythm Electrophysiol 2010; 3:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/41\">",
"      Quail MA, Till J. Question 3 Does a higher initial dose of adenosine improve cardioversion rates in supraventricular tachycardia? Arch Dis Child 2012; 97:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/42\">",
"      Fishberger SB, Hannan RL, Welch EM, Rossi AF. Amiodarone for pediatric resuscitation: a word of caution. Pediatr Cardiol 2009; 30:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/43\">",
"      Perry JC, Fenrich AL, Hulse JE, et al. Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol 1996; 27:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/44\">",
"      Luedtke SA, Kuhn RJ, McCaffrey FM. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia. Ann Pharmacother 1997; 31:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/45\">",
"      Dauchot P, Gravenstein JS. Effects of atropine on the electrocardiogram in different age groups. Clin Pharmacol Ther 1971; 12:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/46\">",
"      Todd GL, Baroldi G, Pieper GM, et al. Experimental catecholamine-induced myocardial necrosis. I. Morphology, quantification and regional distribution of acute contraction band lesions. J Mol Cell Cardiol 1985; 17:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/47\">",
"      Goetting MG, Contreras E. Systemic atropine administration during cardiac arrest does not cause fixed and dilated pupils. Ann Emerg Med 1991; 20:55.",
"     </a>",
"    </li>",
"    <li>",
"     Atropine. In: Martindale: The Complete Drug Reference, Sweetman SC (Ed).  (Ed), Pharmaceutical Press, London. Electronic version 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/49\">",
"      O'Rourke GW, Greene NM. Autonomic blockade and the resting heart rate in man. Am Heart J 1970; 80:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/50\">",
"      Barrington KJ. The myth of a minimum dose for atropine. Pediatrics 2011; 127:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/51\">",
"      Barrington KJ, Byrne PJ. Premedication for neonatal intubation. Am J Perinatol 1998; 15:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/52\">",
"      Ettinger PO, Regan TJ, Oldewurtel HA. Hyperkalemia, cardiac conduction, and the electrocardiogram: a review. Am Heart J 1974; 88:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/53\">",
"      Hoffman JR, Votey SR, Bayer M, Silver L. Effect of hypertonic sodium bicarbonate in the treatment of moderate-to-severe cyclic antidepressant overdose. Am J Emerg Med 1993; 11:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/54\">",
"      Weil MH, Rackow EC, Trevino R, et al. Difference in acid-base state between venous and arterial blood during cardiopulmonary resuscitation. N Engl J Med 1986; 315:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/55\">",
"      Steedman DJ, Robertson CE. Acid base changes in arterial and central venous blood during cardiopulmonary resuscitation. Arch Emerg Med 1992; 9:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/56\">",
"      M&aacute;ttar JA, Weil MH, Shubin H, Stein L. Cardiac arrest in the critically ill. II. Hyperosmolal states following cardiac arrest. Am J Med 1974; 56:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/57\">",
"      Aufderheide TP, Martin DR, Olson DW, et al. Prehospital bicarbonate use in cardiac arrest: a 3-year experience. Am J Emerg Med 1992; 10:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/58\">",
"      Howell JH. Sodium bicarbonate in the perinatal setting--revisited. Clin Perinatol 1987; 14:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/59\">",
"      Cot&eacute; CJ, Greenhow DE, Marshall BE. The hypotensive response to rapid intravenous administration of hypertonic solutions in man and in the rabbit. Anesthesiology 1979; 50:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/60\">",
"      Srinivasan V, Morris MC, Helfaer MA, et al. Calcium use during in-hospital pediatric cardiopulmonary resuscitation: a report from the National Registry of Cardiopulmonary Resuscitation. Pediatrics 2008; 121:e1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/23/15738/abstract/61\">",
"      Broner CW, Stidham GL, Westenkirchner DF, Watson DC. A prospective, randomized, double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children. J Pediatr 1990; 117:986.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6386 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15738=[""].join("\n");
var outline_f15_23_15738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5953323\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5952713\">",
"      RECOMMENDED DRUGS BY CLINICAL CONDITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4897046\">",
"      SUBSTRATE DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Glucose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4897086\">",
"      CARDIAC ARREST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Epinephrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6659759\">",
"      Vasopressin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4897154\">",
"      TACHYARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4895863\">",
"      Adenosine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8196866\">",
"      Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4895234\">",
"      Procainamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6659945\">",
"      Lidocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8196901\">",
"      Magnesium sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4897390\">",
"      LIMITED INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Atropine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sodium bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4895656\">",
"      Calcium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5953323\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6386\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6386|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/30/42470\" title=\"algorithm 1\">",
"      Pediatric cardiac arrest algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/4/20545\" title=\"algorithm 2\">",
"      Pediatric bradycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/37/11860\" title=\"algorithm 3\">",
"      Pediatric tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6386|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/54/24430\" title=\"table 1\">",
"      Doses pediatric resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/42/22189\" title=\"table 2\">",
"      Pediatric supraventricular tachycardia rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/47/18171\" title=\"table 3\">",
"      Classification local anesthetic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6386|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/63/12272\" title=\"waveform 1\">",
"      Conversion of supraventricular tachycardia with adenosine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=related_link\">",
"      Basic life support in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=related_link\">",
"      Continuous oxygen delivery systems for infants, children, and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21272?source=related_link\">",
"      Defibrillation and cardioversion in children (including automated external defibrillation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=related_link\">",
"      Guidelines for pediatric advanced life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=related_link\">",
"      Major side effects of class I antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=related_link\">",
"      Management of supraventricular tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=related_link\">",
"      Neonatal resuscitation in the delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=related_link\">",
"      Opioid intoxication in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=related_link\">",
"      Organophosphate and carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=related_link\">",
"      Oxygen toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=related_link\">",
"      Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=related_link\">",
"      Symptoms of hypermagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35448?source=related_link\">",
"      Therapies of uncertain benefit in basic and advanced cardiac life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_23_15739="Percent nodal metastases";
var content_f15_23_15739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Percentage of nodal metastases as a function of location and tumor size",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        T1",
"       </td>",
"       <td class=\"subtitle1\">",
"        T2",
"       </td>",
"       <td class=\"subtitle1\">",
"        T3",
"       </td>",
"       <td class=\"subtitle1\">",
"        T4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyriform sinus",
"       </td>",
"       <td>",
"        38 to 91",
"       </td>",
"       <td>",
"        67 to 83",
"       </td>",
"       <td>",
"        69 to 80",
"       </td>",
"       <td>",
"        60 to 98",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pharyngeal wall",
"       </td>",
"       <td>",
"        33 to 70",
"       </td>",
"       <td>",
"        31 to 79",
"       </td>",
"       <td>",
"        47 to 85",
"       </td>",
"       <td>",
"        70 to 82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postcricoid space",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. McGavran MH, Bauer WC, Spjut HJ, Ogura JH. Carcinoma of the Pyriform Sinus: the Results of Radical Surgery. Arch Otolaryngol 1963; 78:826.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15739=[""].join("\n");
var outline_f15_23_15739=null;
var title_f15_23_15740="HCG levels in GTD";
var content_f15_23_15740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    USA hCG Reference Service experience, concentration of hCG and hCG-H in serum samples in gestational trophoblastic diseases and non-gestational malignancies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Source",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       n",
"      </td>",
"      <td class=\"subtitle1\">",
"       Total hCG, mIU/ml",
"      </td>",
"      <td class=\"subtitle1\">",
"       hCG-H, mIU/ml equivalents*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Median (range)",
"      </td>",
"      <td class=\"subtitle2\">",
"       Percent of total hCG &plusmn; SD",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Complete hydatidiform mole (prior to evacuation)",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       192,995 (24,160-3,704,084)",
"      </td>",
"      <td>",
"       4.9 &plusmn; 2.1 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Partial hydatidiform mole (prior to evacuation)",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       48,900 (11,600-220,114)",
"      </td>",
"      <td>",
"       3.6 &plusmn; 1.7 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Invasive mole, recurrent mole (at commencement of therapy)",
"      </td>",
"      <td>",
"       72",
"      </td>",
"      <td>",
"       869 (24-30,255)",
"      </td>",
"      <td>",
"       30 &plusmn; 35 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Choriocarcinoma/GTN (at time of diagnosis)",
"      </td>",
"      <td>",
"       102",
"      </td>",
"      <td>",
"       16,298 (5.2-597,000)",
"      </td>",
"      <td>",
"       61 &plusmn; 41 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Quiescent GTD (at time of diagnosis)&bull;",
"      </td>",
"      <td>",
"       101",
"      </td>",
"      <td>",
"       22 (1-212)",
"      </td>",
"      <td>",
"       0.31 percent &plusmn; 2.16 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       PSTT (at time of diagnosis)&bull;",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       30 (1-231)",
"      </td>",
"      <td>",
"       7.1 &plusmn; 13 percent",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    hCG=human chorionic gonadotropin",
"    <br>",
"     hCG-H=hyperglycosylated hCG",
"     <br>",
"      PSTT=Placental site trophoblastic tumor",
"      <br>",
"       GTD=Gestational trophoblastic disease",
"       <br>",
"        GTN=Gestational trophoblastic neoplasia",
"        <div class=\"footnotes\">",
"         SD: standard deviation.",
"         <br>",
"          * Values are measured as equivalents of regular hCG, assuming that 1 ng/ml hCG is 11.1 mIU/ml (using WHO 4th international standard).",
"          <br>",
"           &bull; As measured by USA hCG Reference Service, indicated diagnosis confirmed at biopsy by referring center.",
"          </br>",
"         </br>",
"        </div>",
"        <div class=\"reference\">",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15740=[""].join("\n");
var outline_f15_23_15740=null;
var title_f15_23_15741="Staging vaginal cancer";
var content_f15_23_15741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Staging vaginal cancer (TNM and International Federation of Gynecology and Obstetrics [FIGO])",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       TNM categories",
"      </td>",
"      <td class=\"subtitle2\">",
"       FIGO stages",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       Definition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis*",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       Carcinoma in situ (preinvasive carcinoma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       I",
"      </td>",
"      <td colspan=\"2\">",
"       Tumor confined to vagina",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       II",
"      </td>",
"      <td colspan=\"2\">",
"       Tumor invades paravaginal tissues but not to pelvic wall",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       III",
"      </td>",
"      <td colspan=\"2\">",
"       Tumor extends to pelvic wall&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       IVA",
"      </td>",
"      <td colspan=\"2\">",
"       Tumor invades mucosa of the bladder or rectum and/or extends beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       TNM categories",
"      </td>",
"      <td class=\"subtitle2\">",
"       FIGO stages",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       Definition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       III",
"      </td>",
"      <td colspan=\"2\">",
"       Pelvic or inguinal lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       TNM categories",
"      </td>",
"      <td class=\"subtitle2\">",
"       FIGO stages",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       Definition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td>",
"       IVB",
"      </td>",
"      <td colspan=\"2\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0*",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage II",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage III",
"      </td>",
"      <td>",
"       T1-T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVA",
"      </td>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVB",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * FIGO no longer includes Stage 0 (Tis).",
"     <br>",
"      &bull; Pelvic wall is defined as muscle, fascia, neurovascular structures, or skeletal portions of the bony pelvis. On rectal examination, there is no cancer-free space between the tumor and pelvic wall.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15741=[""].join("\n");
var outline_f15_23_15741=null;
var title_f15_23_15742="Multiple fx";
var content_f15_23_15742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 209px; height: 490px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two-month-old with multiple fractures in various stages of healing (acute distal humerus lateral condyle fracture and old segmental fracture of the radius). Multiple fractures, old or in various stages of healing, are highly suggestive of child abuse.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Susan A Scherl, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15742=[""].join("\n");
var outline_f15_23_15742=null;
var title_f15_23_15743="Erythrodontia in CEP";
var content_f15_23_15743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrodontia in CEP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph taken with the aid of long wavelength ultraviolet light in a patient with congenital erythropoietic porphyria (CEP). Bright fluorescence of the teeth is demonstrated, due to the presence of high concentrations of uroporphyrin deposited in the teeth in this disorder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photograph provided by Shigeru Sassa, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_23_15743=[""].join("\n");
var outline_f15_23_15743=null;
